var title_f29_53_30544="Epithelial cornea defect";
var content_f29_53_30544=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F61760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F61760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Epithelial cornea defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nonhealing epithelial defect in a transplanted cornea in a patient with secondary Sj&ouml;gren's syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of M Reza Dana, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_53_30544=[""].join("\n");
var outline_f29_53_30544=null;
var title_f29_53_30545="Alogliptin: Drug information";
var content_f29_53_30545=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Alogliptin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F16057064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Dipeptidyl Peptidase IV (DPP-IV) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F16057062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nesina&trade;: FDA approved January 2013; anticipated availability is the summer of 2013. Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F16057066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of type 2 diabetes mellitus (noninsulin dependent, NIDDM) as an adjunct to diet and exercise as monotherapy or in combination with other antidiabetic agents",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87804 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-5088ACF45B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_53_30545=[""].join("\n");
var outline_f29_53_30545=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16057064\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16057062\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16057066\">",
"      Use",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87804\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87804|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_53_30546="Renal cell carcinoma (kidney cancer)";
var content_f29_53_30546=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Renal cell carcinoma (kidney cancer) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?29/53/30546/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/53/30546/contributors\" id=\"au4430\">",
"       Michael B Atkins, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/53/30546/contributors\" id=\"au3217\">",
"       Jerome P Richie, MD, FACS",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?29/53/30546/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/53/30546/contributors\" id=\"se4430\">",
"       Michael B Atkins, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?29/53/30546/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/53/30546/contributors\" id=\"de8229\">",
"       Don S Dizon, MD, FACP",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?29/53/30546?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     The kidneys are bean-shaped, approximately fist-sized organs that are located on each side the mid-back, just below the rib cage (",
"     <a class=\"graphic graphic_figure graphicRef79864 \" href=\"UTD.htm?26/28/27072\">",
"      figure 1",
"     </a>",
"     ). The kidneys filter the blood and get rid of excess water and waste in the urine.",
"    </p>",
"    <p>",
"     The most common form of kidney cancer in adults is renal cell carcinoma. Renal cell carcinoma usually does not cause obvious symptoms, especially in the early stages. As a result, the cancer may not be discovered until it is advanced.",
"    </p>",
"    <p>",
"     Treatment of renal cell carcinoma may include surgery to remove part or all of the kidney. In some people, a medicine is used to slow the growth of the cancer.",
"    </p>",
"    <p>",
"     This article discusses the symptoms, diagnosis, and treatment options for renal cell carcinoma. More detailed information about renal cell carcinoma is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21192?source=see_link\">",
"      \"Prognostic factors in patients with renal cell carcinoma\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      RENAL CELL CARCINOMA SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Most people with renal cell carcinoma (RCC) do not have obvious symptoms. This means that RCC is sometimes not found until the cancer is advanced. Of those with symptoms, the most common symptoms include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Blood in the urine (hematuria)",
"      </li>",
"      <li>",
"       Pain in the sides of the mid back (the flank)",
"      </li>",
"      <li>",
"       A lump in the abdomen or side of the back",
"      </li>",
"      <li>",
"       Weight loss",
"      </li>",
"      <li>",
"       Pain in the back, side, or stomach",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If you have any of these symptoms, talk to your doctor or nurse.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      RENAL CELL CARCINOMA DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     If you have symptoms of renal cell carcinoma, your doctor or nurse may order a test, such as an ultrasound or CT scan, to look at the kidneys. In many cases, however, the cancer is found when one of these tests is done for another reason, and incidentally identifies an abnormal mass or growth in the kidney.",
"    </p>",
"    <p>",
"     If you have an ultrasound that shows a growth on your kidney, a CT scan will be done. The CT scan may also tell if the growth appears cancerous",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     has spread outside the kidney (called metastasis).",
"    </p>",
"    <p>",
"     Unlike other cancers, a biopsy is not always needed to be sure that you have renal cell carcinoma. Instead, the diagnosis may be based upon how the tumor looks on the CT scan. Later, the diagnosis is confirmed when the tumor or kidney is removed during surgery.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Staging",
"     </span>",
"     &nbsp;&mdash;&nbsp;Once renal cell carcinoma cancer is diagnosed, the next step is to determine its stage. Staging is a system used to describe the size, aggressiveness, and spread of a cancer. A cancer's stage helps to guide treatment and can help predict the long-term outlook.",
"    </p>",
"    <p>",
"     A renal cell carcinoma's stage is based upon:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       The size of the tumor",
"      </li>",
"      <li>",
"       Spread of the cancer to the nearby lymph nodes",
"      </li>",
"      <li>",
"       If there are signs of cancer in other organs (liver, lung, bone)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Renal cell carcinoma stages range from stage I (the tumor is smaller than 7 cm (about 3 inches) and has not spread outside the kidney) to stage IV (the tumor has spread to the outer layers of the kidney or has spread to distant lymph node(s) or other organ(s)).",
"    </p>",
"    <p>",
"     In general, lower stage cancers are less aggressive or advanced and less likely to come back after treatment compared to higher stage cancers. Stage I, II, and III renal cell carcinoma (RCC) are referred to as localized RCC while stage IV is referred to as advanced or metastatic RCC.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      LOCALIZED RENAL CELL CARCINOMA TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The preferred treatment for most people with localized renal cell carcinoma is surgery to remove part or all of the kidney and if necessary, the regional lymph nodes. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5546?source=see_link\">",
"      \"Surgical management of localized renal cell carcinoma\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The decision to remove part or all of the kidney depends upon your cancer's size, where it is located in your kidney, whether there are one or multiple tumors, and how well your kidneys work.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If you have multiple tumors or your tumor is large or located centrally within the kidney, complete removal of the kidney may be necessary, especially if your other kidney works normally (see",
"       <a class=\"local\" href=\"#H6\">",
"        'Radical nephrectomy'",
"       </a>",
"       below)",
"      </li>",
"      <li>",
"       In other situations, or if your kidneys do not work well, removing part of the kidney may be a better option (see",
"       <a class=\"local\" href=\"#H7\">",
"        'Nephron-sparing treatments'",
"       </a>",
"       below)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Radical nephrectomy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Radical nephrectomy is the medical term for a surgery that removes the entire kidney and surrounding tissues. Most people can live with only one kidney.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Nephron-sparing treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nephron-sparing treatments are treatments for renal cell carcinoma that do not remove the entire kidney. Normally, the kidneys filter waste out of the blood with tiny structures, known as nephrons. Nephron-sparing treatments allow some of the nephrons to continue working. This treatment is generally preferred if it is feasible and especially if your kidneys do not work well.",
"    </p>",
"    <p>",
"     Nephron-sparing treatments include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Surgery to remove part of the kidney (called partial nephrectomy); this is the more common treatment",
"      </li>",
"      <li>",
"       A treatment that destroys the cancer by burning it (called radiofrequency ablation) or freezing it (called cryoablation)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Treatment after surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;For people with localized renal cell carcinoma, further treatment is not usually needed after surgery. Further treatment has not been proven to decrease the chance of the cancer returning.",
"    </p>",
"    <p>",
"     However, it is important to see your doctor on a regular basis after being treated for cancer to monitor for signs that the cancer has returned. (See",
"     <a class=\"local\" href=\"#H13\">",
"      'Follow up after local treatment'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      TREATMENT OF ADVANCED RCC",
"     </span>",
"    </p>",
"    <p>",
"     For people with advanced or metastatic renal cell carcinoma, treatment with a medicine (called medical treatment) may be recommended instead of or along with surgery. Medical treatment may also be recommended if your cancer recurs after surgery.",
"    </p>",
"    <p>",
"     Surgery to remove the kidney or areas outside the kidney where the cancer has spread (metastases) may be done before medical treatment. In people with advanced RCC, surgery does not usually cure the cancer, but it may allow you to have fewer symptoms or delay systemic medical treatment.",
"    </p>",
"    <p>",
"     The three most commonly used medical treatments for advanced RCC are:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Interleukin-2 (IL-2, an immune therapy)",
"      </li>",
"      <li>",
"       Anti-angiogenic therapies, a class of medicines that reduce the blood supply to the tumor, slowing or stopping growth of the tumor",
"      </li>",
"      <li>",
"       Targeted therapies, a class of medicines that slow the growth of the cancer",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Advanced RCC is hard to cure. When possible, people with advanced RCC are encouraged to enroll in a clinical trial (see",
"     <a class=\"local\" href=\"#H14\">",
"      'Clinical trials'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Interleukin-2",
"     </span>",
"     &nbsp;&mdash;&nbsp;Interleukin-2 is a treatment that works by triggering your immune system to attack the cancer cells. The treatment is given by IV over 5 days while you are in the hospital. The treatment is repeated in 15 days, and may be repeated again 12 to 14 weeks after the first dose. IL-2 therapy can produce long term cancer control in 5 to 10 percent of patients. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link\">",
"      \"Immunotherapy of renal cell carcinoma\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Treatment with IL-2 can cause severe and even life-threatening side effects. Side effects can include low blood pressure, fever, kidney failure, and an irregular heart rhythm. As a result, IL-2 is only recommended if you are healthy enough to tolerate the side effects.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Anti-angiogenic therapies",
"     </span>",
"     &nbsp;&mdash;&nbsp;These therapies target the vascular endothelial growth factor (VEGF) pathway, a key pathway stimulating the growth of blood vessels. The tumor requires blood vessels to grow and survive. Kidney tumors depend on these blood vessels, and treatment with anti-angiogenic (anti-VEGF) therapies may slow or stop the tumor from growing for long periods of time.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Targeted therapies",
"     </span>",
"     &nbsp;&mdash;&nbsp;Targeted therapies are medicines designed to slow the growth of tumor cells. The medicines are called \"targeted\" because they work by interfering with a step in the cancer's growth process. Targeted therapies cannot cure the cancer, but they may allow you to live longer and have fewer symptoms. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=see_link\">",
"      \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Anti-angiogenic and targeted therapies are an option for people with advanced or metastatic RCC, either as an alternative to or after failing IL-2 therapy.",
"    </p>",
"    <p>",
"     The most commonly used anti-angiogenic therapies for renal cell carcinoma include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Sunitinib (Sutent)",
"      </li>",
"      <li>",
"       Sorafenib (Nexavar)",
"      </li>",
"      <li>",
"       Pazopanib (Votrient)",
"      </li>",
"      <li>",
"       Bevacizumab (Avastin)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     While targeted therapies include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Temsirolimus (Torisel)",
"      </li>",
"      <li>",
"       Everolimus (Afinitor)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Some of these medications are available as a pill that you take by mouth while others are given into an IV. These medicines are given one at a time rather than in combination. The most common side effects include rashes, being tired, and high blood pressure.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      FOLLOW UP AFTER LOCAL TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Close follow up after local treatment (radical nephrectomy or nephron sparing treatment) is important for anyone with renal cell carcinoma. Follow up visits allow your doctor to look for signs that the cancer has returned.",
"    </p>",
"    <p>",
"     During a follow up visit, you will have an exam, lab tests, and x-ray tests. Depending upon the stage of your cancer, these tests are recommended every 6 to 12 months for at least five years.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Progress in treating renal cell carcinoma requires that better treatments be identified through clinical trials, which are conducted all over the world. A clinical trial is a carefully controlled way to study new treatments or new treatment combinations. Ask for more information about clinical trials, or read about clinical trials at:",
"    </p>",
"    <p>",
"     <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/learningabout\">",
"      www.cancer.gov/clinicaltrials/learningabout",
"     </a>",
"    </p>",
"    <p>",
"     <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"      file://clinicaltrials.gov/",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1943074\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/13/11474?source=see_link\">",
"      Patient information: Kidney cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1943091\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     This topic currently has no corresponding Beyond the Basics content.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1943117\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35336?source=see_link\">",
"      Clinical manifestations, evaluation, and staging of renal cell carcinoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18250?source=see_link\">",
"      Epidemiology, pathology, and pathogenesis of renal cell carcinoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2200?source=see_link\">",
"      Diagnostic approach, differential diagnosis, and treatment of a small renal mass",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link\">",
"      Immunotherapy of renal cell carcinoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=see_link\">",
"      Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21192?source=see_link\">",
"      Prognostic factors in patients with renal cell carcinoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26310?source=see_link\">",
"      Radiofrequency ablation and cryoablation for renal cell carcinoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22630?source=see_link\">",
"      Role of surgery in patients with metastatic renal cell carcinoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5546?source=see_link\">",
"      Surgical management of localized renal cell carcinoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32360?source=see_link\">",
"      Surveillance for metastatic disease after nephrectomy for renal cell carcinoma",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/000516.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/000516.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/patient/Cancer+Types/Kidney+Cancer\">",
"      www.cancer.net/patient/Cancer+Types/Kidney+Cancer",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nci.nih.gov/cancertopics/types/kidney\">",
"      www.nci.nih.gov/cancertopics/types/kidney",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/cancer/kidneycancer/overviewguide/kidney-cancer--adult--renal-cell-carcinoma-overview-what-is-kidney-cancer\">",
"      www.cancer.org/Cancer/KidneyCancer/OverviewGuide/kidney-cancer--adult--renal-cell-carcinoma-overview-what-is-kidney-cancer",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Patient Support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Cancer Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://cancer.about.com/forum\">",
"      file://cancer.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?29/53/30546/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?29/53/30546?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30546/abstract/1\">",
"      Klapper JA, Downey SG, Smith FO, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008; 113:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30546/abstract/2\">",
"      Atkins MB. Management of advanced renal cancer. Kidney Int 2005; 67:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30546/abstract/3\">",
"      Berger A, Brandina R, Atalla MA, et al. Laparoscopic radical nephrectomy for renal cell carcinoma: oncological outcomes at 10 years or more. J Urol 2009; 182:2172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30546/abstract/4\">",
"      Thomas AA, Rini BI, Stephenson AJ, et al. Surgical resection of renal cell carcinoma after targeted therapy. J Urol 2009; 182:881.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f29_53_30546=[""].join("\n");
var outline_f29_53_30546=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           RENAL CELL CARCINOMA SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           RENAL CELL CARCINOMA DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           LOCALIZED RENAL CELL CARCINOMA TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           TREATMENT OF ADVANCED RCC",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           FOLLOW UP AFTER LOCAL TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27072\" title=\"figure 1\">",
"           Urinary tract anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f29_53_30547="Phenylephrine (topical): Drug information";
var content_f29_53_30547=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Phenylephrine (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/36/20036?source=see_link\">",
"    see \"Phenylephrine (topical): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/16/5379?source=see_link\">",
"    see \"Phenylephrine (topical): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9504772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Anu-Med [OTC];",
"     </li>",
"     <li>",
"      Formulation R&trade; [OTC];",
"     </li>",
"     <li>",
"      Medicone&reg; Suppositories [OTC];",
"     </li>",
"     <li>",
"      Preparation H&reg; [OTC];",
"     </li>",
"     <li>",
"      Rectacaine [OTC];",
"     </li>",
"     <li>",
"      Tronolane&reg; Suppository [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9508681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha-Adrenergic Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9504930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Hemorrhoids:",
"     </b>",
"     Rectal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Ointment:",
"     </i>",
"     Apply to clean, dry area up to 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Suppository:",
"     </i>",
"     Insert 1 suppository rectally up to 4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9504929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/16/5379?source=see_link\">",
"      see \"Phenylephrine (topical): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Hemorrhoids:",
"     </b>",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9504931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9505022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, rectal, as hydrochloride: 0.25% (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Formulation R&trade;: 0.25% (30 g, 60 g) [contains benzoic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preparation H&reg;: 0.25% (30 g, 60 g) [contains benzoic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal, as hydrochloride: 0.25% (1s); 0.25% (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anu-Med: 0.25% (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Medicone&reg; Suppositories: 0.25% (12s, 24s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preparation H&reg;: 0.25% (12s, 24s, 48s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectacaine: 0.25% (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tronolane&reg; Suppository: 0.25% (12s, 24s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13307666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9504812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;text-align:justify;display:inline\">",
"     For OTC use as treatment of hemorrhoids",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9504845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rare systemic effects may occur.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9504817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to phenylephrine or any component of the formulation; hypertension; ventricular tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9504818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease, including ischemic heart disease: Use caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes mellitus: Use caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Use with caution in patients with increased intraocular pressure or prostatic hyperplasia. Notify healthcare provider if symptoms do not improve within 7 days or if bleeding occurs.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9504848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11391519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered intravenously, phenylephrine crosses the placenta. Refer to the Phenylephrine (Systemic) monograph for details. There is limited information available supporting the use of topical agents for the treatment of hemorrhoids. Products containing phenylephrine should be used with caution in pregnant women, especially patients with hypertension or diabetes.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11391521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if phenylephrine is excreted into breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Formulation R Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25-3-12-18% (54 g): $4.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Formulation R Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25-3-14-71.9% (28.4 g): $4.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Preparation H Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25-3-14-71.9% (28 g): $6.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Formulation R Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25-3-85.5% (24): $8.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Medicone Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (24): $18.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Preparation H Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25-3-85.5% (24): $12.58",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9504887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potent, direct-acting alpha-adrenergic agonist with virtually no beta-adrenergic activity; produces local vasoconstriction.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9901 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.97.94.19-F6CCE2A0D3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_53_30547=[""].join("\n");
var outline_f29_53_30547=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504772\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9508681\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504930\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504929\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504931\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505022\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307666\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504812\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504845\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504817\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504818\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299871\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504848\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391519\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391521\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322414\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504887\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9901\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9901|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/7/19572?source=related_link\">",
"      Phenylephrine (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/52/21316?source=related_link\">",
"      Phenylephrine (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/10/17572?source=related_link\">",
"      Phenylephrine (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/7/23668?source=related_link\">",
"      Phenylephrine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/50/37668?source=related_link\">",
"      Phenylephrine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/13/40147?source=related_link\">",
"      Phenylephrine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/47/6903?source=related_link\">",
"      Phenylephrine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/59/33717?source=related_link\">",
"      Phenylephrine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/23/13686?source=related_link\">",
"      Phenylephrine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/36/20036?source=related_link\">",
"      Phenylephrine (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/16/5379?source=related_link\">",
"      Phenylephrine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_53_30548="Bacitracin, neomycin, polymyxin B, and hydrocortisone: Patient drug information";
var content_f29_53_30548=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bacitracin, neomycin, polymyxin B, and hydrocortisone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17413?source=see_link\">",
"     see \"Bacitracin, neomycin, polymyxin B, and hydrocortisone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/56/43908?source=see_link\">",
"     see \"Bacitracin, neomycin, polymyxin B, and hydrocortisone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cortisporin&reg; Ointment;",
"     </li>",
"     <li>",
"      Neo-Polycin&trade; HC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F138816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cortisporin&reg; Topical Ointment",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat eye infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692076",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bacitracin, neomycin, polymyxin B, hydrocortisone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705468",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Ointment:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697926",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bright lights may bother you. Wear sunglasses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705468",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Ointment:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695513",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place drug inside the lower lid. Close the eye for 1 to 2 minutes. Roll eyeball around.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695617",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 10 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11167 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-ECB61E16A9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_53_30548=[""].join("\n");
var outline_f29_53_30548=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138815\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138816\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022511\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022510\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022515\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022516\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022518\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022513\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022514\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022519\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022520\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17413?source=related_link\">",
"      Bacitracin, neomycin, polymyxin B, and hydrocortisone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/56/43908?source=related_link\">",
"      Bacitracin, neomycin, polymyxin B, and hydrocortisone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_53_30549="Jessner lymphocytic infiltration of the skin on face";
var content_f29_53_30549=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Jessner's lymphocytic infiltration of the skin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An erythematous, round plaque is present on the lateral forehead.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_53_30549=[""].join("\n");
var outline_f29_53_30549=null;
var title_f29_53_30550="Disopyramide: Pediatric drug information";
var content_f29_53_30550=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Disopyramide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"    see \"Disopyramide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/8/1157?source=see_link\">",
"    see \"Disopyramide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F161671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Norpace&reg;;",
"     </li>",
"     <li>",
"      Norpace&reg; CR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F161672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Norpace&reg;;",
"     </li>",
"     <li>",
"      Rythmodan&reg;;",
"     </li>",
"     <li>",
"      Rythmodan&reg;-LA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1052372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiarrhythmic Agent, Class I-A",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1052366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"      see \"Disopyramide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children (start with lower dose listed):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;1 year: 10-30 mg/kg/day in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-4 years: 10-20 mg/kg/day in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-12 years: 10-15 mg/kg/day in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12-18 years: 6-15 mg/kg/day in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Some patients may require initial loading dose; see product information for details",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;50 kg: 100 mg every 6 hours",
"     <b>",
"      or",
"     </b>",
"     200 mg every 12 hours (controlled release)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;50 kg: 150 mg every 6 hours",
"     <b>",
"      or",
"     </b>",
"     300 mg every 12 hours (controlled release); if no response, may increase to 200 mg every 6 hours; maximum dose required for patients with severe refractory ventricular tachycardia is 400 mg every 6 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Use lower doses (100 mg of nonsustained release every 6-8 hours) in adults with cardiomyopathy or cardiac decompensation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adult dosing adjustment in renal impairment:",
"     </b>",
"     100 mg (nonsustained release) given at the following intervals: See table",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"center\" width=\"225\">",
"     </col>",
"     <col align=\"center\" width=\"175\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Creatinine Clearance",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mL/min)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dosage Interval",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30-40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Every 8 h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15-30",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Every 12 h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;15",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Every 24 h",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F161647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 100 mg, 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norpace&reg;: 100 mg, 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, controlled release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norpace&reg; CR: 100 mg, 150 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F161632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1052377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer on an empty stomach; do not crush, break, or chew controlled release capsules, swallow whole",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1052376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of life-threatening ventricular arrhythmias; suppression and prevention of unifocal and multifocal ventricular premature complexes, coupled ventricular premature complexes, and/or paroxysmal ventricular tachycardia; also effective in the conversion and prevention of recurrence of atrial fibrillation, atrial flutter, and paroxysmal atrial tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F161724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Disopyramide may be confused with desipramine, dipyridamole",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Norpace&reg; may be confused with Norpramin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - low; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F161722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The most common adverse effects are related to cholinergic blockade. The most serious adverse effects of disopyramide are CHF and hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac conduction disturbance, chest pain CHF, edema, hypotension, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, headache, malaise, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Generalized dermatoses, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Cholesterol increased, hypokalemia, triglycerides increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal bloating, abdominal distension, anorexia, constipation, diarrhea, dry throat, flatulence, nausea, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, urinary frequency, urinary hesitancy, urinary retention, urinary urgency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscular pain, muscle weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, dry eyes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agranulocytosis, AV block, BUN increased, cholestatic jaundice, creatinine increased, depression, dysuria, gynecomastia, hepatotoxicity, hypoglycemia, insomnia, new or worsened arrhythmia (proarrhythmic effect), paresthesia, psychotic reaction, respiratory distress, thrombocytopenia, transaminases increased. Rare cases of lupus have been reported (generally in patients previously receiving procainamide), peripheral neuropathy, psychosis, toxic cutaneous blisters.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1052382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to disopyramide or any component; pre-existing second or third degree A-V block (except in patients with a functioning artificial pacemaker); congenital QT prolongation; cardiogenic shock",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1052365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with sick sinus syndrome, Wolf Parkinson White syndrome (WPW) or bundle-branch block. May increase ventricular rate in patients with atrial fibrillation or flutter who have not received digoxin. Use with caution and do not give loading dose in patients with myocarditis or other cardiomyopathy; may cause significant hypotension. Use with caution and decrease dose in patients with renal or hepatic impairment; extended release form is not recommended for patients with severe renal impairment (Cl",
"     <sub>",
"      Cr",
"     </sub>",
"     &lt;40 mL/minute). Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5947627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . In the Cardiac Arrhythmia Suppression Trial (CAST), recent (&gt;6 days but &lt;2 years ago) myocardial infarction patients with asymptomatic, nonlife-threatening ventricular arrhythmias did not benefit and may have been harmed by attempts to suppress the arrhythmia with flecainide or encainide. An increased mortality or nonfatal cardiac arrest rate (7.7%) was seen in the active treatment group compared with patients in the placebo group (3%). The applicability of the CAST results to other populations is unknown.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause or worsen CHF; may cause severe hypotension; not recommended for use in patients with uncompensated or marginally compensated CHF or hypotension unless caused by an arrhythmia. May cause significant widening (&gt;25%) of QRS complex; discontinue disopyramide if this occurs. Lengthening of QT interval and worsening of arrhythmia (including ventricular tachycardia or ventricular fibrillation) may occur; patients with quinidine-associated QT prolongation may be at higher risk; torsade de pointes may occur. Monitor patients carefully and consider discontinuation of disopyramide if QT prolongation is &gt;25% and ectopy continues. May cause heart block; reduce dosage if first-degree heart block develops; discontinue drug if second or third degree AV block or unifascicular, bifascicular, or trifascicular block develops (unless pacemaker is present).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Disopyramide may cause hypoglycemia. Significant anticholinergic activity occurs; avoid use in patients with glaucoma, myasthenia gravis, or urinary retention unless appropriate overriding measures are taken.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Serious and potentially fatal drug interactions may occur. Avoid concurrent use with other drugs known to prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval or decrease myocardial contractibility. Life-threatening interactions have been reported with concomitant use of disopyramide with clarithromycin and erythromycin. Disopyramide is not recommended for use 48 hours before or 24 hours after verapamil.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F161711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F161641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia). Management: Risk of QTc prolongation and Torsades de Pointes may be increased; consider alternative therapy when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Disopyramide may enhance the bradycardic effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EriBULin: May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Disopyramide may enhance the arrhythmogenic effect of Lidocaine (Systemic). Disopyramide may increase the serum concentration of Lidocaine (Systemic). Specifically, the unbound/free fraction of lidocaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Disopyramide may enhance the arrhythmogenic effect of Lidocaine (Topical). Disopyramide may increase the serum concentration of Lidocaine (Topical). Specifically, the unbound/free fraction of lidocaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: May enhance the QTc-prolonging effect of Disopyramide. Management: Consider alternatives to disopyramide in patients with acute lurasidone overdose.  If disopyramide treatment cannot be avoided, monitor for excessive QTc interval prolongation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May enhance the QTc-prolonging effect of Disopyramide. Macrolide Antibiotics may decrease the metabolism of Disopyramide.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia). Management: Concurrent use of propafenone with quinidine, amiodarone, or other class IA or class III antiarrhythmics should be avoided.  Treatment with such agents should be withheld for at least 5 half-lives prior to initiation of propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May enhance the adverse/toxic effect of Disopyramide. Of particular concern is the potential for profound depression of myocardial contractility.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F161643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13494698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Disopyramide levels have been reported in human fetal blood. Disopyramide may stimulate contractions in pregnant women. In a case report, disopyramide use in the third trimester resulted in painful uterine contractions after the first dose and hemorrhage after the second dose (Abbi, 1999).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1052371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, ECG, drug level; serum potassium, glucose, cholesterol, triglycerides, and liver enzymes; especially important to monitor ECG in patients with hepatic or renal disease, heart disease, or others with increased risk of adverse effects",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1052375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Atrial arrhythmias: 2.8-3.2 mcg/mL (SI: 8.3-9.4 micromoles/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ventricular arrhythmias: 3.3-7.5 mcg/mL (SI: 9.7-22 micromoles/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxic: &gt;7 mcg/mL (SI: &gt;20.7 micromoles/L)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1052364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Class IA antiarrhythmic: Decreases myocardial excitability and conduction velocity; reduces disparity in refractory period between normal and infarcted myocardium; possesses anticholinergic, peripheral vasoconstrictive and negative inotropic effects",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1052380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsules, regular:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onset of action: 30-210 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration: 1.5-8.5 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1052381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Concentration dependent, stereoselective, and ranges from 20% to 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Children: 1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver; major metabolite has anticholinergic and antiarrhythmic effects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 60% to 83%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 3.15 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 4-10 hours (mean: 6.7 hours),  increased half-life with hepatic or renal disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 40% to 60% excreted unchanged in urine and 10% to 15% in feces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance is greater and half-life shorter in children vs adults; clearance (children): 3.76 mL/minute/kg",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1052370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/8/1157?source=see_link\">",
"      see \"Disopyramide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; notify physician if urinary retention or worsening of CHF occurs; may cause dry mouth",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F161654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 1 mg/mL oral suspension may be made with a tablet and Simple Syrup, NF. Crush one 100 mg tablet in a mortar and reduce to a fine powder. Add small portions of the vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     100 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 100 mL. Label &ldquo;shake well&rdquo; and &ldquo;refrigerate&rdquo;. Stable for 28 days.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 10 mg/mL oral suspension may be made with tablets and Simple Syrup, NF. Crush ten 100 mg tablets in a mortar and reduce to a fine powder. Add small portions of the vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     100 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 100 mL. Label &ldquo;shake well&rdquo; and &ldquo;refrigerate&rdquo;. Stable for 28 days.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chiba K, Koike K, Nakamoto M, et al, &ldquo;Steady-State Pharmacokinetics and Bioavailability of Total and Unbound Disopyramide in Children With Cardiac Arrhythmias,&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 1992, 14(2):112-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/53/30550/abstract-text/1585394 /pubmed\" id=\"1585394 \" target=\"_blank\">",
"        1585394",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Echizen H, Takahashi H, Nakamura H, et al, &ldquo;Stereoselective Disposition and Metabolism of Disopyramide in Pediatric Patients,&rdquo;",
"      <i>",
"       J Pharmacol Exp Ther",
"      </i>",
"      , 1991, 259(3):953-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/53/30550/abstract-text/1762088/pubmed\" id=\"1762088\" target=\"_blank\">",
"        1762088",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13242 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-194.187.108.93-69C8FD1B77-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_53_30550=[""].join("\n");
var outline_f29_53_30550=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708704\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161671\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161672\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052372\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052366\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161647\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161632\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052377\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052376\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161724\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161722\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052382\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052365\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5947627\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161711\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161641\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161643\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13494698\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052371\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052375\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052364\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052380\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052381\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052370\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161654\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13242\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13242|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=related_link\">",
"      Disopyramide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/8/1157?source=related_link\">",
"      Disopyramide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_53_30551="Natural history of aortic stenosis in adults";
var content_f29_53_30551=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Natural history of aortic stenosis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/53/30551/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/53/30551/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/53/30551/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/53/30551/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/53/30551/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/53/30551/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/53/30551/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In individuals with normal aortic valves, the effective area of valve opening equals the cross-sectional area of the left ventricular outflow tract, which is about 3.0 to 4.0 cm",
"    <sup>",
"     2",
"    </sup>",
"    in adults. As aortic stenosis (AS) develops, a minimal valve gradient is present until the orifice area becomes less than one-half normal. The natural history of aortic stenosis therefore begins with a prolonged asymptomatic period.",
"   </p>",
"   <p>",
"    Once AS is present, serial hemodynamic examinations over periods ranging from two to nine years reveal significant (initially silent) progression in most but not all patients. This progression is manifested by a reduction in the aortic valve area and an increase in the transvalvular systolic pressure gradient. The development of symptoms is an indication for valve replacement since the prognosis in untreated symptomatic patients is poor (",
"    <a class=\"graphic graphic_figure graphicRef81124 \" href=\"UTD.htm?3/63/4094\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30551/abstract/1-6\">",
"     1-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural history, including the rate of progression of asymptomatic AS in adults, will be reviewed here. The pathophysiology and clinical features of aortic stenosis, medical therapy (including issues related to coronary artery bypass graft surgery and noncardiac surgery), and the timing of valve replacement are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=see_link\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2025?source=see_link\">",
"     \"Medical management of asymptomatic aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link\">",
"     \"Indications for valve replacement in aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimation of aortic valve area, aortic jet velocity, and transvalvular gradient by echocardiography or, less often, cardiac catheterization has been used to define patients as having mild, moderate, or severe AS (",
"    <a class=\"graphic graphic_table graphicRef65280 \" href=\"UTD.htm?17/33/17948\">",
"     table 1",
"    </a>",
"    ).",
"    <strong>",
"     Severe",
"    </strong>",
"    AS is said to be present when the calculated effective valve area is less than 1.0 cm",
"    <sup>",
"     2",
"    </sup>",
"    .",
"    <strong>",
"     Critical",
"    </strong>",
"    AS is said to be present when the calculated effective valve area is less than 0.75 cm",
"    <sup>",
"     2",
"    </sup>",
"    or the Doppler aortic jet velocity is over 5",
"    <span class=\"nowrap\">",
"     m/sec.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1208?source=see_link&amp;anchor=H16#H16\">",
"     \"Aortic valve area in aortic stenosis\", section on 'Critical valve area and severity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some consideration of body size should be included in any determination of valve area [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30551/abstract/7\">",
"     7",
"    </a>",
"    ]. However, simply normalizing for body surface area can lead to misleading conclusions, especially in obese patients. In general, somewhat lower values should be used in very small patients and somewhat higher values in very large patients.",
"   </p>",
"   <p>",
"    The term &ldquo;symptomatic AS&rdquo; refers to AS that is causing cardiac symptoms such as heart failure, anginal chest discomfort, or syncope. However, the most common symptoms in patients who are followed prospectively are nonspecific (eg, decreased exercise tolerance, dyspnea on exertion, ankle edema). Care should be taken to avoid attributing noncardiac symptoms to aortic stenosis. Dyspnea may be due to deconditioning or lung disease, ankle edema has many causes other than heart failure, and nonanginal chest or shoulder pain is not a symptom of AS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\", section on 'Symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms in patients with AS and normal left ventricular systolic function rarely occur until the valve area is &lt;1.0 cm",
"    <sup>",
"     2",
"    </sup>",
"    , the aortic jet velocity is over 4.0",
"    <span class=\"nowrap\">",
"     m/sec,",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the mean transvalvular gradient exceeds 40 mmHg. Many patients do not develop symptoms until critical valve obstruction is present, while others have symptoms when the stenosis is less severe, particularly if there is coexisting aortic regurgitation or systemic atrial hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\", section on 'Other clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2893326\">",
"    <span class=\"h1\">",
"     PROGRESSION OF ASYMPTOMATIC AS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21854343\">",
"    <span class=\"h2\">",
"     Observational studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of patients undergoing serial cardiac catheterization have identified subgroups of patients with AS with distinctly different progression rates [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30551/abstract/8-14\">",
"     8-14",
"    </a>",
"    ]. Serial echocardiography studies have provided data similar to that obtained in cardiac catheterization studies, although the time intervals between follow-up have been shorter and these studies are less prone to selection bias [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30551/abstract/15-23\">",
"     15-23",
"    </a>",
"    ]. The average rate of progression has been similar in numerous studies, but the rate of progression varies widely among individual patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30551/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The average rate of increase in the mean systolic pressure gradient is 4 to 7 mmHg per year, but some patients show an increase of as much as 15 to 19 mmHg per year.",
"     </li>",
"     <li>",
"      Valve area declines at an average rate of 0.1 cm",
"      <sup>",
"       2",
"      </sup>",
"      per year, but some patients have little or no progression and others progress more rapidly.",
"     </li>",
"     <li>",
"      Aortic jet velocity increases by an average of 0.3",
"      <span class=\"nowrap\">",
"       m/sec",
"      </span>",
"      per year, but this is also variable (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Medical University of Vienna'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with mild disease (ie, aortic jet velocity less than 3.0",
"    <span class=\"nowrap\">",
"     m/sec)",
"    </span>",
"    are unlikely to develop symptoms due to AS over the ensuing five years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30551/abstract/16\">",
"     16",
"    </a>",
"    ]. A substantial number of patients with severe AS are not yet symptomatic but these patients have low event free survival rates (56 to 63 percent at two years and 25 to 33 percent at four to five years) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30551/abstract/17,24\">",
"     17,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from observational studies of patients with asymptomatic AS suggest that peak aortic velocity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rate of progression of peak aortic velocity is associated with risk of death or aortic valve replacement. Studies at three different sites illustrate the range of predictive factors and rates of progression:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     University of Washington",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of hemodynamic factors was demonstrated in a prospective study of 123 patients with AS in whom yearly echocardiography and exercise testing were performed for a mean of 2.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30551/abstract/16\">",
"     16",
"    </a>",
"    ]. Entry criteria included an aortic jet velocity &ge;2.5",
"    <span class=\"nowrap\">",
"     m/sec",
"    </span>",
"    and the absence of symptoms due to aortic stenosis. The end point was defined as death or aortic valve surgery.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Event-free survival at one, three, and five years was 93, 62, and 26 percent, respectively (",
"      <a class=\"graphic graphic_figure graphicRef53975 \" href=\"UTD.htm?3/36/3661\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The aortic jet velocity increased by 0.32&plusmn;0.34",
"      <span class=\"nowrap\">",
"       m/sec",
"      </span>",
"      per year, the mean gradient by 7&plusmn;7 mmHg per year, and the aortic valve area decreased by 0.12&plusmn;0.19 cm",
"      <sup>",
"       2",
"      </sup>",
"      per year. Multivariate predictors of outcome were jet velocity at baseline, the rate of change of aortic jet velocity, and functional status score. Factors such as age, sex, or cause of AS were not predictive of outcome.",
"     </li>",
"     <li>",
"      The likelihood of remaining alive and free of valve surgery at two years varied inversely with disease severity as estimated from the baseline aortic jet velocity: the respective values were 84, 66, and 21 percent when the baseline aortic jet velocity was &lt;3.0, 3.0 to 4.0, and &gt;4.0",
"      <span class=\"nowrap\">",
"       m/sec,",
"      </span>",
"      respectively (",
"      <a class=\"graphic graphic_figure graphicRef67551 \" href=\"UTD.htm?6/52/6990\">",
"       figure 3",
"      </a>",
"      ). These values defined patients with mild, moderate, and severe aortic stenosis (",
"      <a class=\"graphic graphic_table graphicRef65280 \" href=\"UTD.htm?17/33/17948\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Medical University of Vienna",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective study evaluated 126 asymptomatic patients with severe aortic stenosis, defined as an aortic jet velocity &ge;4",
"    <span class=\"nowrap\">",
"     m/sec,",
"    </span>",
"    who were followed for a mean of 22 months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30551/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Event-free survival (with end point defined as death or aortic valve replacement for symptoms) was 67 percent at one year, 56 percent at two years, and 33 percent at four years.",
"     </li>",
"     <li>",
"      Only the extent of aortic valve calcification was an independent predictor of outcome. Patients with no or mild valvular calcification, compared to those with moderate or severe calcification, had significantly higher rates of event-free survival at one and four years (92 versus 60 percent and 75 versus 20 percent, respectively) (",
"      <a class=\"graphic graphic_figure graphicRef56191 \" href=\"UTD.htm?33/18/34093\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Not surprisingly, patients who had events had a higher rate of progression of stenosis. Among patients with moderate to severe calcification with increase in aortic jet velocity of &ge;0.3",
"      <span class=\"nowrap\">",
"       m/sec",
"      </span>",
"      within one year, the cardiac event rate was 79 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Investigators at this institution also prospectively followed a series of 116 asymptomatic patients with very severe AS, defined by a peak aortic jet velocity of &ge;5",
"    <span class=\"nowrap\">",
"     m/s",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30551/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Event-free survival (with the end points of death or indication for aortic valve replacement including symptoms, left ventricular systolic dysfunction, or rapid hemodynamic progression) was 64, 36, 25, 12 and 3 percent at one, two, three, four, and six years.",
"     </li>",
"     <li>",
"      Peak aortic valve velocity, but not aortic valve area, was an independent predictor of event-free survival. Patients with a peak aortic valve velocity &ge;5.5",
"      <span class=\"nowrap\">",
"       m/s",
"      </span>",
"      had event-free survivals of 44, 25, 11, and 4 percent at one, two, three, and four years compared with 76, 43, 33, and 17 percent for patients with peak aortic velocities between 5.0 and 5.5",
"      <span class=\"nowrap\">",
"       m/s.",
"      </span>",
"     </li>",
"     <li>",
"      All but seven patients had moderate to severe aortic valve calcification. Valve calcification was not associated with event-free survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Mayo Clinic",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large retrospective study included 622 patients with severe, asymptomatic aortic stenosis (peak aortic jet velocity &ge;4",
"    <span class=\"nowrap\">",
"     m/sec",
"    </span>",
"    and mean aortic valve area 0.9 cm",
"    <sup>",
"     2",
"    </sup>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30551/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The probability of remaining free of cardiac death or aortic valve replacement was 80, 63, and 25 percent at one, two, and five years; the rate of remaining free of cardiac symptoms and unoperated was 82, 67, and 33 percent at the same time points.",
"     </li>",
"     <li>",
"      Patients with peak aortic jet velocity &ge;4.5",
"      <span class=\"nowrap\">",
"       m/sec",
"      </span>",
"      had increased event rates (relative risk 1.34 for symptoms and 1.48 for valve replacement or death).",
"     </li>",
"     <li>",
"      The rate of sudden death while still asymptomatic and without surgery was less than 1 percent per year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A major limitation of this study is that among the 352 patients who underwent surgery, 131 (37 percent) were referred for surgery by their physician while they were still asymptomatic, which is not the treatment strategy recommended by current guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21857697\">",
"    <span class=\"h2\">",
"     Risk factors for progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of progression of the stenotic lesion and the time to onset of symptoms varies significantly among patients. Whether patients at high risk for rapid progression can be successfully identified remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30551/abstract/15\">",
"     15",
"    </a>",
"    ]. Several prospective series have attempted to identify risk factors for progression in asymptomatic patients (with symptomatic patients being treated surgically) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30551/abstract/16-18,24,26,27\">",
"     16-18,24,26,27",
"    </a>",
"    ]. Among the factors that may be important are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Aortic jet velocity and valve area",
"     </li>",
"     <li>",
"      Degree of valve calcification",
"     </li>",
"     <li>",
"      Response to exercise testing",
"     </li>",
"     <li>",
"      Cause of aortic stenosis",
"     </li>",
"     <li>",
"      Hypercholesterolemia",
"     </li>",
"     <li>",
"      Renal insufficiency",
"     </li>",
"     <li>",
"      Hypercalcemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other patient-related risk factors that have been identified are older age, male gender, and smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30551/abstract/28\">",
"     28",
"    </a>",
"    ]. Other valve characteristics that may have prognostic value include the energy loss index and the rate of change in aortic valve area during a cardiac cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30551/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1208?source=see_link\">",
"     \"Aortic valve area in aortic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential roles of exercise testing and brain natriuretic peptide levels in risk stratifying patients with AS are discussed separately (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link&amp;anchor=H13#H13\">",
"     \"Indications for valve replacement in aortic stenosis in adults\", section on 'Asymptomatic severe aortic stenosis'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21857839\">",
"    <span class=\"h3\">",
"     Limitations of hemodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial hemodynamic measurements alone have not been proven clinically useful in asymptomatic patients since the absolute valve area or transvalvular pressure gradient does",
"    <strong>",
"     not",
"    </strong>",
"    &nbsp;define the optimal time for valve replacement. As many as one-third patients with symptomatic AS do not have critical AS (valve area less than 0.75 cm",
"    <sup>",
"     2",
"    </sup>",
"    ). However, serial echocardiography, which also provides information about left ventricular function and associated lesions, is an important part of an integrated approach that includes a detailed history, a careful physical examination, and evaluation of exercise tolerance. Guidelines for serial monitoring are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=see_link&amp;anchor=H33#H33\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\", section on 'Echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Effect of cause of AS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three primary causes of valvular AS: a congenitally bicuspid valve with superimposed calcification (unicuspid or bicuspid); degenerative calcific disease of a trileaflet valve; and, much less common in developed countries, rheumatic valve disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\", section on 'Etiology of valvular AS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with congenital or degenerative disease, progression to valve replacement occurs earliest with a unicuspid valve, later with a bicuspid valve, and latest with a tricuspid valve. These relationships were illustrated in a study of 932 adults who underwent surgery for isolated AS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30551/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients with mitral valve replacement or mitral stenosis were excluded to ensure that patients with rheumatic valve disease were not included. Also excluded were patients with a previous aortic valvotomy, indicating severe valve obstruction due to congenital disease.",
"   </p>",
"   <p>",
"    An anatomically abnormal valve was present in 54 percent: 49 percent had a bicuspid valve and 4 percent had a unicuspid valve, but the frequency varied importantly with age:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 7 percent of patients who underwent surgery at &le;50 years of age, approximately two-thirds had a bicuspid valve and one-third had a unicuspid valve. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=see_link\">",
"       \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among the 40 percent of patients who underwent surgery between the ages of 50 and 70, approximately two-thirds had a bicuspid valve and one-third a tricuspid valve; only rare patients had a unicuspid valve.",
"     </li>",
"     <li>",
"      Among the remaining patients over age 70, approximately 60 percent had a tricuspid valve and 40 percent had a bicuspid valve. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34377?source=see_link&amp;anchor=H2#H2\">",
"       \"Valvular heart disease in elderly adults\", section on 'Aortic stenosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21858414\">",
"    <span class=\"h4\">",
"     Aortic valve sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic valve thickening (sclerosis) without stenosis is common in elderly adults. It is typically detected either as a systolic murmur on physical examination or by echocardiography, and is associated with increased cardiovascular mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38279?source=see_link\">",
"     \"Aortic valve sclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aortic sclerosis may progress to significant AS. In a review of 2131 patients with aortic valve thickening detected on echocardiography, AS developed in 338 (16 percent) after seven years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30551/abstract/32\">",
"     32",
"    </a>",
"    ]. The stenosis was mild to moderate in 84 percent of these patients and severe in 16 percent. Only mitral annular calcification was significantly associated with progression in multivariable analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hypercholesterolemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association with hypercholesterolemia suggests that the valve lesion in AS may simulate atheroma (as may aortic valve sclerosis) and that its progression may be related to known atherosclerotic risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30551/abstract/18,28,33\">",
"     18,28,33",
"    </a>",
"    ]. These observations provided the rationale for evaluating statin therapy in patients with aortic stenosis, which is thus far of unproven benefit. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2025?source=see_link&amp;anchor=H4#H4\">",
"     \"Medical management of asymptomatic aortic stenosis in adults\", section on 'Hypercholesterolemia and statin therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other predictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to these risk factors, it has been suggested that asymptomatic patients at increased risk for developing symptoms in the next year can be identified by exercise testing and measurement of the plasma concentration of brain natriuretic peptide or N-terminal pro-BNP. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link&amp;anchor=H17#H17\">",
"     \"Indications for valve replacement in aortic stenosis in adults\", section on 'Possible role of exercise testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link&amp;anchor=H18#H18\">",
"     \"Indications for valve replacement in aortic stenosis in adults\", section on 'Possible role of brain natriuretic peptide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21854682\">",
"    <span class=\"h1\">",
"     PROGNOSIS OF SYMPTOMATIC AS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with symptomatic severe AS who do not undergo valve replacement have a poor prognosis (",
"    <a class=\"graphic graphic_figure graphicRef81124 \" href=\"UTD.htm?3/63/4094\">",
"     figure 1",
"    </a>",
"    ). Mortality in patients with AS dramatically increases after the development of the cardiac symptoms (",
"    <a class=\"graphic graphic_figure graphicRef81124 \" href=\"UTD.htm?3/63/4094\">",
"     figure 1",
"    </a>",
"    ). As a result, prompt valve replacement is recommended in such patients (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link&amp;anchor=H5#H5\">",
"     \"Indications for valve replacement in aortic stenosis in adults\", section on 'Symptomatic patients'",
"    </a>",
"    ). Poor clinical outcomes in symptomatic AS patients were documented in early studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30551/abstract/1-3,13\">",
"     1-3,13",
"    </a>",
"    ], and have continued to be observed in later series of medically treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30551/abstract/1,4-6\">",
"     1,4-6",
"    </a>",
"    ]. In later series, some medically treated symptomatic patients underwent balloon aortic valvuloplasty for palliation, but their clinical outcomes were likely not substantially changed by this procedure which has been shown not to improve prognosis in adults with severe AS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39411?source=see_link&amp;anchor=H114805108#H114805108\">",
"     \"Percutaneous aortic valvotomy\", section on 'Limitations'",
"    </a>",
"    .) The high mortality rates observed in symptomatic patients who do not undergo valve replacement may be in part due to comorbidities that preclude surgery.",
"   </p>",
"   <p>",
"    The following examples demonstrate the high mortality rate associated with severe symptomatic AS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A review of studies performed during 1913 to 1970 found that mean survival after onset of heart failure ranged from 0.5 to 2.8 years, after onset of syncope ranged from 0.8 to 3.8 years, and after onset of angina ranged from 2 to 4.7 years [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30551/abstract/13\">",
"       13",
"      </a>",
"      ]. Studies performed during 1967 to 1982 reported two-year actuarial mortality rates of 24 to 69 percent in patients with New York Heart Association functional class III to IV symptoms.",
"     </li>",
"     <li>",
"      In the PARTNER trial, 179 patients with AS with heart failure symptoms were assigned to the standard therapy arm [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30551/abstract/5\">",
"       5",
"      </a>",
"      ]. The majority of these patients received balloon aortic valvuloplasty (64 percent during the first 30 days and 20 percent later). The mortality rate at one year was 51 percent in this group.",
"     </li>",
"     <li>",
"      In an observational study of symptomatic AS patients not eligible for a transcatheter aortic valve implantation trial, 274 patients received medical treatment (including balloon aortic valvuloplasty in 65 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30551/abstract/6\">",
"       6",
"      </a>",
"      ]. Mortality was 32 percent during median follow-up of one year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21856010\">",
"    <span class=\"h2\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary hypertension (pulmonary artery pressure &gt;30 mmHg) commonly occurs in symptomatic patients with AS and is associated with a more severe clinical picture and a poor prognosis after aortic valve replacement.",
"   </p>",
"   <p>",
"    These relationships were illustrated in a study of 388 symptomatic patients with isolated AS who underwent cardiac catheterization; pulmonary hypertension was absent in 35 percent, mild to moderate pulmonary hypertension (defined as pulmonary artery systolic pressure 31 to 50 mmHg) was present in 50 percent and severe pulmonary hypertension in 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30551/abstract/34\">",
"     34",
"    </a>",
"    ]. The only factors associated with severe pulmonary hypertension were overt heart failure and elevated left ventricular end-diastolic pressure; neither the aortic valve area nor the left ventricular ejection fraction was related to the pulmonary artery pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"     \"Overview of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/53/36690?source=see_link\">",
"       \"Patient information: Aortic stenosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The classic symptoms of AS are heart failure, angina, and syncope. However, the most common symptoms in patients who are followed prospectively are nonspecific (eg, decreased exercise tolerance and dyspnea on exertion) so care must be taken in attributing these symptoms to AS. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AS develops at a younger age in patients with bicuspid aortic valve as compared to those with tricuspid aortic valve but there is substantial overlap in age ranges. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Effect of cause of AS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hemodynamic progression of AS is variable. The aortic valve area declines at an average rate of 0.1 cm",
"      <sup>",
"       2",
"      </sup>",
"      per year but some patients have little or no progression and others progress more rapidly. (See",
"      <a class=\"local\" href=\"#H2893326\">",
"       'Progression of asymptomatic AS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Data from observational studies of patients with asymptomatic AS suggest that peak aortic velocity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rate of progression of peak aortic velocity is associated with risk of death or aortic valve replacement. (See",
"      <a class=\"local\" href=\"#H21854343\">",
"       'Observational studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serial hemodynamic measurements alone have not been proven clinically useful in asymptomatic patients since the absolute valve area or transvalvular pressure gradient are",
"      <strong>",
"       not",
"      </strong>",
"      &nbsp;closely related to the onset of symptoms nor do they define the optimal time for valve replacement. (See",
"      <a class=\"local\" href=\"#H21857839\">",
"       'Limitations of hemodynamics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mortality in patients with AS dramatically increases after the development of the cardiac symptoms (",
"      <a class=\"graphic graphic_figure graphicRef81124 \" href=\"UTD.htm?3/63/4094\">",
"       figure 1",
"      </a>",
"      ) (See",
"      <a class=\"local\" href=\"#H21854682\">",
"       'Prognosis of symptomatic AS'",
"      </a>",
"      above.). Prompt valve replacement is recommended in such patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link&amp;anchor=H5#H5\">",
"       \"Indications for valve replacement in aortic stenosis in adults\", section on 'Symptomatic patients'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13488475\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. Schick for his contributions as an author to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/1\">",
"      Chizner MA, Pearle DL, deLeon AC Jr. The natural history of aortic stenosis in adults. Am Heart J 1980; 99:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/2\">",
"      Ross J Jr, Braunwald E. Aortic stenosis. Circulation 1968; 38:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/3\">",
"      Schwarz F, Baumann P, Manthey J, et al. The effect of aortic valve replacement on survival. Circulation 1982; 66:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/4\">",
"      Kitai T, Honda S, Okada Y, et al. Clinical outcomes in non-surgically managed patients with very severe versus severe aortic stenosis. Heart 2011; 97:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/5\">",
"      Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/6\">",
"      Ben-Dor I, Pichard AD, Gonzalez MA, et al. Correlates and causes of death in patients with severe symptomatic aortic stenosis who are not eligible to participate in a clinical trial of transcatheter aortic valve implantation. Circulation 2010; 122:S37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/7\">",
"      Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/8\">",
"      Cheitlin MD, Gertz EW, Brundage BH, et al. Rate of progression of severity of valvular aortic stenosis in the adult. Am Heart J 1979; 98:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/9\">",
"      Wagner S, Selzer A. Patterns of progression of aortic stenosis: a longitudinal hemodynamic study. Circulation 1982; 65:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/10\">",
"      Cha SD, Naeem SM, Maranhao V, Gooch AS. Sequential study of left ventricular function in aortic valvular stenosis. Cathet Cardiovasc Diagn 1982; 8:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/11\">",
"      Jonasson R, Jonsson B, Nordlander R, et al. Rate of progression of severity of valvular aortic stenosis. Acta Med Scand 1983; 213:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/12\">",
"      Nestico PF, DePace NL, Kimbiris D, et al. Progression of isolated aortic stenosis: analysis of 29 patients having more than 1 cardiac catheterization. Am J Cardiol 1983; 52:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/13\">",
"      Turina J, Hess O, Sepulcri F, Krayenbuehl HP. Spontaneous course of aortic valve disease. Eur Heart J 1987; 8:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/14\">",
"      Davies SW, Gershlick AH, Balcon R. Progression of valvar aortic stenosis: a long-term retrospective study. Eur Heart J 1991; 12:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/15\">",
"      Faggiano P, Aurigemma GP, Rusconi C, Gaasch WH. Progression of valvular aortic stenosis in adults: literature review and clinical implications. Am Heart J 1996; 132:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/16\">",
"      Otto CM, Burwash IG, Legget ME, et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 1997; 95:2262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/17\">",
"      Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000; 343:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/18\">",
"      Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation 2000; 101:2497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/19\">",
"      Otto CM, Pearlman AS, Gardner CL. Hemodynamic progression of aortic stenosis in adults assessed by Doppler echocardiography. J Am Coll Cardiol 1989; 13:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/20\">",
"      Roger VL, Tajik AJ, Bailey KR, et al. Progression of aortic stenosis in adults: new appraisal using Doppler echocardiography. Am Heart J 1990; 119:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/21\">",
"      Faggiano P, Ghizzoni G, Sorgato A, et al. Rate of progression of valvular aortic stenosis in adults. Am J Cardiol 1992; 70:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/22\">",
"      Peter M, Hoffmann A, Parker C, et al. Progression of aortic stenosis. Role of age and concomitant coronary artery disease. Chest 1993; 103:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/23\">",
"      Brener SJ, Duffy CI, Thomas JD, Stewart WJ. Progression of aortic stenosis in 394 patients: relation to changes in myocardial and mitral valve dysfunction. J Am Coll Cardiol 1995; 25:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/24\">",
"      Pellikka PA, Sarano ME, Nishimura RA, et al. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation 2005; 111:3290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/25\">",
"      Rosenhek R, Zilberszac R, Schemper M, et al. Natural history of very severe aortic stenosis. Circulation 2010; 121:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/26\">",
"      Bahler RC, Desser DR, Finkelhor RS, et al. Factors leading to progression of valvular aortic stenosis. Am J Cardiol 1999; 84:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/27\">",
"      Pohle K, M&auml;ffert R, Ropers D, et al. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation 2001; 104:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/28\">",
"      Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005; 111:3316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/29\">",
"      Garcia D, Pibarot P, Dumesnil JG, et al. Assessment of aortic valve stenosis severity: A new index based on the energy loss concept. Circulation 2000; 101:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/30\">",
"      Lester SJ, McElhinney DB, Miller JP, et al. Rate of change in aortic valve area during a cardiac cycle can predict the rate of hemodynamic progression of aortic stenosis. Circulation 2000; 101:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/31\">",
"      Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation 2005; 111:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/32\">",
"      Cosmi JE, Kort S, Tunick PA, et al. The risk of the development of aortic stenosis in patients with \"benign\" aortic valve thickening. Arch Intern Med 2002; 162:2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/33\">",
"      Agmon Y, Khandheria BK, Meissner I, et al. Aortic valve sclerosis and aortic atherosclerosis: different manifestations of the same disease? Insights from a population-based study. J Am Coll Cardiol 2001; 38:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30551/abstract/34\">",
"      Faggiano P, Antonini-Canterin F, Ribichini F, et al. Pulmonary artery hypertension in adult patients with symptomatic valvular aortic stenosis. Am J Cardiol 2000; 85:204.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8165 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-118.97.94.19-A006EFEBA2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_53_30551=[""].join("\n");
var outline_f29_53_30551=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2893326\">",
"      PROGRESSION OF ASYMPTOMATIC AS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21854343\">",
"      Observational studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - University of Washington",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Medical University of Vienna",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Mayo Clinic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21857697\">",
"      Risk factors for progression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21857839\">",
"      - Limitations of hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Effect of cause of AS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21858414\">",
"      Aortic valve sclerosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hypercholesterolemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other predictors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21854682\">",
"      PROGNOSIS OF SYMPTOMATIC AS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21856010\">",
"      Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13488475\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8165\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8165|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/63/4094\" title=\"figure 1\">",
"      Natural history of AS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/36/3661\" title=\"figure 2\">",
"      Survival in asymptomatic AS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/52/6990\" title=\"figure 3\">",
"      AS survival and jet velocity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/18/34093\" title=\"figure 4\">",
"      Outcome AS valve calcification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8165|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/33/17948\" title=\"table 1\">",
"      Severity of AS in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1208?source=related_link\">",
"      Aortic valve area in aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38279?source=related_link\">",
"      Aortic valve sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=related_link\">",
"      Clinical features and evaluation of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=related_link\">",
"      Clinical manifestations and diagnosis of bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=related_link\">",
"      Indications for valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2025?source=related_link\">",
"      Medical management of asymptomatic aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/53/36690?source=related_link\">",
"      Patient information: Aortic stenosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39411?source=related_link\">",
"      Percutaneous aortic valvotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34377?source=related_link\">",
"      Valvular heart disease in elderly adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_53_30552="Overview and differential diagnosis of papilledema";
var content_f29_53_30552=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview and differential diagnosis of papilledema",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/53/30552/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/53/30552/contributors\">",
"     Don C Bienfang, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/53/30552/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/53/30552/contributors\">",
"     Paul W Brazis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/53/30552/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/53/30552/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/53/30552/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the term papilledema is often used broadly to denote a swollen optic nerve head, the term papilledema should be reserved for optic disc swelling that is due to raised intracranial pressure.",
"   </p>",
"   <p>",
"    This topic will provide an overview and differential diagnosis of papilledema. The entity of increased intracranial pressure and specific causes of papilledema are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGIES AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Papilledema occurs when raised intracranial pressure is transmitted to the optic nerve sheath. The raised pressure mechanically disrupts axoplasmic flow within the nerve. Obstipation of intra-axonal fluid results in swelling of the axons and leakage of water, protein, and other cellular contents into the extracellular space of the optic disc giving rise to optic disc edema [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Venous obstruction and dilation, nerve fiber ischemia, and vascular telangiectasias are secondary phenomena.",
"   </p>",
"   <p>",
"    Any entity that increases intracranial pressure may lead to papilledema. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intracranial mass lesions (eg, tumor, hematoma)",
"     </li>",
"     <li>",
"      Cerebral edema (such as in acute hypoxic ischemic encephalopathy, large cerebral infarction, severe traumatic brain injury)",
"     </li>",
"     <li>",
"      Increased cerebrospinal fluid (CSF) production, eg, choroid plexus papilloma",
"     </li>",
"     <li>",
"      Decreased CSF absorption, eg, arachnoid granulation adhesions after bacterial meningitis",
"     </li>",
"     <li>",
"      Obstructive hydrocephalus",
"     </li>",
"     <li>",
"      Obstruction of venous outflow, eg, venous sinus thrombosis, jugular vein compression, neck surgery",
"     </li>",
"     <li>",
"      Idiopathic intracranial hypertension (pseudotumor cerebri)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rarer entities causing increased intracranial pressure include increased arterial inflow as from an arteriovenous fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], intraspinal lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], chronic respiratory illness [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], and other toxic metabolic conditions that cause diffuse cerebral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/9\">",
"     9",
"    </a>",
"    ]. Reported cases of papilledema in acute or chronic inflammatory demyelinating neuropathy may represent a consequence of elevated CSF protein, which may impair resorption or circulation of CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/10-13\">",
"     10-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Idiopathic intracranial hypertension (pseudotumor cerebri) is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15769?source=see_link\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=see_link\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/54/41833?source=see_link\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Papilledema is usually discovered when a patient is evaluated for other symptoms of increased intracranial pressure, rather than for symptoms directly resulting from optic nerve pathology.",
"   </p>",
"   <p>",
"    Because the causes of intracranial hypertension are generalized phenomena, papilledema is almost universally bilateral, although it may be asymmetric. If there is underlying optic nerve injury or disease, then the appearance of papilledema may be unilateral, since the damaged nerve does not swell. The classic example is the Foster Kennedy syndrome in which a frontal lobe tumor compresses and destroys the optic nerve on one side before causing increased intracranial pressure. This gives rise to optic atrophy in one eye and disc edema in the other.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Symptoms of increased intracranial pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache is a cardinal symptom of increased intracranial pressure. However, few features of the headache specifically point to intracranial hypertension as a cause. Nausea and vomiting are frequent in this setting, but they are also a manifestation of migraine. Worrisome features include a positional quality to the headache, usually worsening with recumbency, as well as a diurnal pattern; headaches associated with intracranial hypertension are classically worse in early morning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another classic symptom of increased intracranial pressure is binocular horizontal diplopia resulting from unilateral or bilateral lateral rectus paresis. Cranial nerve six, the abducens nerve, is believed to be peculiarly vulnerable to the effects of increased intracranial pressure because of its long course in the subarachnoid space and its bend to enter the cavernous sinus.",
"   </p>",
"   <p>",
"    A pulsatile machinery-like sound in the ear, probably due to venous sinus obstruction, is also common and often persistent even after the raised intracranial pressure is relieved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Visual symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;While rarely the presenting symptom, visual symptoms are common in patients with papilledema. These are typically visual obscurations that clear completely, are often unilateral, and typically very brief (just seconds) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/14\">",
"     14",
"    </a>",
"    ]. They may occur spontaneously or with changes in position, and they are believed to represent transient fluctuations in nerve head perfusion. Their presence correlates with the degree of intracranial pressure elevation. Increasing intensity, frequency, and duration of these symptoms can be a prognostic sign for visual loss, but this symptom is not reliably predictive.",
"   </p>",
"   <p>",
"    It is unusual for patients to have persistent deficits of visual acuity or field loss until quite late in the course. Untreated, chronic papilledema can lead to progressive visual field loss in the form of peripheral field contraction, nerve fiber bundle defects, and even blindness [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The field loss often mimics the field loss of glaucoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fundoscopic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the findings in papilledema evolve over time, ophthalmologists often characterize papilledema into stages: early, fully developed, and chronic or late.",
"   </p>",
"   <p>",
"    Clinicians often photograph patients' fundi in order to follow changes in the examination and monitor response to treatment. Another approach might be to use a grading scheme, but these have not been well validated or universally accepted [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Early",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the earliest findings in papilledema is loss of spontaneous venous pulsations, occurring with pressure elevations of only 200 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/18-28\">",
"     18-28",
"    </a>",
"    ]. This is a sensitive rather than specific sign, as 20 percent of normal individuals do not have detectable venous pulsations. These pulsations are best seen in the section of the central retinal vein that is diving into the optic nerve cup.",
"   </p>",
"   <p>",
"    The optic cup is retained early on. However, splinter hemorrhages in the nerve fiber layer, at or beyond the disc margin, may be seen early. This is also a nonspecific sign, especially in older patients (",
"    <a class=\"graphic graphic_picture graphicRef72814 \" href=\"UTD.htm?17/53/18256\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Fully developed",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the edema progress, the optic disc becomes elevated, the cup is obliterated, and the disc margins become obscured. Blood vessels are buried as they course the disc. Serpentine engorgement of retinal veins is evident, and the disc appears hyperemic. The edema extends into the retina, giving the appearance of an enlarged optic nerve head. Multiple flame hemorrhages and cotton wool spots, resulting from nerve fiber infarction, appear. Retinal microfolds form around the swollen disc. At this stage, the blind spot will be increased (",
"    <a class=\"graphic graphic_picture graphicRef64616 \" href=\"UTD.htm?11/23/11632\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Chronic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The central cup remains obliterated. Hemorrhagic and exudative components resolve. The appearance of hard exudates in the nerve fiber layer indicate a process of some months duration. The nerve now appears flat with irregular margins; nerve fiber attrition leads to disc pallor (",
"    <a class=\"graphic graphic_picture graphicRef68815 \" href=\"UTD.htm?37/14/38126\">",
"     picture 3",
"    </a>",
"    ). One usually can detect some loss of visual field at this stage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many causes of an elevated optic nerve head. While the term papilledema is sometimes used to describe the findings in these conditions, it should be reserved for patients who have elevated disc heads as a consequence of increased intracranial pressure. The causes of papilledema (ie, increased intracranial pressure) are listed above (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Etiologies and pathogenesis'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    While there is overlap between the two categories, it is useful to consider those conditions that cause bilateral abnormalities versus those that are more usually unilateral (",
"    <a class=\"graphic graphic_table graphicRef54401 \" href=\"UTD.htm?21/28/21963\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Bilateral disc abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fundoscopic findings, the clinical setting, and the presence of associated visual loss may help distinguish the following entities from true papilledema.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pseudopapilledema &mdash; Congenital anomalies of the disc, including drusen and myelinated nerve fibers, and even farsightedness or hyperopia may cause the appearance of disc swelling or pseudopapilledema. This term is reserved for conditions that are not due to disease states.",
"      <br/>",
"      <br/>",
"      Drusen are hyaline bodies thought to be remnants of calcific axonal degeneration. Drusen tend to be buried in children (sometimes raising concern for increased intracranial pressure) and become more exposed in adults. Most, 75 to 85 percent, are bilateral [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. Present in about 2 percent of the population, they may be inherited as an autosomal dominant condition. Usually asymptomatic, some will have measurable visual field abnormalities, including enlarged blind spot, field constriction, and inferior nasal visual field loss. An afferent pupillary defect may be present if the condition is unilateral or asymmetric.",
"      <br/>",
"      <br/>",
"      Disc drusen appear as a lumpy mass with refractile bodies within (",
"      <a class=\"graphic graphic_picture graphicRef72232 \" href=\"UTD.htm?4/13/4304\">",
"       picture 4",
"      </a>",
"      ). Another anomaly, myelinated nerve fibers are white, cover the underlying retina, and have scalloped edges. In contrast to papilledema, the appearance of the nerve fiber layer in pseudopapilledema appears normal, not hazy. The absence of spontaneous venous pulsations is not useful here, as they are often absent in pseudopapilledema. Other clues to the presence of a congenital anomaly are an absent portion (often nasal) of the nerve head and unusual patterns of the blood vessels as they emerge from the nerve head [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/31\">",
"       31",
"      </a>",
"      ]. Other signs of true papilledema, cotton wool spots, hemorrhages, hyperemia, and venous congestion are absent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/29\">",
"       29",
"      </a>",
"      ]. CT scanning, ultrasonography and optical coherence tomography clarify the diagnosis of drusen by revealing calcium deposits not visible on visual examination.",
"     </li>",
"     <li>",
"      Malignant hypertension &mdash; Severe systemic hypertension can cause a change in the optic nerve head that resembles papilledema. However, the swelling of the nerve head is usually mild. Recognizable hypertensive changes are seen in the vessels away from the nerve head in the posterior pole. These include hemorrhages, exudates, cotton wool spots, and even a \"star\" figure pointing to the fovea (",
"      <a class=\"graphic graphic_picture graphicRef78225 \" href=\"UTD.htm?38/27/39359\">",
"       picture 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef57183 \" href=\"UTD.htm?18/44/19136\">",
"       picture 6",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. The optic nerve functions well, but damage to the retina can compromise vision and produce scotomata, dimming in vision, diplopia, and photopsia [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link\">",
"       \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21859?source=see_link\">",
"       \"Ocular effects of hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diabetic papillopathy &mdash; While relatively benign, this is a troublesome entity to diagnose because it mimics both papilledema from raised intracranial pressure and anterior ischemic optic neuropathy (AION). Optic edema may vary from minimal to extensive with telangiectasias, hemorrhages, and macular star (",
"      <a class=\"graphic graphic_picture graphicRef63843 \" href=\"UTD.htm?37/29/38367\">",
"       picture 7",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/35\">",
"       35",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      When diabetic papillopathy is bilateral or occurs in a young juvenile diabetic as traditionally described, it is not likely to be mistaken for AION [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. However, many cases are described in the literature in which the pathology is unilateral and the patient older. The prognosis is good, but during the acute phase there may be loss of central vision, enlarged blind spots, or field defects. These usually resolve. Impaired visual acuity is rare. Ischemia of the optic nerve is considered to be the probable mechanism; this process is independent of the diabetic retinopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/37\">",
"       37",
"      </a>",
"      ]. The prognosis might be worse in older patients with type II diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/38\">",
"       38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44293?source=see_link\">",
"       \"Diabetic papillopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Others &mdash; Hyperviscosity, hypotension, and blood loss have been reported to cause bilateral disc edema [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/39\">",
"       39",
"      </a>",
"      ]. Toxic optic neuropathies producing papilledema early in their course have been described with methanol,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      , ethylene glycol, and other toxins [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/9\">",
"       9",
"      </a>",
"      ]. Optic atrophy emerges more rapidly in these conditions while it tends to appear later in chronic papilledema. Bilateral disc edema may result from optic nerve compression by infiltrated extraocular muscles in severe thyroid ophthalmopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Unilateral disc abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the entities that cause unilateral disc elevation can be broadly classified into ischemic, inflammatory, and infiltrative lesions. Because they are usually unilateral, they are not confused with true papilledema. However, in some situations, as noted below, these can be bilateral and raise concern for papilledema. Similarly, in some patients papilledema may be sufficiently asymmetric as to seem unilateral.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anterior ischemic optic neuropathy &mdash; Anterior ischemic optic neuropathy (AION) may be arteritic (eg, giant cell arteritis) or nonarteritic [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/28\">",
"       28",
"      </a>",
"      ]. The latter occurs in older individuals and has been associated with atherosclerotic risk factors, particularly hypertension and diabetes. Nonarteritic AION has also been described in patients treated with phosphodiesterase-5 inhibitors such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/58/27558?source=see_link\">",
"       \"Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20442?source=see_link\">",
"       \"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=see_link&amp;anchor=H9#H9\">",
"       \"Treatment of male sexual dysfunction\", section on 'Visual effects'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"       \"Clinical manifestations of giant cell (temporal) arteritis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      AION is almost always unilateral except in giant cell arteritis. There is always immediate loss of some or all of the vision; altitudinal defects are classic. An afferent pupillary defect is common. Prognosis for vision recovery is poor.",
"      <br/>",
"      <br/>",
"      The swelling is not congested as it is with raised intracranial pressure but is usually pallid; if there are hemorrhages, they are small splinter shaped on the edge of the disk [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Papillitis, neuroretinitis &mdash; Papillitis is optic neuritis of the anterior portion of the optic nerve. It does not have the same implications as retrobulbar neuritis to the underlying etiology. For papillitis, the underlying causes are much broader, while retrobulbar neuritis is usually due to demyelinating disease or multiple sclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/41\">",
"       41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=see_link&amp;anchor=H10#H10\">",
"       \"Epidemiology and clinical features of multiple sclerosis in adults\", section on 'Optic neuritis'",
"      </a>",
"      .) When there is associated inflammation in the retina, as manifest by macular exudates, it is called neuroretinitis, and it is virtually never demyelinating in origin. Causes include viral syndromes, toxoplasmosis, cat scratch disease, sarcoidosis, syphilis, Lyme disease, and other vasculitides including systemic lupus erythematosus and Wegener's granulomatosis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/42-46\">",
"       42-46",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Papillitis is almost always unilateral. There is loss of vision, and the pupillary light reflex is abnormal in the affected eye. Pain, especially with eye movement, is common.",
"      <br/>",
"      <br/>",
"      On funduscopic examination, the nerve is diffusely swollen and congested. There are few hemorrhages, but there may be some cells in the vitreous just in front of the nerve and, in some cases, a group of yellow-white linear deposits pointing like the spokes of a wheel around the fovea of the retina (",
"      <a class=\"graphic graphic_picture graphicRef67875 \" href=\"UTD.htm?7/23/7536\">",
"       picture 8",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Sarcoidosis &mdash; Optic nerve involvement is rarely the initial presentation of sarcoidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/47\">",
"       47",
"      </a>",
"      ]. Sarcoidosis can affect the meninges and cause true papilledema. Some patients may present with a solitary sarcoid nodule of the nerve head. A yellowish mass is seen often with other typical lesions of sarcoid in the retina, conjunctiva, or anterior chamber. This is almost always unilateral. There may be loss of vision associated with this mass; occasionally, patients will be asymptomatic [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/48\">",
"       48",
"      </a>",
"      ]. Other patients with sarcoid can develop disc swelling from vasculitis, uveitis, or more subtle infiltration of the optic nerve head. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20616?source=see_link\">",
"       \"Neurologic sarcoidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Central retinal vein occlusion &mdash; Occlusion or thrombosis of the central retinal vein is associated with chronic glaucoma, atherosclerotic risk factors (age, diabetes, hypertension), hyperviscosity, and coagulopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/49\">",
"       49",
"      </a>",
"      ]. The cause is often unknown. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4311?source=see_link\">",
"       \"Retinal vein occlusion: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The disc is typically mildly congested. Hemorrhages are prominent and extend far beyond the posterior pole of the eye into the retinal periphery; these are much more extensive than in papilledema. Vision loss corresponds to the hemorrhages and any superimposed retinal ischemia (",
"      <a class=\"graphic graphic_picture graphicRef72976 \" href=\"UTD.htm?32/53/33616\">",
"       picture 9",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Papillophlebitis &mdash; This presumed inflammatory condition occurs in young people and has a good prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/51\">",
"       51",
"      </a>",
"      ]. The nerve is swollen. Funduscopic examination suggests a mild central retinal vein occlusion. Enlargement of the blind spot correlates with the amount of retinal hemorrhage in the macula [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/52\">",
"       52",
"      </a>",
"      ]. Spontaneous improvement is common.",
"     </li>",
"     <li>",
"      Malignancy &mdash; Metastatic tumors rarely invade the nerve head. Breast and lung cancers are the most common culprits; others include meningioma, glioma, hamartoma, dermoid tumors, lymphoma, and leukemia [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/53,54\">",
"       53,54",
"      </a>",
"      ]. The nerve head appears to be destroyed by the invading tissue (",
"      <a class=\"graphic graphic_picture graphicRef73722 \" href=\"UTD.htm?23/9/23711\">",
"       picture 10",
"      </a>",
"      ). Little of the normal architecture remains. When invasion or compression of the optic nerve occurs more posteriorly, it can appear similar to raised intracranial pressure. There is progressive loss of vision in all cases [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/55\">",
"       55",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/16/39176?source=see_link\">",
"       \"Optic pathway glioma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Leber's hereditary optic neuropathy &mdash; At the onset of the expression of this hereditary condition the optic nerve head appears to be modestly elevated [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/56\">",
"       56",
"      </a>",
"      ]. It usually starts out in only one eye but eventually affects both. The blood vessels around the nerve have a telangiectatic appearance; however, this finding needs to be looked for carefully to be seen. There are no hemorrhages. Vision loss is always present. Profound optic atrophy then develops. In most cases, there is a history of this condition in the family. Genetic testing can confirm the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=see_link&amp;anchor=H23#H23\">",
"       \"Hereditary neuropathies associated with generalized disorders\", section on 'Leber hereditary optic neuropathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other causes &mdash; Disc swelling from low intraocular pressure or chronic intraocular inflammation may be seen after eye surgery (cataract surgery or glaucoma) or after injuries (often iatrogenic) to the globe [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/57\">",
"       57",
"      </a>",
"      ]. They are always unilateral and easily confirmed by measuring the eye pressure and the slit lamp examination.",
"      <br/>",
"      <br/>",
"      An optic neuropathy occurring 6 to 24 months after radiation therapy is often associated with disc edema at onset [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H32#H32\">",
"       \"Complications of cranial irradiation\", section on 'Optic neuropathy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic testing can help differentiate papilledema from other causes of disc edema, follow the course of papilledema, and determine the underlying etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a patient presents with findings suggestive of papilledema, diagnostic evaluation should proceed expeditiously. The first step is neuroimaging of the brain. MRI with gadolinium contrast is generally preferred, but CT scan can be ordered initially if access to MRI is delayed. MRI will detect intracranial mass lesions and hydrocephalus. Additional sequences, magnetic resonance venography (MRV), can be used to detect venous obstruction in the dural sinuses and in the neck. Rarely, increased intracranial pressure may arise from spinal lesions; therefore, if this diagnosis is suggested by clinical signs or symptoms (back or neck pain, myelopathic signs, abnormal spinal fluid) an MRI of the spine should be ordered as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;If neuroimaging is normal, lumbar puncture should be done for opening pressure and analysis. The technique of measuring the opening pressure is described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19561?source=see_link\">",
"     \"Lumbar puncture: Technique; indications; contraindications; and complications in adults\"",
"    </a>",
"    .) Using correct technique, elevated pressure is defined as greater than 250 mmH20; measures between 200 and 250 mmH2O are considered equivocal. What constitutes normal pressure levels in children is still a matter of debate. Intracranial hypertension in the absence of other cause defines the entity of idiopathic intracranial hypertension or pseudotumor cerebri.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Visual field testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formal visual field testing with perimetry is very useful in the detection of subclinical visual field abnormalities and quantifying changes over time. This can be helpful in following the progress of the visual sequelae of papilledema and monitoring response to treatment. The size of the blind spot is an indirect measure of the degree of disc edema. Measurement in an individual patient must be done under exactly the same refractive conditions each time, as blind spot size is sensitive to refractive error. Constrictions in field perimetry and development of sector field defects are signs of impending serious visual loss. This finding is more valuable for prognosis than either symptoms or fundus appearance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Fluorescein angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     Fluorescein",
"    </a>",
"    angiography may be helpful in the detection of early papilledema, showing dye leakage, disc vascularity, and excess early and late disc fluorescence. Ophthalmologists, however, find it incompletely reliable, especially in equivocal situations, and usually unnecessary in this clinical setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Optical coherence tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Where available, optical coherence tomography may be useful to monitor the swelling of the nerve and also to clarify the effect upon and changes within the surrounding retina. This technique is very dependent upon the skills of the person performing the test and thus is prone to error. Modern technology (spectral rather than time based) has improved reliability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of increased intracranial pressure is specific to the underlying etiology and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/54/41833?source=see_link\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     VISUAL PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Permanent loss of vision is a common consequence of papilledema that is untreated or unresponsive to treatment. Clinical findings predictive of visual loss are high-grade disc edema, peripapillary subretinal hemorrhages, opticociliary shunt vessels, abnormal vision at presentation, and the development of visual field loss. Anemia, old age, myopia, glaucoma, and systemic hypertension have been found to be risk factors for a poor prognosis in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30552/abstract/60\">",
"     60",
"    </a>",
"    ]. Progressive changes in the visual examination are useful to predict patients at risk; however, vision loss sometimes occurs abruptly. Visual field loss attributed to hemorrhage can be expected to resolve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term papilledema is most properly applied to optic disc edema occurring as a consequence of intracranial hypertension.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The causes of papilledema often have serious consequences for impending morbidity and mortality; hence, diagnostic evaluation is urgent. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiologies and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unilateral disc edema and abnormal visual acuity at presentation suggest alternative diagnoses. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The first step in the evaluation for the cause of papilledema should be a neuroimaging study; a brain MRI is preferred, but a CT scan should be done if an MRI is not immediately available. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lumbar puncture with measurement of opening pressure and analysis of cerebrospinal fluid should follow a normal neuroimaging study. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Lumbar puncture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serial clinical evaluations including measurements of visual acuity, fundoscopic examination, and visual field testing with perimetry are invaluable in following the course of papilledema and response to treatment. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Visual field testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/1\">",
"      Minckler DS, Tso MO, Zimmerman LE. A light microscopic, autoradiographic study of axoplasmic transport in the optic nerve head during ocular hypotony, increased intraocular pressure, and papilledema. Am J Ophthalmol 1976; 82:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/2\">",
"      Tso MO, Hayreh SS. Optic disc edema in raised intracranial pressure. IV. Axoplasmic transport in experimental papilledema. Arch Ophthalmol 1977; 95:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/3\">",
"      Biousse V, Newman NJ. Intracranial vascular abnormalities. Ophthalmol Clin North Am 2001; 14:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/4\">",
"      Adelman JU. Headaches and papilledema secondary to dural arteriovenous malformation. Headache 1998; 38:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/5\">",
"      Costello F, Kardon RH, Wall M, et al. Papilledema as the presenting manifestation of spinal schwannoma. J Neuroophthalmol 2002; 22:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/6\">",
"      Amlashi SF, Riffaud L. Images in clinical medicine. Papilledema and spinal cord tumor. N Engl J Med 2004; 350:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/7\">",
"      Brockmeier B, Burbach H, Runge M, Altenkirch H. Raised intracranial pressure in chronic respiratory disease. Lancet 1997; 349:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/8\">",
"      Purvin VA, Kawasaki A, Yee RD. Papilledema and obstructive sleep apnea syndrome. Arch Ophthalmol 2000; 118:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/9\">",
"      Delany C, Jay WM. Papilledema and abducens nerve palsy following ethylene glycol ingestion. Semin Ophthalmol 2004; 19:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/10\">",
"      Morrison KE, Davies PT. Chronic inflammatory demyelinating polyneuropathy presenting with headache and papilledema. Headache 1999; 39:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/11\">",
"      Thomas S, Tan J, Lawden M, Sampath R. Optic nerve sheath fenestration for intracranial hypertension associated with chronic inflammatory demyelinating polyneuropathy. Ophthal Plast Reconstr Surg 2004; 20:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/12\">",
"      Fantin A, Feist RM, Reddy CV. Intracranial hypertension and papilloedema in chronic inflammatory demyelinating polyneuropathy. Br J Ophthalmol 1993; 77:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/13\">",
"      Erahin Y, Mutluer S, Yurtseven T. Hydrocephalus in Guillain-Barr&eacute; syndrome. Clin Neurol Neurosurg 1995; 97:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/14\">",
"      Sadun AA, Currie JN, Lessell S. Transient visual obscurations with elevated optic discs. Ann Neurol 1984; 16:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/15\">",
"      Pearson PA, Baker RS, Khorram D, Smith TJ. Evaluation of optic nerve sheath fenestration in pseudotumor cerebri using automated perimetry. Ophthalmology 1991; 98:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/16\">",
"      Wall M, Hart WM Jr, Burde RM. Visual field defects in idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol 1983; 96:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/17\">",
"      Fris&eacute;n L. Swelling of the optic nerve head: a staging scheme. J Neurol Neurosurg Psychiatry 1982; 45:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/18\">",
"      Elliot RH. THE RETINAL PULSE. Br J Ophthalmol 1921; 5:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/19\">",
"      ENGEL S. Venous pulsation as a symptom of early glaucoma. Am J Ophthalmol 1946; 29:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/20\">",
"      Hedges TR Jr, Baron EM, Hedges TR 3rd, Sinclair SH. The retinal venous pulse. Its relation to optic disc characteristics and choroidal pulse. Ophthalmology 1994; 101:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/21\">",
"      Levin BE. The clinical significance of spontaneous pulsations of the retinal vein. Arch Neurol 1978; 35:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/22\">",
"      Levine DN. Spontaneous pulsation of the retinal veins. Microvasc Res 1998; 56:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/23\">",
"      Lorentzen SE. Incidence of spontaneous venous pulsation in the retina. Acta Ophthalmol (Copenh) 1970; 48:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/24\">",
"      Pines, N. Some clinical notes on the nature of the retinal venous pulse. Brit J Ophthalmol 1938; 22:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/25\">",
"      Walsh TJ, Garden JW, Gallagher B. Obliteration of retinal venous pulsations during elevation of cerebrospinal-fluid pressure. Am J Ophthalmol 1969; 67:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/26\">",
"      Weinstein, P. Significance of venous pulsation of the eyeground. Brit J Ophthalmol 1939; 23:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/27\">",
"      Williamson-Noble, FA. Venous pulsation. Trans Ophthalmol UK 1952; 72:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/28\">",
"      Friedman DI. Papilledema and pseudotumor cerebri. Ophthalmol Clin North Am 2001; 14:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/29\">",
"      Davis PL, Jay WM. Optic nerve head drusen. Semin Ophthalmol 2003; 18:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/30\">",
"      Auw-Haedrich C, Staubach F, Witschel H. Optic disk drusen. Surv Ophthalmol 2002; 47:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/31\">",
"      Rosenberg MA, Savino PJ, Glaser JS. A clinical analysis of pseudopapilledema. I. Population, laterality, acuity, refractive error, ophthalmoscopic characteristics, and coincident disease. Arch Ophthalmol 1979; 97:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/32\">",
"      Lee AG, Beaver HA. Acute bilateral optic disk edema with a macular star figure in a 12-year-old girl. Surv Ophthalmol 2002; 47:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/33\">",
"      Spencer CG, Lip GY, Beevers DG. Recurrent malignant hypertension: a report of two cases and review of the literature. J Intern Med 1999; 246:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/34\">",
"      Kishi S, Tso MO, Hayreh SS. Fundus lesions in malignant hypertension. II. A pathologic study of experimental hypertensive optic neuropathy. Arch Ophthalmol 1985; 103:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/35\">",
"      Vaphiades MS. The disk edema dilemma. Surv Ophthalmol 2002; 47:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/36\">",
"      Wu GF, Balcer LJ. Endocrine and metabolic deficiency. Ophthalmol Clin North Am 2004; 17:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/37\">",
"      Pavan PR, Aiello LM, Wafai MZ, et al. Optic disc edema in juvenile-onset diabetes. Arch Ophthalmol 1980; 98:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/38\">",
"      Bayraktar Z, Alacali N, Bayraktar S. Diabetic papillopathy in type II diabetic patients. Retina 2002; 22:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/39\">",
"      Biousse V, Rucker JC, Vignal C, et al. Anemia and papilledema. Am J Ophthalmol 2003; 135:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/40\">",
"      Rizzo JF 3rd, Lessell S. Optic neuritis and ischemic optic neuropathy. Overlapping clinical profiles. Arch Ophthalmol 1991; 109:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/41\">",
"      KENNEDY C, CARROLL FD. Optic neuritis in children. Trans Am Acad Ophthalmol Otolaryngol 1960; 64:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/42\">",
"      Balcer LJ, Winterkorn JM, Galetta SL. Neuro-ophthalmic manifestations of Lyme disease. J Neuroophthalmol 1997; 17:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/43\">",
"      Khubchandani R, Rane T, Agarwal P, et al. Bilateral neuroretinitis associated with mumps. Arch Neurol 2002; 59:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/44\">",
"      Perrotta S, Nobili B, Grassia C, et al. Bilateral neuroretinitis in a 6-year-old boy with acquired toxoplasmosis. Arch Ophthalmol 2003; 121:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/45\">",
"      Labalette P, Bermond D, Dedes V, Savage C. Cat-scratch disease neuroretinitis diagnosed by a polymerase chain reaction approach. Am J Ophthalmol 2001; 132:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/46\">",
"      Cinefro RJ, Frenkel M. Systemic lupus erythematosus presenting as optic neuritis. Ann Ophthalmol 1978; 10:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/47\">",
"      Pelton RW, Lee AG, Orengo-Nania SD, Patrinely JR. Bilateral optic disk edema caused by sarcoidosis mimicking pseudotumor cerebri. Am J Ophthalmol 1999; 127:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/48\">",
"      Beardsley TL, Brown SV, Sydnor CF, et al. Eleven cases of sarcoidosis of the optic nerve. Am J Ophthalmol 1984; 97:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/49\">",
"      Prisco D, Marcucci R. Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiol Haemost Thromb 2002; 32:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/50\">",
"      Quinlan PM, Elman MJ, Bhatt AK, et al. The natural course of central retinal vein occlusion. Am J Ophthalmol 1990; 110:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/51\">",
"      Ellenberger C Jr, Messner KH. Papillophlebitis: benign retinopathy resembling papilledema or papillitis. Ann Neurol 1978; 3:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/52\">",
"      Lonn LI, Hoyt WF. Papillophlebitis: a cause of protracted yet benign optic disc edema. Eye Ear Nose Throat Mon 1966; 45:62 passim.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/53\">",
"      Mayo GL, Carter JE, McKinnon SJ. Bilateral optic disk edema and blindness as initial presentation of acute lymphocytic leukemia. Am J Ophthalmol 2002; 134:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/54\">",
"      Wabbels B, Demmler A, Seitz J, et al. Unilateral adult malignant optic nerve glioma. Graefes Arch Clin Exp Ophthalmol 2004; 242:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/55\">",
"      Nikaido H, Mishima H, Ono H, et al. Leukemic involvement of the optic nerve. Am J Ophthalmol 1988; 105:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/56\">",
"      Nikoskelainen EK, Huoponen K, Juvonen V, et al. Ophthalmologic findings in Leber hereditary optic neuropathy, with special reference to mtDNA mutations. Ophthalmology 1996; 103:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/57\">",
"      Gass JD, Norton EW. Cystoid macular edema and papilledema following cataract extraction: a fluorescein fundoscopic and angiographic study. 1966. Retina 2003; 23:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/58\">",
"      Shrieve DC, Hazard L, Boucher K, Jensen RL. Dose fractionation in stereotactic radiotherapy for parasellar meningiomas: radiobiological considerations of efficacy and optic nerve tolerance. J Neurosurg 2004; 101 Suppl 3:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/59\">",
"      Jiang GL, Tucker SL, Guttenberger R, et al. Radiation-induced injury to the visual pathway. Radiother Oncol 1994; 30:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30552/abstract/60\">",
"      Orcutt JC, Page NG, Sanders MD. Factors affecting visual loss in benign intracranial hypertension. Ophthalmology 1984; 91:1303.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5241 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-5917900B73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_53_30552=[""].join("\n");
var outline_f29_53_30552=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGIES AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Symptoms of increased intracranial pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Visual symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fundoscopic findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Early",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Fully developed",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Chronic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Bilateral disc abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Unilateral disc abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSTIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Visual field testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Fluorescein angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Optical coherence tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      VISUAL PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5241\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5241|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/53/18256\" title=\"picture 1\">",
"      Early papilledema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/23/11632\" title=\"picture 2\">",
"      Fully developed papilledema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/14/38126\" title=\"picture 3\">",
"      Late chronic papilledema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/13/4304\" title=\"picture 4\">",
"      Disc drusen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/27/39359\" title=\"picture 5\">",
"      Grade IV HTN retinopathy I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/44/19136\" title=\"picture 6\">",
"      Grade IV HTN retinopathy II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/29/38367\" title=\"picture 7\">",
"      Diabetic papillopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/23/7536\" title=\"picture 8\">",
"      Papillitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/53/33616\" title=\"picture 9\">",
"      Retinal vein occlusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/9/23711\" title=\"picture 10\">",
"      Optic nerve lung metastasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5241|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/28/21963\" title=\"table 1\">",
"      Differential diagnosis of papilledema",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44293?source=related_link\">",
"      Diabetic papillopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=related_link\">",
"      Hereditary neuropathies associated with generalized disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15769?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/54/41833?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19561?source=related_link\">",
"      Lumbar puncture: Technique; indications; contraindications; and complications in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20616?source=related_link\">",
"      Neurologic sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/58/27558?source=related_link\">",
"      Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20442?source=related_link\">",
"      Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21859?source=related_link\">",
"      Ocular effects of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/16/39176?source=related_link\">",
"      Optic pathway glioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4311?source=related_link\">",
"      Retinal vein occlusion: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=related_link\">",
"      Treatment of male sexual dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_53_30553="Extended-spectrum beta-lactamases";
var content_f29_53_30553=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Extended-spectrum beta-lactamases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/53/30553/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/53/30553/contributors\">",
"     L Silvia Munoz-Price, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/53/30553/contributors\">",
"     George A Jacoby, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/53/30553/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/53/30553/contributors\">",
"     David C Hooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/53/30553/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/53/30553/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/53/30553/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extended-spectrum beta-lactamases (ESBL) are enzymes that confer resistance to most beta-lactam antibiotics, including penicillins, cephalosporins, and the monobactam",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    . Infections with ESBL-producing organisms have been associated with poor outcomes.",
"   </p>",
"   <p>",
"    Community and hospital-acquired ESBL-producing Enterobacteriaceae are prevalent worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/1\">",
"     1",
"    </a>",
"    ]. Reliable identification of ESBL-producing organisms in clinical laboratories can be challenging, so their prevalence is likely underestimated. Carbapenems are the best antimicrobial agent for infections caused by such organisms.",
"   </p>",
"   <p>",
"    The types and detection of extended-spectrum beta-lactamases as well as the epidemiology and treatment of organisms that produce them are discussed in this topic. The clinical features and diagnosis of the infections that ESBL-producing organisms often cause are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20681?source=see_link\">",
"     \"Gram-negative bacillary bacteremia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/10999?source=see_link\">",
"     \"Acute complicated cystitis and pyelonephritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=see_link\">",
"     \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38426?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BETA-LACTAMASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta-lactamases are enzymes that open the beta-lactam ring, inactivating the antibiotic. The first plasmid-mediated beta lactamase in gram-negative bacteria was discovered in Greece in the 1960s. It was named TEM after the patient from whom it was isolated (Temoniera) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/2\">",
"     2",
"    </a>",
"    ]. Subsequently, a closely related enzyme was discovered and named TEM-2. It was identical in biochemical properties to the more common TEM-1 but differed by a single amino acid with a resulting change in the isoelectric point of the enzyme.",
"   </p>",
"   <p>",
"    These two enzymes are the most common plasmid-mediated beta-lactamases in gram-negative bacteria, including Enterobacteriaceae, Pseudomonas aeruginosa, Haemophilus influenzae, and Neisseria gonorrhoeae. TEM-1 and TEM-2 hydrolyze penicillins and narrow spectrum cephalosporins, such as cephalothin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    . However, they are not effective against higher generation cephalosporins with an oxyimino side chain, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    . Consequently, when these antibiotics were first introduced, they were effective against a broad group of otherwise resistant bacteria. A related but less common enzyme was termed SHV, because sulfhydryl reagents had a variable effect on substrate specificity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26663?source=see_link\">",
"     \"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38519?source=see_link\">",
"     \"Cephalosporins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EXTENDED-SPECTRUM BETA-LACTAMASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not long after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    came into clinical use in Europe, strains of Klebsiella pneumoniae were discovered in Germany with transferable resistance to the oxyimino-cephalosporins (eg, cefotaxime,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/3\">",
"     3",
"    </a>",
"    ]. The enzyme responsible was related to SHV and was named SHV-2. TEM-related extended-spectrum beta-lactamases (ESBLs) were discovered in France in 1984 and in the United States in 1988.",
"   </p>",
"   <p>",
"    The ESBL family is heterogeneous. SHV and TEM-type ESBLs arose by amino acid substitutions that allowed narrower spectrum enzymes to attack the new oxyimino-beta-lactams. Others, notably members of the CTX-M family, represent plasmid acquisition of broad-spectrum beta-lactamases originally determined by chromosomal genes.",
"   </p>",
"   <p>",
"    ESBLs vary in activity against different oxyimino-beta-lactam substrates but cannot attack the cephamycins (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17269?source=see_link\">",
"     cefotetan",
"    </a>",
"    and cefmetazole) and the carbapenems (imipenem,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/42/6822?source=see_link\">",
"     doripenem",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"     ertapenem",
"    </a>",
"    ). They are also generally susceptible to beta-lactamase inhibitors, such as clavulanate, sulbactam, and tazobactam, which consequently can be combined with a beta-lactam substrate to test for the presence of this resistance mechanism.",
"   </p>",
"   <p>",
"    ESBLs have been found exclusively in gram-negative organisms, primarily in Klebsiella pneumoniae, Klebsiella oxytoca, and Escherichia coli but also in Acinetobacter, Burkholderia, Citrobacter, Enterobacter, Morganella, Proteus, Pseudomonas, Salmonella, Serratia, and Shigella spp.",
"   </p>",
"   <p>",
"    Infection due to ESBL-producing E. coli has become widespread in hospitals around the world [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/4\">",
"     4",
"    </a>",
"    ]. Community-associated infection due to ESBL has also been recognized as an important clinical problem in the United States and Europe. In addition, a substantial portion of community-onset infection due to ESBL-producing E. coli has been observed among patients with no discernible healthcare-associated risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     ESBL varieties",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     TEM beta-lactamases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The amino acid substitutions responsible for the ESBL phenotype cluster around the active site of the enzyme and change its configuration, allowing access to oxyimino-beta-lactam substrates. Single amino acid substitutions at positions 104, 164, 238, and 240 produce the ESBL phenotype, but ESBLs with the broadest spectrum usually have more than a single amino acid substitution. Based upon different combinations of changes, currently 200 TEM-type enzymes have been described. Most are ESBLs, but some are resistant to beta-lactamase inhibitors, and a few are both ESBLs and inhibitor resistant. TEM-10, TEM-12, and TEM-26 are among the most common in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     SHV beta-lactamases",
"    </span>",
"    &nbsp;&mdash;&nbsp;ESBLs in this family also have amino acid changes around the active site, most commonly at positions 238 or 238 and 240. More than 160 SHV varieties are known, and they are found worldwide. SHV-5 and SHV-12 are among the most common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     CTX-M beta-lactamases",
"    </span>",
"    &nbsp;&mdash;&nbsp;These enzymes were named for their greater activity against",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    than other oxyimino-beta-lactam substrates (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    ). Despite their name, a few are more active on ceftazidime than cefotaxime. Rather than arising by mutation, they represent examples of plasmid acquisition of beta-lactamase genes normally found on the chromosome of Kluyvera species, a group of rarely pathogenic commensal organisms.",
"   </p>",
"   <p>",
"    More than 130 CTX-M enzymes have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/6\">",
"     6",
"    </a>",
"    ]. They have been found in many different Enterobacteriaceae including Salmonella, are the most common ESBL type worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/7\">",
"     7",
"    </a>",
"    ], and are increasingly prevalent in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/8\">",
"     8",
"    </a>",
"    ]. A single E. coli clonal group, ST131 (O25:H24), may have accounted for a large proportion of antimicrobial resistance in E. coli infections in the United States among clinical isolates collected from hospitalized patients in 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/9\">",
"     9",
"    </a>",
"    ]. Subsequently, it appeared that a single expanded ST131 strain was the source for many subsequent fluoroquinolone-resistant and multidrug-resistant isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     OXA beta-lactamases",
"    </span>",
"    &nbsp;&mdash;&nbsp;OXA beta-lactamases were long recognized as a less common but also plasmid-mediated beta-lactamase variety that could hydrolyze",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    and related anti-staphylococcal penicillins. Amino acid substitutions in OXA enzymes can also give the ESBL phenotype. OXA-type ESBLs have been found mainly in Pseudomonas aeruginosa isolates from Turkey and France. OXA beta-lactamases with carbapenemase activity have also been described. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9754?source=see_link&amp;anchor=H5#H5\">",
"     \"Carbapenemases\", section on 'Class D beta-lactamases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other plasmid-mediated ESBL families, such as PER, VEB, and GES, have been described but are uncommon and have been found mainly in P. aeruginosa and at a limited number of geographic sites [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition to conferring high-level resistance to antipseudomonal beta-lactams, these ESBLs also degrade cephalosporins, and monobactams. Other rare ESBLs found in Enterobacteriaceae are BES, SFO, and TLA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39528?source=see_link\">",
"     \"Treatment of Pseudomonas aeruginosa infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LABORATORY DETECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of extended-spectrum beta-lactamases (ESBLs) is based upon the resistance they confer to oxyimino-beta-lactam substrates (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    ) and to the ability of a beta-lactamase inhibitor, usually clavulanate, to block this resistance. Other enzymes have different features that can be misleading in the laboratory. AmpC-type beta-lactamases, which are now determined by plasmid as well as chromosomal genes, can provide oxyimino-beta-lactam resistance, but they are resistant to inhibition by clavulanate and usually confer resistance to cephamycins (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17269?source=see_link\">",
"     cefotetan",
"    </a>",
"    , and cefmetazole), which ESBLs do not.",
"   </p>",
"   <p>",
"    Problems in identification arise because ESBLs are heterogeneous. OXA-type ESBLs, for example, are poorly inhibited by clavulanate. Some ESBLs are best detected with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    and others with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    (such as most CTX-M enzymes). Consequently, susceptibility to several oxyimino-beta-lactams must be tested; criteria for ESBL detection have changed over time; and clinical laboratories vary in their success in diagnosis.",
"   </p>",
"   <p>",
"    Previously, the Clinical and Laboratory Standards Institute (CLSI) recommended screening isolates of E. coli, K. pneumoniae, K. oxytoca, or Proteus mirabilis by disk diffusion or broth dilution for resistance, followed by a confirmatory test for increased susceptibility in the presence of clavulanate [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/12\">",
"     12",
"    </a>",
"    ]. In 2010, however, the CLSI published new minimum inhibitory concentration (MIC) and disk diffusion breakpoints for the Enterobacteriaceae [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. The new MIC breakpoints are one to three doubling dilutions lower than the original breakpoints, and the new disk diffusion criteria include larger zone diameters than those in previous guidelines. In 2010, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) similarly changed the breakpoint criteria for susceptibility [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/17\">",
"     17",
"    </a>",
"    ]. Thus, many organisms that previously would have been categorized as susceptible using the former breakpoints may now be considered intermediate or resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/18\">",
"     18",
"    </a>",
"    ]. Whether these new breakpoints eliminate the need to perform ESBL screening and confirmatory tests for making treatment decisions is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/19\">",
"     19",
"    </a>",
"    ]. While the disk diffusion breakpoints can be implemented immediately, there are barriers to immediate implementation of the new MIC breakpoints; clinicians should review local practices with their own microbiology laboratories.",
"   </p>",
"   <p>",
"    Nonetheless, ESBL testing may be performed for infection control purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition to disk diffusion and broth dilution techniques, other techniques for ESBL detection include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Automated systems (Vitek, MicroScan, and BD Diagnostics), which use disk diffusion or broth dilution techniques",
"     </li>",
"     <li>",
"      The double disk test, in which a disk with clavulanate placed near a disk with an oxyimino-beta-lactam enhances susceptibility to the latter compound",
"     </li>",
"     <li>",
"      An E-test strip with clavulanate added to one side of a dual oxyimino-beta-lactam gradient",
"     </li>",
"     <li>",
"      Pyrosequencing and microarray technologies [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Identification of the ESBL present in a particular strain is generally limited to research laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae have been reported worldwide, most often in hospital specimens but also in samples from the community. Prevalence rates vary from hospital to hospital and from country to country as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a sample of more than 4600 K. pneumoniae isolates from 1997 to 1999, the percentage expressing an ESBL phenotype was highest in isolates from Latin America (45 percent), the Western Pacific (25 percent), and Europe (23 percent) and lowest in strains from the United States and Canada (7.6 and 4.9 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Comparable percentages for the ESBL phenotype in more than 12,800 E. coli strains were: Latin America (8.5 percent), Western Pacific (7.9 percent), Europe (5.3 percent), Canada (4.2 percent), and the United States (3.3 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      E. coli producing a CTX-M type ESBL is an emerging cause of community-acquired urinary tract infection in young women in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/23\">",
"       23",
"      </a>",
"      ], Europe [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/24\">",
"       24",
"      </a>",
"      ], Hong Kong [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/25\">",
"       25",
"      </a>",
"      ], India [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/26\">",
"       26",
"      </a>",
"      ] and elsewhere.",
"     </li>",
"     <li>",
"      In a prospective study of 455 consecutive episodes of K. pneumoniae bacteremia in 12 hospitals in seven countries in 1996 and 1997, 85 (19 percent) were due to an ESBL-producing organism [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/27\">",
"       27",
"      </a>",
"      ]. The rate was higher in the 253 nosocomial infections (31 percent), particularly those acquired in the intensive care unit (43 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study that applied microarray technology to identify ESBL genes in over 1000 E. coli, K. pneumoniae, K. oxytoca, and P. mirabilis strains that were phenotypically ESBL positive and collected worldwide, the most common ESBL types were CTX-M-15, CTX-M-14, and SHV-12 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the frequency of ESBL-positive isolates is high in a single institution, it is more likely that a single ESBL type is involved. Outbreaks have been due both to a single ESBL-producing strain and to a single ESBL plasmid carried by unrelated strains. A resistant strain or plasmid may cause problems in several hospitals locally or involve a large geographic area. Community clinics and nursing homes have also been identified as potential reservoirs for ESBL-producing K. pneumoniae and E. coli [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18777551\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although ESBL-producing organisms are a growing cause of nosocomial infections and outbreaks as well as community-acquired infections, data on the actual risk of transmission of ESBLs within and outside the hospital setting are limited.",
"   </p>",
"   <p>",
"    In one observational study from a tertiary care hospital in Switzerland, active surveillance cultures for ESBL carriage were performed in patients who shared a hospital room for at least 24 hours (contact patients, n = 133) with patients found to be infected or colonized with an ESBL-producing organism (index patients, n = 93) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/30\">",
"     30",
"    </a>",
"    ]. Only seven contacts (5.3 percent) were found to be colonized with an ESBL-producing organism, and only two harbored a strain that was genetically identical to that in the index patient, suggesting a low overall transmission rate (1.5 percent).",
"   </p>",
"   <p>",
"    A study from a separate tertiary care hospital in Switzerland reported slightly higher in-hospital transmission rates of 4.5 percent for ESBL-producing E. coli (4 of 88 contacts exposed to 40 index patients) and 8.3 percent for ESBL-producing K. pneumoniae (7 of 24 contacts exposed to 8 index patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/31\">",
"     31",
"    </a>",
"    ]. Even higher rates of transmission were observed among household contacts of index patients (23 and 25 percent for E. coli and K. pneumoniae, respectively).",
"   </p>",
"   <p>",
"    Additionally, environmental, animal, and food contamination with ESBL-producing gram-negative organisms has been extensively documented. As examples, ESBL producers have been detected in city rivers (eg, the River Thames in London, England), wild seagulls (eg, in Porto and Miami Beach [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]), and livestock and companion animals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/34\">",
"     34",
"    </a>",
"    ]. More alarmingly, ESBL-producing gram-negative organisms have also been identified in retail meat obtained from supermarkets [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. A foodborne nosocomial outbreak among 156 patients in Spain provided evidence that food can be a transmission vector for ESBL-producing Enterobacteriaceae [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/38\">",
"     38",
"    </a>",
"    ]. Up to 35 percent of the kitchen surfaces were colonized, and 14 percent of food handlers were fecal carriers of a single strain of SHV-1 and CTX-M-15 producing K. pneumoniae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for the development of colonization or infection with ESBL-producing organisms include [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/28,39-43\">",
"     28,39-43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Length of hospital stay",
"     </li>",
"     <li>",
"      Length of ICU stay",
"     </li>",
"     <li>",
"      Presence of central venous or arterial catheters",
"     </li>",
"     <li>",
"      Emergency abdominal surgery",
"     </li>",
"     <li>",
"      Presence of a gastrostomy or jejunostomy tube",
"     </li>",
"     <li>",
"      Gut colonization",
"     </li>",
"     <li>",
"      Low birth weight",
"     </li>",
"     <li>",
"      Prior administration of any antibiotic",
"     </li>",
"     <li>",
"      Prior residence in a long-term care facility (eg, nursing home)",
"     </li>",
"     <li>",
"      Severity of illness",
"     </li>",
"     <li>",
"      Presence of a urinary catheter",
"     </li>",
"     <li>",
"      Ventilatory assistance",
"     </li>",
"     <li>",
"      Hemodialysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Community-acquired infection with ESBL-producing organisms is no longer uncommon. Risk factors include previous antibiotic therapy, use of corticosteroids, and presence of a percutaneous gastrostomy or jejunostomy tube [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been postulated that the digestive tract constitutes the main reservoir for ESBL-producing Enterobacteriaceae [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/45\">",
"     45",
"    </a>",
"    ]. Travel to Asia also appears to be an emerging risk factor; gastroenteritis while traveling may be a surrogate parameter for contact with fecally contaminated water or food. This was illustrated in a prospective study including 100 Swedish adults; upon return home (median trip duration, two weeks), 24 of them were found to be colonized with ESBL-producing E. coli [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only current proven therapeutic option for severe infections caused by extended-spectrum beta-lactamase (ESBL)-producing organisms is the carbapenem family (imipenem,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/42/6822?source=see_link\">",
"     doripenem",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"     ertapenem",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     In vitro studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;ESBL-producing organisms vary in their susceptibility to different oxyimino-beta-lactams; despite resistance to some, they may appear sensitive to others. Strains making TEM and SHV-type ESBLs usually appear susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    and to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    , but both drugs show an inoculum effect with diminished susceptibility as the inoculum is raised from 10(5) to 10(7) organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/47\">",
"     47",
"    </a>",
"    ]. Some CTX-M- and OXA-type ESBLs test resistant to cefepime despite use of a low inoculum.",
"   </p>",
"   <p>",
"    Strains producing only ESBLs test susceptible to cephamycins (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17269?source=see_link\">",
"     cefotetan",
"    </a>",
"    , and cefmetazole) and carbapenems in vitro and show little if any inoculum effect with these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ESBL-producing isolates typically show greater than average resistance to other agents including aminoglycosides and fluoroquinolones. These relationships were illustrated in a review of 85 episodes of bacteremia due to ESBL-producing K. pneumoniae from 12 hospitals in seven countries [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/27\">",
"     27",
"    </a>",
"    ]. All isolates were susceptible to imipenem or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    , while 71 percent were resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    , 47 percent to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    , and 20 percent to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Human studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized controlled trials of therapy for ESBL infections. Most of the reports are a compilation of a small number of cases treated with different antibiotics, mainly in outbreak settings. Whether results can be generalized to infections with other ESBL types is generally not known.",
"   </p>",
"   <p>",
"    The choice of an appropriate antibiotic is essential since failure to treat with an antibiotic active against ESBL-producing K. pneumoniae is associated with lack of an adequate response and increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/27,49\">",
"     27,49",
"    </a>",
"    ]. The potential magnitude of this effect was illustrated in a review of 85 patients with ESBL-producing K. pneumoniae infection from 12 hospitals in seven countries; 20 patients (24 percent) died [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/27\">",
"     27",
"    </a>",
"    ]. Failure to treat with an antibiotic that had in vitro activity against the cultured isolate during the first five days after the culture result was known was associated with a significantly higher mortality rate compared to treatment with active antibiotics (64 versus 14 percent). Administration of a carbapenem (imipenem,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    , and perhaps",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"     ertapenem",
"    </a>",
"    ) alone or with other antibiotics was associated with a significantly lower mortality than those treated with active noncarbapenem antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Carbapenems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with imipenem or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    has produced the best outcomes in terms of survival and bacteriologic clearance. The efficacy of therapy with these agents is best illustrated by a prospective observational study of 85 episodes of bacteremia due to ESBL-producing K. pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/27\">",
"     27",
"    </a>",
"    ]. Among 27 patients treated with carbapenem monotherapy (imipenem in 24 and meropenem in 3), there was only one death (3.7 percent) at 14 days. In contrast, there were seven deaths among the 11 patients (64 percent) who did not receive any antibiotic active against these organisms and four deaths in nine patients (44 percent) treated with cephalosporin monotherapy or a",
"    <span class=\"nowrap\">",
"     beta-lactam/beta-lactamase",
"    </span>",
"    inhibitor combination such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    . On multivariate analysis, carbapenem use was independently associated with reduced mortality (odds ratio 0.09, 95% CI 0.01-0.65). Similar efficacy of imipenem was noted in a smaller study of ten patients: eight had a complete response and two failed therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no clear differences in efficacy between imipenem and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    . The choice to use one over the other is predominantly based on toxicity profiles in specific hosts. As an example, meropenem is favored in the setting of seizures or pregnancy because of the possible central nervous system toxicity and unknown safety in pregnancy of imipenem. Meropenem also may be easier to dose in the setting of changing or impaired renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44789?source=see_link&amp;anchor=H3#H3\">",
"     \"Combination beta-lactamase inhibitors, carbapenems, and monobactams\", section on 'Carbapenems'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/42/6822?source=see_link\">",
"     doripenem",
"    </a>",
"    is a relatively new carbapenem, the clinical data for its use in infections with organisms that produce ESBL are limited but overall suggest equivalent efficacy when compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    or imipenem [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44789?source=see_link&amp;anchor=H7#H7\">",
"     \"Combination beta-lactamase inhibitors, carbapenems, and monobactams\", section on 'Doripenem'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"     Ertapenem",
"    </a>",
"    has the advantage of once-daily dosing and has good in vitro activity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/48\">",
"     48",
"    </a>",
"    ], and clinical data regarding its use are growing. In two retrospective studies from the United States and Taiwan of patients with bloodstream infections due to Enterobacteriaceae that produced ESBL, treatment with ertapenem (n = 72 and 75, respectively) was associated with similar mortality rates as treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    or imipenem (n = 132 and 176) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Although patients treated with ertapenem in the study from the US had less invasive disease and a lower frequency of severe sepsis, adjusted analysis controlling for disease state and severity still showed equivalent mortality rates in the two groups. Smaller studies have reported favorable clinical response and microbiologic cure rates using ertapenem for ventilator-associated pneumonia and urinary tract infections due to ESBL-producing organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. However, some ESBL-producing isolates are resistant to ertapenem, and resistance may also develop on therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/55,58\">",
"     55,58",
"    </a>",
"    ]. We reserve the use of ertapenem for infections with susceptible ESBL-producing organisms that are not associated with severe sepsis. It can be a useful alternative for outpatient treatment of such infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44789?source=see_link&amp;anchor=H6#H6\">",
"     \"Combination beta-lactamase inhibitors, carbapenems, and monobactams\", section on 'Ertapenem'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Cephalosporins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of severe infections due to ESBL-producing K. pneumoniae with an oxyimino-beta-lactam (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    ) is likely to result in treatment failure, even if the organism demonstrates in vitro susceptibility [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/27,49,59\">",
"     27,49,59",
"    </a>",
"    ]. In a review of 28 patients with ESBL-producing Klebsiella pneumoniae with reported susceptibility to cephalosporins, 15 failed to respond to cephalosporin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/49\">",
"     49",
"    </a>",
"    ]. A possible explanation for the inferior outcomes in patients treated with apparently active cephalosporins may be the inoculum effect, in which there is a marked increase in MIC with increased inoculum [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While ESBL-producing bacteria generally test susceptible to cephamycins, resistance has developed after their use due to loss of porin channels for cephamycin entry, and there is little clinical experience to demonstrate their efficacy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     Cefepime",
"    </a>",
"    may be effective against ESBL-producing organisms if administered in high doses [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/60,61\">",
"     60,61",
"    </a>",
"    ] rather than standard doses (1 g every 12 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/62\">",
"     62",
"    </a>",
"    ]. In a European study of nosocomial pneumonia due to ESBL-producing pathogens, nine of thirteen patients treated with high-dose cefepime (2 g every eight hours) responded clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/60\">",
"     60",
"    </a>",
"    ]. However, most available data do not encourage cefepime use for ESBL-producing pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Piperacillin-tazobactam",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment failures have been described with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    for treatment of infection due to ESBL isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/27,64-66\">",
"     27,64-66",
"    </a>",
"    ]. In addition, resistance may develop during therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/65\">",
"     65",
"    </a>",
"    ]. Piperacillin-tazobactam may be effective for ESBL isolates with piperacillin-tazobactam MIC",
"    <span class=\"nowrap\">",
"     &le;16/4",
"    </span>",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    and for urinary tract infections, regardless of susceptibility [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/67\">",
"     67",
"    </a>",
"    ]. The latter observation is a presumed reflection of the much higher drug concentrations seen in urine compared to plasma.",
"   </p>",
"   <p>",
"    A retrospective study of bloodstream infections due to ESBL-producing organisms showed that patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    had the same mortality as those treated with carbapenems [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/68\">",
"     68",
"    </a>",
"    ]. The source of infection in most of these cases was either the urinary or biliary tract. However, given the multiple potential confounding factors in this study, caution should still be observed if selecting this antibiotic, especially among patients with severe infections. We do not recommend its use for infections with ESBL-producing organisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data regarding the use of quinolones",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aminoglycosides are also sparse. One study evaluated bacteremia caused by ESBL-producing K. pneumoniae that were susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/50\">",
"     50",
"    </a>",
"    ]. Among seven patients treated with ciprofloxacin, five failed treatment and two had a partial response; patients treated with imipenem did much better (complete response in eight of ten).",
"   </p>",
"   <p>",
"    There are no clinical data supporting the use of double antibiotic coverage for treatment of ESBL producing organisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20111594\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with an extended-spectrum beta-lactamase (ESBL)-producing organism usually does not warrant a longer course of therapy than generally indicated for the type of infection. Duration of therapy for specific infections is discussed separately in the corresponding topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20681?source=see_link&amp;anchor=H17#H17\">",
"     \"Gram-negative bacillary bacteremia in adults\", section on 'Duration of therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/10999?source=see_link&amp;anchor=H12414288#H12414288\">",
"     \"Acute complicated cystitis and pyelonephritis\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Duration'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     CLINICAL OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies evaluating clinical outcomes in patients with extended-spectrum beta-lactamase (ESBL) infections have shown a trend toward higher mortality, longer hospital stay, greater hospital expenses, and reduced rates of clinical and microbiologic response [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/27,69-71\">",
"     27,69-71",
"    </a>",
"    ]. In a meta-analysis of 32 studies of bacteremia with Enterobacteriaceae, infection with ESBL-producing organisms was associated with higher mortality than non-ESBL-producing organisms, (OR 2.35, 95% CI 1.90-2.91) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/72\">",
"     72",
"    </a>",
"    ]. Evaluation of the studies that performed adjusted analyses suggested that much of the increased mortality may be due to ineffective empiric therapy. As mentioned above, mortality rates of 3.7 percent have been described with carbapenems, with much higher mortality rates with antibiotics not active against these organisms (7 of 11 [64 percent]) and with cephalosporin monotherapy or a",
"    <span class=\"nowrap\">",
"     beta-lactam/beta-lactamase",
"    </span>",
"    inhibitor combination such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    (4 of 9 [44 percent]) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some individuals infected or colonized by ESBL producing organisms continue to shed bacteria for prolonged periods [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/73\">",
"     73",
"    </a>",
"    ]. Among 42 patients with infection due to ESBL-producing E. coli, persistent colonization was observed after a median of 58 months among five patients. It is unclear whether systemic antibiotic therapy affects colonization status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     INFECTION CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two main strategies to control outbreaks due to extended-spectrum beta-lactamase (ESBL)-producing bacteria have been described: barrier protection of infected or colonized patients, and restriction of beta-lactam use [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/70,74\">",
"     70,74",
"    </a>",
"    ]. Institution of both barrier protection and restriction of cephalosporin use in one study was associated with a decrease in the number of infections caused by ESBL-producing K. pneumoniae (4.9 episodes to 0.6 episodes per 1000 patient-days) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The institution of barrier methods without antibiotic restriction has also been evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/30,75\">",
"     30,75",
"    </a>",
"    ]. All personnel in contact with patients infected with or carriers of ESBL-producing Enterobacteriaceae were required to use gowns and gloves. In one study, barrier production was associated with a decrease in the incidence of hospital-acquired ESBL from 172 patients to 19 over three years, despite increased the use of cephalosporins [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30553/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20111524\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extended-spectrum beta-lactamases (ESBLs) are enzymes that inactivate and confer resistance to most beta-lactam antibiotics, including penicillins, cephalosporins, and the monobactam",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      . They are found exclusively in gram-negative organisms, primarily Klebsiella pneumoniae, Klebsiella oxytoca, and Escherichia coli. Many different varieties of ESBL exist. They differ in their activity against particular beta-lactam substrates and in their geographical distribution. Most ESBLs do not break down cephamycins or carbapenems and are susceptible to beta-lactamase inhibitors. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Extended-spectrum beta-lactamases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory detection of an ESBL in an organism is based on resistance to particular cephalosporins and the ability of a beta-lactamase inhibitor to block this resistance. However, the heterogeneity of the ESBL varieties can make identification difficult. Thus, the Clinical and Laboratory Standards Institute has adjusted susceptibility breakpoint recommendations for gram-negative bacilli. As a result, many organisms that previously would have been categorized as susceptible using the former breakpoints may now be considered intermediate or resistant. This often precludes the need to identify the ESBL in order to make treatment decisions. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Laboratory detection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ESBL-producing gram-negative bacilli have been reported worldwide. They are most often isolated from hospitalized patients but are an increasing cause of community-acquired infections. Risk factors for infection include prior administration of an antibiotic, presence of urinary or vascular catheters, and longer hospital or ICU stays. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The best therapeutic option for severe infections caused by ESBL-producing organisms is a carbapenem (imipenem,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/42/6822?source=see_link\">",
"       doripenem",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"       ertapenem",
"      </a>",
"      ). We use meropenem or imipenem for most ESBL infections. Ertapenem is an acceptable option in the absence of resistance or severe sepsis and can be particularly useful in the outpatient setting. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Carbapenems'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"       Cefepime",
"      </a>",
"      may be effective against ESBL-producing organisms that test susceptible if administered in high doses (ie, 2 g every eight hours). Use of other cephalosporins and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"       piperacillin-tazobactam",
"      </a>",
"      has been associated with treatment failures. There is little clinical evidence for cephamycin use, which has been associated with development of resistance. Resistance to aminoglycosides and fluoroquinolones is also common in these organisms. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment options'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infections with ESBL-producing organisms are associated with higher mortality rates, longer hospital stays, greater hospital expenses, and reduced rates of clinical and microbiologic response compared with similar infections with gram-negative bacteria that do not produce ESBL. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Clinical outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The spread of ESBL-producing organisms within institutions can be slowed by the use of barrier protection and restriction of later generation cephalosporins. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Infection control'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/1\">",
"      Ben-Ami R, Rodr&iacute;guez-Ba&ntilde;o J, Arslan H, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009; 49:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/2\">",
"      Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/3\">",
"      Kliebe C, Nies BA, Meyer JF, et al. Evolution of plasmid-coded resistance to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1985; 28:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/4\">",
"      Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/5\">",
"      Doi Y, Park YS, Rivera JI, et al. Community-associated extended-spectrum &beta;-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis 2013; 56:641.",
"     </a>",
"    </li>",
"    <li>",
"     www.lahey.org/studies/webt.htm (Accessed on June 01, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/7\">",
"      Cant&oacute;n R, Coque TM. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol 2006; 9:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/8\">",
"      Lascols C, Hackel M, Hujer AM, et al. Using nucleic acid microarrays to perform molecular epidemiology and detect novel &beta;-lactamases: a snapshot of extended-spectrum &beta;-lactamases throughout the world. J Clin Microbiol 2012; 50:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/9\">",
"      Johnson JR, Johnston B, Clabots C, et al. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 2010; 51:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/10\">",
"      Johnson JR, Tchesnokova V, Johnston B, et al. Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. J Infect Dis 2013; 207:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/11\">",
"      Endimiani A, Luzzaro F, Pini B, et al. Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase. BMC Infect Dis 2006; 6:52.",
"     </a>",
"    </li>",
"    <li>",
"     National Committee for Clinical Laboratory Standards, Wayne, PA 1999.",
"    </li>",
"    <li>",
"     Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; Twenty-first informational supplement; M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.",
"    </li>",
"    <li>",
"     Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement; M100-S20. June 2010 Update. Clinical and Laboratory Standards Institute, Wayne, PA",
"    </li>",
"    <li>",
"     Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement; M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.",
"    </li>",
"    <li>",
"     CLSI M100-S20 (2010) Cephalosporin and Aztreonam Breakpoint Revisions Fact Sheet file://www.clsi.org/Content/NavigationMenu/Committees/Microbiology/AST/CephalosporinandAztreonamBreakpointRevisionFactSheet/CephalosporinAztreonamBreakpointFactSheet.pdf (Accessed on January 26, 2011).",
"    </li>",
"    <li>",
"     European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 1.1. EUCAST, 2010. file://www.eucast.org/clinical_breakpoints/ (Accessed on May 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/18\">",
"      Hombach M, Bloemberg GV, B&ouml;ttger EC. Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli. J Antimicrob Chemother 2012; 67:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/19\">",
"      Livermore DM, Andrews JM, Hawkey PM, et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother 2012; 67:1569.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing; Twenty-second informational supplement; M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA. file://www.clsi.org/source/orders/free/m100-s22.pdf (Accessed on October 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/21\">",
"      Gazin M, Paasch F, Goossens H, et al. Current trends in culture-based and molecular detection of extended-spectrum-&beta;-lactamase-harboring and carbapenem-resistant Enterobacteriaceae. J Clin Microbiol 2012; 50:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/22\">",
"      Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001; 32 Suppl 2:S94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/23\">",
"      Doi Y, Adams J, O'Keefe A, et al. Community-acquired extended-spectrum beta-lactamase producers, United States. Emerg Infect Dis 2007; 13:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/24\">",
"      Woodford N, Ward ME, Kaufmann ME, et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. J Antimicrob Chemother 2004; 54:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/25\">",
"      Ho PL, Poon WW, Loke SL, et al. Community emergence of CTX-M type extended-spectrum beta-lactamases among urinary Escherichia coli from women. J Antimicrob Chemother 2007; 60:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/26\">",
"      Freeman JT, McBride SJ, Heffernan H, et al. Community-onset genitourinary tract infection due to CTX-M-15-Producing Escherichia coli among travelers to the Indian subcontinent in New Zealand. Clin Infect Dis 2008; 47:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/27\">",
"      Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004; 39:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/28\">",
"      Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med 2004; 140:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/29\">",
"      Wiener J, Quinn JP, Bradford PA, et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999; 281:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/30\">",
"      Tschudin-Sutter S, Frei R, Dangel M, et al. Rate of transmission of extended-spectrum Beta-lactamase-producing enterobacteriaceae without contact isolation. Clin Infect Dis 2012; 55:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/31\">",
"      Hilty M, Betsch BY, B&ouml;gli-Stuber K, et al. Transmission dynamics of extended-spectrum &beta;-lactamase-producing Enterobacteriaceae in the tertiary care hospital and the household setting. Clin Infect Dis 2012; 55:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/32\">",
"      Sim&otilde;es RR, Poirel L, Da Costa PM, Nordmann P. Seagulls and beaches as reservoirs for multidrug-resistant Escherichia coli. Emerg Infect Dis 2010; 16:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/33\">",
"      Poirel L, Potron A, De La Cuesta C, et al. Wild coastline birds as reservoirs of broad-spectrum-&beta;-lactamase-producing Enterobacteriaceae in Miami Beach, Florida. Antimicrob Agents Chemother 2012; 56:2756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/34\">",
"      Ewers C, Bethe A, Semmler T, et al. Extended-spectrum &beta;-lactamase-producing and AmpC-producing Escherichia coli from livestock and companion animals, and their putative impact on public health: a global perspective. Clin Microbiol Infect 2012; 18:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/35\">",
"      Doi Y, Paterson DL, Egea P, et al. Extended-spectrum and CMY-type beta-lactamase-producing Escherichia coli in clinical samples and retail meat from Pittsburgh, USA and Seville, Spain. Clin Microbiol Infect 2010; 16:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/36\">",
"      Kluytmans JA, Overdevest IT, Willemsen I, et al. Extended-spectrum &beta;-lactamase-producing Escherichia coli from retail chicken meat and humans: comparison of strains, plasmids, resistance genes, and virulence factors. Clin Infect Dis 2013; 56:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/37\">",
"      Liebana E, Carattoli A, Coque TM, et al. Public Health Risks of Enterobacterial Isolates Producing Extended-Spectrum &beta;-Lactamases or AmpC &beta;-Lactamases in Food and Food-Producing Animals: An EU Perspective of Epidemiology, Analytical Methods, Risk Factors, and Control Options. Clin Infect Dis 2013; 56:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/38\">",
"      Calbo E, Freixas N, Xercavins M, et al. Foodborne nosocomial outbreak of SHV1 and CTX-M-15-producing Klebsiella pneumoniae: epidemiology and control. Clin Infect Dis 2011; 52:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/39\">",
"      Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005; 352:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/40\">",
"      Park YS, Adams-Haduch JM, Shutt KA, et al. Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United States. Antimicrob Agents Chemother 2012; 56:1870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/41\">",
"      Kang CI, Wi YM, Lee MY, et al. Epidemiology and risk factors of community onset infections caused by extended-spectrum &beta;-lactamase-producing Escherichia coli strains. J Clin Microbiol 2012; 50:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/42\">",
"      Rodr&iacute;guez-Ba&ntilde;o J, Pic&oacute;n E, Gij&oacute;n P, et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 2010; 50:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/43\">",
"      Bert F, Larroque B, Paugam-Burtz C, et al. Pretransplant fecal carriage of extended-spectrum &beta;-lactamase-producing Enterobacteriaceae and infection after liver transplant, France. Emerg Infect Dis 2012; 18:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/44\">",
"      Lee JA, Kang CI, Joo EJ, et al. Epidemiology and clinical features of community-onset bacteremia caused by extended-spectrum &beta;-lactamase-producing Klebsiella pneumoniae. Microb Drug Resist 2011; 17:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/45\">",
"      Lucet JC, R&eacute;gnier B. [Enterobacteria producing extended spectrum beta-lactamases]. Pathol Biol (Paris) 1998; 46:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/46\">",
"      T&auml;ngd&eacute;n T, Cars O, Melhus A, L&ouml;wdin E. Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers. Antimicrob Agents Chemother 2010; 54:3564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/47\">",
"      Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001; 45:3548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/48\">",
"      Jacoby G, Han P, Tran J. Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant gram-negative clinical pathogens. Antimicrob Agents Chemother 1997; 41:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/49\">",
"      Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39:2206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/50\">",
"      Endimiani A, Luzzaro F, Perilli M, et al. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis 2004; 38:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/51\">",
"      Kaniga K, Flamm R, Tong SY, et al. Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. Antimicrob Agents Chemother 2010; 54:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/52\">",
"      Collins VL, Marchaim D, Pogue JM, et al. Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-&beta;-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2012; 56:2173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/53\">",
"      Lee NY, Lee CC, Huang WH, et al. Carbapenem therapy for bacteremia due to extended-spectrum-&beta;-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility. Antimicrob Agents Chemother 2012; 56:2888.",
"     </a>",
"    </li>",
"    <li>",
"     Munoz LS, Hovsepian M, Snydman DR, et al. Ertapenem for the treatment of extended spectrum beta-lactamase (ESBL) producing organisms. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004, Abstract # K-1591.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/55\">",
"      Berg ML, Crank CW, Philbrick AH, Hayden MK. Efficacy of ertapenem for consolidation therapy of extended-spectrum beta-lactamase-producing gram-negative infections: a case series report. Ann Pharmacother 2008; 42:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/56\">",
"      Bazaz R, Chapman AL, Winstanley TG. Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-beta-lactamase-producing Gram-negative organisms. J Antimicrob Chemother 2010; 65:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/57\">",
"      Fong JJ, Ros&eacute; L, Radigan EA. Clinical outcomes with ertapenem as a first-line treatment option of infections caused by extended-spectrum &beta;-lactamase producing gram-negative bacteria. Ann Pharmacother 2012; 46:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/58\">",
"      Lartigue MF, Poirel L, Poyart C, et al. Ertapenem resistance of Escherichia coli. Emerg Infect Dis 2007; 13:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/59\">",
"      Lee NY, Lee CC, Huang WH, et al. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis 2013; 56:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/60\">",
"      Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003; 47:3442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/61\">",
"      Goethaert K, Van Looveren M, Lammens C, et al. High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients. Clin Microbiol Infect 2006; 12:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/62\">",
"      Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness. J Infect 2005; 51:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/63\">",
"      Chopra T, Marchaim D, Veltman J, et al. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-&beta;-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother 2012; 56:3936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/64\">",
"      Wong-Beringer A, Hindler J, Loeloff M, et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 2002; 34:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/65\">",
"      Zimhony O, Chmelnitsky I, Bardenstein R, et al. Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility. Antimicrob Agents Chemother 2006; 50:3179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/66\">",
"      Paterson DL, Singh N, Gayowski T, Marino IR. Fatal infection due to extended-spectrum beta-lactamase-producing Escherichia coli: implications for antibiotic choice for spontaneous bacterial peritonitis. Clin Infect Dis 1999; 28:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/67\">",
"      Gavin PJ, Suseno MT, Thomson RB Jr, et al. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother 2006; 50:2244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/68\">",
"      Rodr&iacute;guez-Ba&ntilde;o J, Navarro MD, Retamar P, et al. &beta;-Lactam/&beta;-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum &beta;-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012; 54:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/69\">",
"      Lautenbach E, Patel JB, Bilker WB, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/70\">",
"      Meyer KS, Urban C, Eagan JA, et al. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993; 119:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/71\">",
"      Tumbarello M, Spanu T, Sanguinetti M, et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006; 50:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/72\">",
"      Rottier WC, Ammerlaan HS, Bonten MJ. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum &beta;-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother 2012; 67:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/73\">",
"      Alsterlund R, Axelsson C, Olsson-Liljequist B. Long-term carriage of extended-spectrum beta-lactamase-producing Escherichia coli. Scand J Infect Dis 2012; 44:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/74\">",
"      Pe&ntilde;a C, Pujol M, Ardanuy C, et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1998; 42:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30553/abstract/75\">",
"      Lucet JC, Decr&eacute; D, Fichelle A, et al. Control of a prolonged outbreak of extended-spectrum beta-lactamase-producing enterobacteriaceae in a university hospital. Clin Infect Dis 1999; 29:1411.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 469 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-218.28.111.102-E73EFF4BA8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_53_30553=[""].join("\n");
var outline_f29_53_30553=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20111524\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BETA-LACTAMASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EXTENDED-SPECTRUM BETA-LACTAMASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ESBL varieties",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - TEM beta-lactamases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - SHV beta-lactamases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - CTX-M beta-lactamases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - OXA beta-lactamases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LABORATORY DETECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18777551\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      In vitro studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Human studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Carbapenems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Cephalosporins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Piperacillin-tazobactam",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20111594\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CLINICAL OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      INFECTION CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20111524\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/47/10999?source=related_link\">",
"      Acute complicated cystitis and pyelonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26663?source=related_link\">",
"      Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9754?source=related_link\">",
"      Carbapenemases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38519?source=related_link\">",
"      Cephalosporins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38426?source=related_link\">",
"      Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44789?source=related_link\">",
"      Combination beta-lactamase inhibitors, carbapenems, and monobactams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=related_link\">",
"      Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20681?source=related_link\">",
"      Gram-negative bacillary bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39528?source=related_link\">",
"      Treatment of Pseudomonas aeruginosa infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=related_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_53_30554="Chronic urticaria: Treatment of refractory symptoms";
var content_f29_53_30554=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic urticaria: Treatment of refractory symptoms",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/53/30554/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/53/30554/contributors\">",
"     David A Khan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/53/30554/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/53/30554/contributors\">",
"     Sarbjit Saini, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/53/30554/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/53/30554/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/53/30554/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/53/30554/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic urticaria (CU) is defined by the presence of urticaria (hives) on most days of the week, for a duration of longer than six weeks. Associated angioedema occurs in about 40 percent of patients.",
"   </p>",
"   <p>",
"    Standard management of CU primarily involves H1 antihistamines, sometimes at higher than usual doses and in combination with H2 antihistamines and leukotriene modifiers or other adjunctive agents. Short courses of systemic glucocorticoids to control severe exacerbations may be needed. In this review, patients whose symptoms are not controlled over time using with these standard therapies are considered to have refractory symptoms.",
"   </p>",
"   <p>",
"    Therapeutic options for patients with refractory CU will be reviewed here, as well as the evidence in support of the efficacy of each treatment. Standard management, as well as the diagnosis, pathogenesis, and prognosis of chronic urticaria, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=see_link\">",
"     \"Chronic urticaria: Standard management and patient education\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=see_link\">",
"     \"Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1920020\">",
"    <span class=\"h1\">",
"     DEFINITION OF CHRONIC URTICARIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this review, the term CU refers to patients with chronic idiopathic urticaria, with or without intermittent angioedema. Disorders involving isolated angioedema, urticarial vasculitis, and specific physical forms of CU (such as delayed pressure urticaria, cholinergic urticaria, or cold urticaria) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=see_link\">",
"     \"An overview of angioedema: Pathogenesis and causes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/60/32714?source=see_link\">",
"     \"Urticarial vasculitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24666?source=see_link\">",
"     \"Physical urticarias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15721?source=see_link\">",
"     \"Cold urticaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The terms chronic urticaria and chronic idiopathic urticaria are used synonymously in this discussion. Some studies distinguish between patients with and without positive autologous serum skin tests (ASST) or other laboratory indicators of an autoimmune process. This distinction is mentioned in the text only if a study found a difference between these two patient groups. The interpretation of a positive ASST in patients with CU is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=see_link&amp;anchor=H14#H14\">",
"     \"Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history\", section on 'Autoimmune theory'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1919908\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients whose symptoms are not controlled over time using standard therapy may receive repeated courses of glucocorticoids, or have extended periods of glucocorticoids exposure (eg, months of treatment). In view of the potentially severe side effects associated with long-term treatment, oral corticosteroids should be used for short periods and at the minimally effective dose necessary to achieve control. In this situation, and ideally before the patient has been exposed to months of glucocorticoid therapy, the clinician should consider other antiinflammatory, immunosuppressant, or immunomodulatory agents, as the risks of long-term glucocorticoid therapy are well known. In addition, glucocorticoids are not believed to induce lasting remission or alter the natural history of CU, while some of the agents discussed here may have these properties. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no standardized approach to the management of refractory CU, and published guidelines only list options to be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Therefore, the approach of the author, which is based on clinical experience, is presented here to provide additional guidance. Therapy must be individualized. The decision to use a certain medication should be based upon an assessment of risk versus benefit for that specific patient, taking into account concomitant medical conditions and patient preferences.",
"   </p>",
"   <p>",
"    When introducing these more advanced treatments, antihistamines and other standard agents that were clearly helpful to the patient are typically continued. Any medications of uncertain benefit should be discontinued, so that medications do not accumulate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H642386\">",
"    <span class=\"h2\">",
"     Terminology",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this discussion, the term &ldquo;antiinflammatory&rdquo; denotes a class of agents with predominantly antiinflammatory activities, which have low potential toxicity and less proven efficacy for CU. We have applied this term to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    . The term &ldquo;immunosuppressants&rdquo; is applied to drugs that have more potent immune suppression activity and greater potential toxicity, as well as more evidence for efficacy. We have categorized the calcineurin inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil in this way. Clearly, there is overlap in the mechanisms of actions of agents in these two categories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1920133\">",
"    <span class=\"h2\">",
"     Choice of initial intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author&rsquo;s approach involves stratifying patients by the presence or absence of glucocorticoid toxicity (eg, significant weight gain, hypertension, gastritis, hyperglycemia, etc) (",
"    <a class=\"graphic graphic_table graphicRef65998 \" href=\"UTD.htm?15/62/16365\">",
"     table 1",
"    </a>",
"    ). For those who already display evidence of toxicity, there is a more urgent need to control symptoms so that glucocorticoids can be reduced or discontinued. For this group, we suggest adding an immunosuppressant agent (in preference to an antiinflammatory drug) as an initial intervention, as these therapies seem to produce a more rapid effect and appear to be more reliably effective in our clinical experience.",
"   </p>",
"   <p>",
"    In contrast, in patients",
"    <strong>",
"     without",
"    </strong>",
"    glucocorticoid toxicity, we begin with antiinflammatory agents, which are generally less toxic, have a slower onset of action, and appear to be less reliably effective in our clinical experience. As noted previously, this approach is based solely on clinical experience.",
"   </p>",
"   <p>",
"    It is important for treating clinicians to be knowledgeable about potential adverse effects and monitoring when administering the agents discussed in this topic. Consultation with other specialists (eg, dermatologists, rheumatologists) may be appropriate depending on the medication, as well as the experience and comfort level of the treating clinician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1920120\">",
"    <span class=\"h2\">",
"     Goal of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of therapy in patients with refractory CU is to achieve a level of symptom control and improvement in quality of life that is acceptable to the patient, while minimizing therapy-related side effects. Patients differ in their preferences: some want to pursue complete remission, while others would rather minimize medications and accept a low level of ongoing symptoms. In addition, it should be kept in mind that although CU can be a disabling disorder, it does not lead to permanent organ damage and it ultimately resolves in the majority of patients, with or without treatment. Thus, a treatment that appears to be inducing serious adverse side effects is not warranted. The natural history of CU is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=see_link&amp;anchor=H24#H24\">",
"     \"Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history\", section on 'Natural history and prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANTIINFLAMMATORY AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiinflammatory agents that have been studied in the treatment of CU include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    . A strategy for choosing one agent over another is presented below. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Treatment strategies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Dapsone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    is a sulfone antimicrobial agent. In CU, it may act by suppressing prostaglandin and leukotriene activity, interfering with release or function of neutrophil lysosomal enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], disrupting integrin-mediated neutrophil adhesiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/6\">",
"     6",
"    </a>",
"    ], inhibiting neutrophil recruitment and activation signals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/7\">",
"     7",
"    </a>",
"    ], and scavenging oxygen free radical intermediates [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/8\">",
"     8",
"    </a>",
"    ]. Dapsone has traditionally been thought to be helpful in cutaneous diseases in which neutrophils play a prominent role [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/9\">",
"     9",
"    </a>",
"    ]. Some cases of CU have a neutrophil-rich infiltrate on biopsy, although whether this histopathologic finding predicts response to dapsone in patients with CU is unproven.",
"   </p>",
"   <p>",
"    Studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    for the treatment CU include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case series of 11 CU patients, refractory to antihistamines alone, reported clinical improvement in nine subjects within several weeks (ultimately allowing discontinuation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      therapy) with a low dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      (25 mg daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/10\">",
"       10",
"      </a>",
"      ]. In the two remaining patients, the dose was increased to 50 mg daily, which resulted in a complete response in one subject and partial response in the other. Seven patients had remission lasting variable periods of time after stopping use of the drug. We have also observed sustained remission in &gt;50 percent of dapsone responders in our own practice.",
"     </li>",
"     <li>",
"      Preliminary, unpublished results from a randomized, crossover study performed at the author's center showed improvement in 15 of 22 CU patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      , 100 mg daily [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/11\">",
"       11",
"      </a>",
"      ]. Improvement was evident within days in some patients, whereas others required several weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    is generally well tolerated, widely available, and inexpensive. However, it can cause severe hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Therefore, it is our practice to test for G6PD deficiency before initiating treatment. The various diagnostic tests for G6PD deficiency are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=see_link\">",
"     \"Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    usually causes a small decline in hemoglobin (1 to 2",
"    <span class=\"nowrap\">",
"     grams/dL),",
"    </span>",
"    even in patients who do not have G6PD deficiency. We follow complete blood counts (CBC) monthly for the first three months of therapy and then every two to three months thereafter. We also follow liver function tests because hepatotoxicity is another uncommon side effect. Peripheral neuropathy, methemoglobinemia, and drug allergic reactions, such as the drug rash with eosinophilia and systemic symptoms (DRESS) are rare, but serious reactions that warrant immediate discontinuation of dapsone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of methemoglobinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Sulfasalazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     Sulfasalazine",
"    </a>",
"    is an antiinflammatory 5-aminosalicylic acid (5-ASA) derivative. Mechanisms of action with possible relevance in CU include alteration of adenosine release [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/14\">",
"     14",
"    </a>",
"    ], decreased leukotriene and prostaglandin synthesis, inhibition of IgE-mediated mast cell degranulation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/15\">",
"     15",
"    </a>",
"    ], attenuation of neutrophil respiratory burst [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/16\">",
"     16",
"    </a>",
"    ], and inhibition of early-phase events in the proliferation and differentiation of B-lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/17\">",
"     17",
"    </a>",
"    ]. Sulfasalazine is metabolized to sulfapyridine and 5-ASA within the gastrointestinal tract and most of the 5-ASA is degraded locally in the colon without much systemic distribution. Thus, the sulfapyridine may be largely responsible for its therapeutic activity in patients with CU.",
"   </p>",
"   <p>",
"    Data are limited about the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    in CU:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest observational series, 19 patients with CU were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      and 14 experienced significant improvement, with four others showing modest benefit and one worsening [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/18\">",
"       18",
"      </a>",
"      ]. Several patients were able to stop taking other medications, including glucocorticoids. Doses were increased in a stepwise fashion and response occurred within one month, although doses above 2 g daily had no additional clinical benefit in this group. Some patients experienced lasting remission after cessation of therapy.",
"     </li>",
"     <li>",
"      Other case reports successfully used doses between 2 and 3 grams daily [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. Sustained remission was not described.",
"     </li>",
"     <li>",
"      Treatment failures are also reported [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    is well tolerated by most patients. Side effects include nausea, headache, mild or transient leukopenia, and transaminitis. Drawbacks include the advisability of gradual dose escalation, which may prolong the time to clinical response, as well as the need for laboratory monitoring. British guidelines recommend monitoring with CBC, blood urea nitrogen, creatinine, electrolytes, and liver function tests monthly during the first three months, then every three months thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/22\">",
"     22",
"    </a>",
"    ]. Folate supplements should be co-administered to women who are pregnant or could potentially conceive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Hydroxychloroquine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     Hydroxychloroquine",
"    </a>",
"    is an antiinflammatory drug and antimalarial agent. The relative safety and low cost of hydroxychloroquine makes it a reasonable agent in the treatment of refractory CU. The major disadvantage is a relatively slow onset of action. Mechanisms of action include suppression of T-lymphocyte activation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/23\">",
"     23",
"    </a>",
"    ] and disruption of antigen processing and other cellular processes by alkalinization of intracellular vacuoles in macrophages and other antigen presenting cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the best available study, 18 patients with CU were treated with a combination of therapies for CU (H1 antihistamines, H2 antihistamines, glucocorticoids, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"       doxepin",
"      </a>",
"      ) and randomized to receive either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily) or no additional drug [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/25\">",
"       25",
"      </a>",
"      ]. After three months of treatment, patients in the hydroxychloroquine arm demonstrated improved quality of life. Hydroxychloroquine was well tolerated and there was a trend (not reaching significance) toward reduced medication use and urticarial activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     Hydroxychloroquine",
"    </a>",
"    rarely causes serious side effects. The most common adverse reactions are related to the gastrointestinal tract (nausea), skin (various macular lesions), and central nervous system (headache). Ophthalmologic problems, including corneal deposits (reversible) and retinopathy (potentially vision threatening) are possible, but rare with the low daily doses used in CU. The issue of ophthalmologic screening in patients taking hydroxychloroquine is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=see_link&amp;anchor=H17#H17\">",
"     \"Antimalarial drugs in the treatment of rheumatic disease\", section on 'Ocular health'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any standard CU therapies that did not appear to be helpful to the patient should be discontinued before antiinflammatory agents are added. A baseline CBC and chemistry panel with liver function tests should be obtained prior to initiation of any of these therapies. We consider the following in choosing among these agents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We most commonly start with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      , after additionally checking for G6PD deficiency. In adults, we start with a dose of 100 mg daily. In two weeks, we obtain a CBC and liver function tests and repeat these monthly for three months, and then less often. A 10 to 20 percent decline in hemoglobin or hematocrit is common and we do not stop therapy unless the decrease exceeds 25 percent. The dose can be reduced once there is a clear clinical response. A four to six week trial is usually sufficient to determine effectiveness. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Dapsone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We choose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      instead for patients with underlying anemia or concomitant delayed pressure urticaria. In adults, we start with a dose of 500 mg twice a day for one week, and then increase to 1 gram twice a day. Laboratory monitoring with a CBC, liver function tests, and urinalysis is performed every month for the first three months, and then less often. A four to six week trial is usually sufficient to determine effectiveness. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Sulfasalazine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We choose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      for patients with uncontrolled CU, but only modest impairment in quality of life, as this agent is slow to work and patients with more severe impairment may not be able to tolerate the duration of the trial. In adults, we start with a dose of 200 mg twice a day. A three month trial is usually required to determine effectiveness. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Hydroxychloroquine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A strategy to circumvent the long latency time of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    is to start either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    at the same time. If the patient responds within a few weeks, the hydroxychloroquine can be discontinued as it was unlikely to have been responsible for the improvement. If no benefit is apparent with dual therapy after four to six weeks, the other agent (dapsone or sulfasalazine) may be discontinued and the hydroxychloroquine continued for a total trial of 12 weeks.",
"   </p>",
"   <p>",
"    We usually try",
"    <strong>",
"     two",
"    </strong>",
"    antiinflammatory agents before proceeding to immunosuppressant or immunomodulatory agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Maintenance of successful therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient's symptoms are controlled, we usually maintain the effective dose of antiinflammatory agent while tapering and discontinuing glucocorticoids. If symptoms remain controlled on the antiinflammatory agent and antihistamines for a period of months, we then gradually begin reducing medications. If the patient is on sedating antihistamines or has not responded significantly to antihistamines, we taper these first and then the antiinflammatory is reduced over a period of several months, as tolerated. No studies have evaluated the ideal length of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     IMMUNOSUPPRESSANT AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who are glucocorticoid-dependent and already suffering from toxicity, we typically elect to use an immunosuppressant",
"    <strong>",
"     prior",
"    </strong>",
"    to antiinflammatory therapy, as our clinical experience suggests that immunosuppressants are more reliably effective. In addition, we use immunosuppressant therapies in patients with inadequate or no response to antiinflammatory agents, after discontinuing the antiinflammatory drug. (See",
"    <a class=\"local\" href=\"#H1920133\">",
"     'Choice of initial intervention'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1920489\">",
"    <span class=\"h2\">",
"     Agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressant agents used in the treatment of CU include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcineurin inhibitors, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , have been used successfully to treat chronic urticaria, and are the preferred treatment for severe symptoms according to some experts [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/26\">",
"     26",
"    </a>",
"    ]. These drugs inhibit calcium-dependent release of and responsiveness to histamine, leukotriene C4, and other mediators in mast cells and other cell types [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/27\">",
"     27",
"    </a>",
"    ]. These agents also have anti-T lymphocyte activity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/28\">",
"     28",
"    </a>",
"    ]. Cyclosporine may also disrupt tumor necrosis factor alpha activity and secondarily inhibit neutrophil accumulation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/29\">",
"     29",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    has similar therapeutic effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    has several desirable properties, including rapid onset (sometimes within days) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/30-32\">",
"     30-32",
"    </a>",
"    ], a degree of efficacy comparable to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/3,33\">",
"     3,33",
"    </a>",
"    ], and the possibility of lasting remission [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/32,34,35\">",
"     32,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following studies provide information about efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    at different doses: Early studies described significant improvement with relatively high doses (5 to 6 mg per kg daily), but patients often discontinued therapy because of adverse effects, with relapse of their urticaria [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/36\">",
"     36",
"    </a>",
"    ]. Mild adverse effects are frequent and dose-related, and dose reduction may eliminate these. Severe side effects are uncommon, but include hypertension and renal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      (5 mg per kg daily) was compared head-to-head with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (20 mg once daily) in an eight week trial of 20 patients with CU refractory to antihistamines [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/33\">",
"       33",
"      </a>",
"      ]. Nine of 10 patients receiving cyclosporine were symptom free within five days of starting therapy, and the last patient cleared within 15 days. Two patients suffered headache, tremors, and nausea, which resolved with lowering the dose to 3 mg per kg daily. No patient developed hypertension or renal function changes. Two patients had recurrent mild symptoms three months later. In comparison, all patients receiving prednisone also became symptom free \"in a few days.\" One patient developed hypertension and two experienced weight gain. After the treatment period, four prednisone-treated patients promptly relapsed. Thus, cyclosporine appeared to induce a longer lasting remission.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most subsequent studies have used lower doses (eg, 2 to 4 mg per kg daily), as well as the strategy of starting high and tapering down to the lowest effective dose [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/30,31,34,37-41\">",
"     30,31,34,37-41",
"    </a>",
"    ]. This approach can achieve long-term benefit while minimizing significant side effects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 54 children (9 to 16 years of age) with CU evaluated the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      for refractory symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/42\">",
"       42",
"      </a>",
"      ]. Of the 54, seven children had symptoms that were not controlled with high-dose antihistamines plus alternate-day",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      and required daily oral prednisone. In these seven, cyclosporine (3",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      divided into two doses per day) was added, and attempts were made to taper glucocorticoids. Cyclosporine levels were maintained &le;200",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      to avoid adverse effects. Hives were completely controlled in all patients. This was achieved in one to four weeks for six subjects, and eight weeks for one. Once symptoms were controlled for one month, cyclosporine doses were reduced every two to four weeks and then discontinued. Four patients had relapses that again responded to cyclosporine, but all were eventually able to discontinue all medications with apparent remission of the disease. No children had significant side effects.",
"     </li>",
"     <li>",
"      A case series described 120 patients with CU refractory to high-dose antihistamines who were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , beginning with 3",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      for two months [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/40\">",
"       40",
"      </a>",
"      ]. If the patient responded after two months, cyclosporine was tapered and discontinued during the next month and the patient was followed for relapse. Symptoms and safety measures (blood pressure and creatinine) were monitored every two months. Patients responded as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      17 percent did not tolerate",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      due to early emergence of side effects (gastrointestinal upset, peripheral neuropathy, or headache).",
"     </li>",
"     <li>",
"      15 percent had no improvement after at least one month of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and were considered treatment failures.",
"     </li>",
"     <li>",
"      25 percent had complete remission of disease and were able to stop",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      after three months. They were followed thereafter and did not relapse for at least three years.",
"     </li>",
"     <li>",
"      27 percent had some improvement and were able to manage their CU on antihistamines alone after finishing three months of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      17 percent improved but were unable to discontinue",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and required extended treatment with 1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      and antihistamines. Eight were able to stop cyclosporine after 8 to 14 months, while the other 12 continued for 5 to 10 years with no blood pressure elevation, laboratory abnormalities, or malignancies. This group provided reassuring data about long-term safety.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A small number of randomized controlled trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    for CU have been published, although these generally involved subjects who had failed only standard doses of antihistamines, so the severity of these patients' disease may have been overestimated. The following are representative studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thirty patients were randomized to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (4 mg per kg daily) or placebo for four weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/43\">",
"       43",
"      </a>",
"      ]. Initial nonresponders were offered open-label cyclosporine for four weeks. Eight of 19 (42 percent) receiving cyclosporine improved, compared to none receiving placebo. In addition, 11 of 17 initial nonresponders responded after an additional four weeks of open-label treatment. Adverse effects were common in this study (29 of 30 subjects) and most commonly involved paresthesias, gastrointestinal symptoms, and headache. All 30 patients in this study had positive autologous serum skin tests (ASSTs), although other studies have found no correlation between ASST and cyclosporine response [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another randomized trial evaluated the effects of adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      in 99 patients with CU [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/39\">",
"       39",
"      </a>",
"      ]. The cyclosporine dose was 5 mg per kg daily for the first 28 days, which was then tapered to 3 mg per kg daily. All subjects were treated with cetirizine daily, plus either cyclosporine for 16 weeks, cyclosporine for eight weeks followed by placebo for eight weeks, or placebo for all 16 weeks. Symptom scores improved significantly in both groups receiving cyclosporine. Two patients discontinued treatment because of hypertension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal duration of therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is not known. Some studies indicate that a longer duration of therapy is more likely to induce sustained benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/45\">",
"     45",
"    </a>",
"    ], but other studies have found that the majority of patients respond within three months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/40\">",
"     40",
"    </a>",
"    ]. Blood pressure, blood urea nitrogen, and creatinine should be monitored monthly and fasting lipids periodically [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/22\">",
"     22",
"    </a>",
"    ]. Serum levels may be followed to ensure that the dose is not excessive, although the optimal therapeutic level for CU has not been defined. In our experience, drug levels of calcineurin inhibitors have a poor correlation with overall effectiveness, and therefore we do not pursue a specific target drug level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h4\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    in CU is limited. In one case series, 19 patients with severe CU were treated with low-dose tacrolimus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/46\">",
"     46",
"    </a>",
"    ]. Two patients discontinued tacrolimus due to side effects. At 12 weeks, 71 percent (12 patients) had responded to a significant degree, nine of whom were able to stop antihistamines, and three were able to stop glucocorticoids. One responder had a lasting drug-free remission and had previously failed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , so there may be important differences between the calcineurin inhibitors in the treatment of CU. The monitoring suggested with tacrolimus is similar to that with cyclosporine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Sirolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    (rapamycin) was reported to be effective in two of three patients in a case report [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/47\">",
"     47",
"    </a>",
"    ]. The patients had previously failed multiple alternative therapies including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/3/43059?source=see_link\">",
"     olsalazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil. Of note, sirolimus and the related agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    have been implicated in causing isolated angioedema [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/48-51\">",
"     48-51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Mycophenolate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    acts as an antimetabolite selectively for lymphocytes and also impairs expression of adhesion molecules and secondary leukocyte migration [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/52\">",
"     52",
"    </a>",
"    ]. Although unrelated to the calcineurin inhibitors, mycophenolate has some of the same properties with fewer reported adverse effects. The most common problems are gastrointestinal symptoms and leukopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2855?source=see_link\">",
"     \"Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Very few studies are available on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    in chronic urticaria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An open series evaluated nine patients with \"severe\" CU, defined as symptoms unresponsive over a six-week period to antihistamines",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      more than two week-long courses of oral glucocorticoids. Patients were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      (1 gram twice daily) for 12 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/53\">",
"       53",
"      </a>",
"      ]. Six patients experienced marked improvement in urticaria scores, all patients were able to discontinue glucocorticoids by the end of the 12 week trial, and improvement persisted for at least six months after discontinuation.",
"     </li>",
"     <li>",
"      In another series of 19 patients, the majority of who failed other alternative therapies, doses ranging from 1 to 6 grams were administered, divided into two daily doses [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/54\">",
"       54",
"      </a>",
"      ]. Time to initial response ranged from one to nine weeks and complete control of symptoms was achieved in 60 percent, after a mean treatment period of 14 weeks. Subjects who tapered off the drug subsequently had remissions lasting between 2 and 16 weeks at the conclusion of the study. Gastrointestinal adverse effects were common, occurring in 53 percent of subjects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No serious adverse effects or laboratory abnormalities were reported in either series. If these findings are confirmed by future studies,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    would represent a highly attractive alternative to the calcineurin inhibitors, although further data are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Choice of agent and dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;With",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    , a trial of one-month is typically adequate to determine efficacy. Most patients with CU have relatively rapid responses (within days). The optimal duration of immunosuppressant therapies is unknown. We typically treat patients at a dose required for complete or near complete control of urticaria for three months, then taper the dose over several months as tolerated. The majority of patients are able to be treated for six to nine month periods, although some require long-term therapy (years) at the lowest effective dose.",
"   </p>",
"   <p>",
"    The following is one approach to administering these agents to patients with CU.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       Tacrolimus",
"      </a>",
"      &mdash; We prefer tacrolimus as an initial immunosuppressant. Although there are more data in support of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , we prefer tacrolimus because anecdotally, we have observed more frequent problematic side effects with cyclosporine than tacrolimus. Most of our patients are women, and cyclosporine can cause hirsutism and gingival hyperplasia. Baseline laboratories including renal function are required prior to starting calcineurin inhibitors.",
"      <br/>",
"      <br/>",
"      We start tacrolimus at a dose of 1 mg twice daily for one week, and increase to 2 mg twice daily if no therapeutic benefit is seen within one to two weeks. In our experience, most patients will respond to doses &le;4 mg daily of tacrolimus. Higher doses can be used in patients who partially respond or have no response to lower doses and monitoring of tacrolimus levels and renal function is recommended to avoid renal toxicity. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Tacrolimus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      &mdash; The optimal dose of cyclosporine for CU has not been determined. Until more definitive studies are available, we suggest starting with a dose of 3 mg per kg, divided into two doses. Most patients respond within three months, after which the dose can be gradually reduced and in many cases, treatment discontinued. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Cyclosporine'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Certain patients appear to respond better to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      or cyclosporine, although if one of these agents has not helped, we generally try",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      next.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      <strong>",
"       mofetil",
"      </strong>",
"      &mdash; Mycophenolate mofetil is typically started at 1000 mg twice daily and may be increased to 1500 mg twice daily after several weeks if needed. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Mycophenolate'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     THERAPIES WITH SIGNIFICANT LIMITATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are additional agents that can be useful in the management of CU, although each has limitations, including one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High cost (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      and immune globulin)",
"     </li>",
"     <li>",
"      The potential for serious adverse effects (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , antifibrinolytics, anticoagulants, androgens)",
"     </li>",
"     <li>",
"      Limited evidence of benefit (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      , methylxanthines, phototherapy)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Inconvenience/intensive",
"      </span>",
"      monitoring requirements (eg, plasmapheresis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Glucocorticoids remain the standard comparator for these therapies. Glucocorticoids have the advantages of high efficacy and low cost, and the disadvantages of predictable long-term toxicity and lack of disease-modifying effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Omalizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     Omalizumab",
"    </a>",
"    , a monoclonal antibody directed against IgE, was initially found effective in case reports and small series in patients with both positive and negative autologous serum skin tests, those with physical urticarias, and urticarial vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/55-63\">",
"     55-63",
"    </a>",
"    ]. Subsequent randomized trials have demonstrated efficacy of omalizumab in CU not responsive to standard doses of H1 antihistamines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    10 mg daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest randomized multicenter trial, 323 patients (ages 12 to 75 years) with persistent moderate-to-severe CU symptoms were treated with three monthly injections of either placebo or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      at doses of 75, 150, or 300 mg subcutaneously, and observed for an additional four months [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/66\">",
"       66",
"      </a>",
"      ]. The primary endpoint was a change in mean weekly itch severity scores (on a scale from 0 to 21, with a minimally important difference of 5) at the end of 12 weeks. Mean itch scores decreased in all groups (-5, -6, -8, -10 points in placebo, 75, 150, and 300 mg groups respectively); the improvement in scores was statistically significant only in the groups receiving 150 and 300 mg doses. The percentages of subjects with complete resolution of urticaria were 10, 18, 23, and 53, respectively. Following the active treatment stage of the study, patients&rsquo; symptoms gradually returned during the four months of observation, but did not reach the severity at the start of the study.",
"     </li>",
"     <li>",
"      A smaller randomized multicenter trial included 49 patients with persistent CU [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/65\">",
"       65",
"      </a>",
"      ]. All subjects had demonstrable IgE autoantibodies to thyroid peroxidase (a test not commercially available), although the role of this antibody in the pathogenesis of CU, if any, has not been demonstrated.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       Omalizumab",
"      </a>",
"      was dosed according to weight and total IgE level, based upon dosing for asthma. The primary endpoint was the change in weekly urticaria activity scores (UAS7) after 24 weeks of therapy. Compared with placebo, omalizumab therapy was associated with a significantly greater reduction in UAS7 scores from baseline (-18 versus -8 points) and a significantly higher rate of complete control of CU (70 versus 5 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     Omalizumab",
"    </a>",
"    is effective in CU but is only approved in the United States for the treatment of asthma. Reimbursement for this costly therapy by third-party payers for use in CU must be arranged on a patient-by-patient basis.",
"   </p>",
"   <p>",
"    The optimal dose and duration of therapy has not been determined and it is not known if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    has any long-term disease-modifying effects. In addition, comparative studies with other CU therapies have not yet been performed. However, based upon the studies reviewed above, it would be reasonable to start with a dose of 150 mg every four weeks, and if the response is not adequate, then increase to 300 mg every four weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=see_link\">",
"     \"Anti-IgE therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune globulin may be an appropriate earlier option in patients in whom an immunomodulator would be preferable to an immunosuppressive agent, such as those with a history of malignancy.",
"   </p>",
"   <p>",
"    Immune globulin is an immunomodulatory agent that alters cell adhesion, immunoregulatory molecules, complement function, cytokine levels, autoantibody production, and anti-idiotypic networks [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/67\">",
"     67",
"    </a>",
"    ]. It can be administered intravenously (IVIG) or subcutaneously (SCIG), although the higher doses used in some studies of CU can only be administered intravenously. Adverse effects are generally predictable and manageable. Similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    , barriers to use include expense, approval by insurance carriers, and inconvenience. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=see_link\">",
"     \"Intravenous immune globulin: Adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Success in CU was first reported in an open trial of 10 patients who were treated with five days of IVIG (0.4 grams per kilogram per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/68\">",
"     68",
"    </a>",
"    ]. All had positive autologous serum skin test (ASST) and basophil histamine-release test results and many had failed glucocorticoids and various other agents. Responses occurred within days, ranged from modest transient benefit to complete and lasting remission. The three patients who exhibited complete remission (one after a second course) were symptom-free at least three years after the last course of IVIG.",
"   </p>",
"   <p>",
"    IVIG may be dosed in several ways, and the optimal dose, number of infusions to administer, and schedule are unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/69-75\">",
"     69-75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lowest dose described was 0.15 grams per kg, given once every four weeks, in 29 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/70\">",
"       70",
"      </a>",
"      ]. Treatment duration ranged from 6 to 51 months. Twenty-six patients improved, including 19 who experienced complete remission.",
"     </li>",
"     <li>",
"      Another patient was treated with a 10-fold higher (2 grams per kg), infused once, and responded within 48 hours with improvement that lasted seven months [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/71\">",
"       71",
"      </a>",
"      ]. However, repeating the infusion produced only moderate benefit that failed to persist.",
"     </li>",
"     <li>",
"      In two other reports representing a total of four patients, five-day infusions resulted in two complete responses, one partial benefit, and one failure [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/72,73\">",
"       72,73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other failures have also been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/74,75\">",
"       74,75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H681450\">",
"    <span class=\"h2\">",
"     TNF-inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;TNF-&alpha; has been shown to be upregulated in the epidermis in lesional and nonlesional skin of CU patients but not controls [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/76\">",
"     76",
"    </a>",
"    ]. TNF-inhibitors, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , have been studied in the treatment of CU. Reports of effectiveness are currently limited. A single patient with delayed pressure urticaria and psoriasis had improvement with etanercept (25 mg subcutaneously twice weekly) and maintained improvement with infliximab [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/77\">",
"     77",
"    </a>",
"    ]. A case series of three patients with CU and three with urticarial vasculitis who were refractory to numerous alternative agents showed all six patients responded to therapy, some with complete resolution. Etanercept, adalimumab, and infliximab were used in this series and some patients had preferential responses to one agent over another.",
"   </p>",
"   <p>",
"    TNF-inhibitors have several adverse effects including injection-site or infusion-related reactions, infectious complications, and others. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Optimal dosing of TNF-inhibitors for CU is unknown, but doses similar to those for other cutaneous diseases have been used. As with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    and IVIG, barriers to use include expense, approval by insurance carriers, and inconvenience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Colchicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    may act to relieve CU by suppressing leukotriene generation or by decreasing leukocyte adhesiveness and migration [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. However, evidence for effectiveness is lacking. Despite this, colchicine has a favorable safety profile at recommended doses, minimal requirements for monitoring, low cost, and a generally rapid onset of action.",
"   </p>",
"   <p>",
"    The single available randomized controlled trial evaluated 12 patients with delayed pressure urticaria, and failed to demonstrate any effect compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/80\">",
"     80",
"    </a>",
"    ]. Evidence of benefit in patients with chronic idiopathic urticaria is limited to anecdotal reports and retrospective series [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. Our clinical experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    in CU has been disappointing in that only a small number of patients seem to respond.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Androgens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgens, which are effective in the treatment of hereditary angioedema, have been studied in chronic idiopathic urticaria and angioedema [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. A randomized trial of 58 patients with CU refractory to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    compared stanozolol, 2 mg twice daily, with placebo over a 12-week period [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/85\">",
"     85",
"    </a>",
"    ]. The stanozolol group had a greater clinical response with respect to frequency of marked improvement (65 percent versus 29 percent) and mean reduction in clinical scores. Short-term adverse effects were reported as \"infrequent,\" with two patients having transient elevations in transaminases that normalized without treatment cessation. This study was criticized because both treatment groups showed continued reduction in urticarial activity that had not plateaued by the end of the study.",
"   </p>",
"   <p>",
"    The long-term adverse effects of androgens include hypercholesterolemia, hypertension, acne, mood disorders, and transaminitis, and monitoring is recommended. Although androgens may compare favorably with glucocorticoids in many patients, these side effects limit their use in children, women, and some men. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29658?source=see_link&amp;anchor=H15#H15\">",
"     \"Hereditary angioedema: Prevention of attacks\", section on 'Attenuated androgens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    reduces neutrophil accumulation in inflamed skin [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/86\">",
"     86",
"    </a>",
"    ], diminishes activated leukocyte adhesiveness and other adenosine-mediated antiinflammatory properties [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/87\">",
"     87",
"    </a>",
"    ], decreases leukotriene synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/88\">",
"     88",
"    </a>",
"    ], and alters cytokine activity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/89\">",
"     89",
"    </a>",
"    ]. Adverse effects can be serious and frequent monitoring is advised. These issues are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence of efficacy in CU is limited to case reports and small series [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/90-95\">",
"     90-95",
"    </a>",
"    ]. One of the larger series described 16 patients, 10 with CU, 4 with urticarial vasculitis, and 2 with angioedema without urticaria [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/94\">",
"     94",
"    </a>",
"    ]. Three of the CU patients also had delayed pressure urticaria. Of the 16 treated patients, there were 12 that noted some benefit along with steroid-sparing effects. The doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    required ranged from 5 to 25",
"    <span class=\"nowrap\">",
"     mg/week.",
"    </span>",
"    Effects were typically observed after four weeks of therapy. The authors do not state whether patients could be removed from therapy. Negative studies also exist [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    has generally been reserved for patients in whom multiple other alternative agents have failed. It is believed to act on plasma cells to reduce autoantibody production in autoimmune CU [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/96\">",
"     96",
"    </a>",
"    ]. Evidence of efficacy is limited to case reports of patients with positive ASSTs who had failed multiple other therapies, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/97-99\">",
"     97-99",
"    </a>",
"    ]. In one report, improvement began four weeks into the initial infusions and continued to complete resolution by six months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/97\">",
"     97",
"    </a>",
"    ]. The patient continued to be asymptomatic 12 months after the last infusion.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    use is limited by expense, inconvenience, need for monitoring, and risk of serious adverse effects (including delayed secondary neoplasia and hemorrhagic cystitis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Antifibrinolytics and anticoagulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inflammatory pathways believed relevant to",
"    <span class=\"nowrap\">",
"     urticaria/angioedema",
"    </span>",
"    are interconnected with pathways of coagulation and fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/63,100\">",
"     63,100",
"    </a>",
"    ]. Agents acting on different points in these pathways theoretically shunt mediators along altered routes and reduce pro-urticarial factors.",
"   </p>",
"   <p>",
"    Antifibrinolytic agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/52/6982?source=see_link\">",
"     aprotinin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    ) have long been used to treat disorders of angioedema, and their utility in some patients with chronic urticaria was first noted in the 1970s [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/101-104\">",
"     101-104",
"    </a>",
"    ]. The anticoagulants",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    were also studied in CU [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/100,105-111\">",
"     100,105-111",
"    </a>",
"    ]. However, the risks of these agents generally outweigh the potential benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Methylxanthines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of methylxanthines to treat CU has also been considered [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. A double-blind, placebo-controlled study of 134 CU patients evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    200 mg twice a day for six months followed by 200 mg once a day for six months, compared to placebo, as add-on therapy to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/113\">",
"     113",
"    </a>",
"    ]. Both groups experienced large improvements in all symptoms assessed, and the theophylline group had statistically significant improvement in overall urticaria scores. However, pruritus did not improve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Non-drug therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-drug treatments that have been studied in CU include phototherapy, autohemotherapy, and plasmapheresis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Phototherapy",
"      </strong>",
"      &mdash; Phototherapy has been administered to patients with CU [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/114,115\">",
"       114,115",
"      </a>",
"      ], although it has been applied more often to the treatment of solar urticaria and other physical urticarias. Phototherapy is a reasonable option for patients able to commit to frequent visits or for those intolerant to systemic medications. Skin that is directly irradiated improves most dramatically, suggesting local mediators and cells as primary targets. Histamine release from mast cells may also be reduced [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/116\">",
"       116",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Several types of phototherapy (eg, PUVA, narrow band UV-B and UV-A) have been shown to have modest clinical benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/115,117\">",
"       115,117",
"      </a>",
"      ]. Phototherapy is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33160?source=see_link\">",
"       \"Psoralen plus ultraviolet A (PUVA) photochemotherapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24666?source=see_link&amp;anchor=H36#H36\">",
"       \"Physical urticarias\", section on 'Solar urticaria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Autohemotherapy",
"      </strong>",
"      &mdash; Autohemotherapy involves parenteral injection of autologous blood in an attempt to desensitize patients to pro-urticarial factors in the patient's own serum. An initial report of this was promising [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/118\">",
"       118",
"      </a>",
"      ]. Following that report, a single-blind placebo-controlled trial of 56 patients randomized to weekly subcutaneous injections of either autologous, whole, untreated blood, (2.5 mL the first week and 5 mL thereafter), or isotonic sodium chloride solution for eight weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/119\">",
"       119",
"      </a>",
"      ]. Patients with ASST positivity experienced some reduction in urticarial lesions, decreased antihistamine use, and improved quality of life, although the differences were not statistically significant. The ASST-negative patients did not have appreciable benefit. A second randomized trial compared weekly injections of autologous whole blood or autologous serum to placebo in 88 patients and reported improvement in both active treatment groups, but not greater than that in the placebo group [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/120\">",
"       120",
"      </a>",
"      ]. We do not use this treatment.",
"     </li>",
"     <li>",
"      <strong>",
"       Plasmapheresis",
"      </strong>",
"      &mdash; Plasmapheresis removes a variety of proteins and other substances from plasma, and may have immunomodulatory effects through one of several mechanisms [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/121,122\">",
"       121,122",
"      </a>",
"      ]. One study described eight patients with severe CU who underwent plasmapheresis. Two had complete resolution, two improved, and two did not change [",
"      <a class=\"abstract\" href=\"UTD.htm?29/53/30554/abstract/123\">",
"       123",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/17/18706?source=see_link\">",
"       \"Patient information: Chronic hives (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CU should be considered refractory when symptoms are not controlled by antihistamines in combination with other standard therapies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=see_link\">",
"       \"Chronic urticaria: Standard management and patient education\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who require frequent and repeated courses of oral glucocorticoids, or extended periods of glucocorticoid treatment (ie, months at a time) are candidates for the other therapies presented in this review. The most effective combination of antihistamines and the lowest possible dose of glucocorticoids for that patient should be continued while trials of other agents are conducted. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no standardized approach to the management of severe refractory chronic urticaria (CU), and therapy must be individualized. The effectiveness of the therapies discussed in this review is supported by low-quality evidence in most cases, and the approach presented is largely based upon clinical experience.",
"     </li>",
"     <li>",
"      For patients",
"      <strong>",
"       without",
"      </strong>",
"      evidence of steroid toxicity, we suggest antiinflammatory agents (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      ) in preference of other drugs as an initial intervention (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We usually begin with dapsone, after checking for G6PD deficiency. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Antiinflammatory agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients",
"      <strong>",
"       with",
"      </strong>",
"      evidence of steroid toxicity, we suggest an immunosuppressant or immunomodulatory agent (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ) in preference to antiinflammatory agents as an initial intervention (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The author usually begins with tacrolimus. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Immunosuppressant agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are a variety of other drugs and therapies for refractory CU, although each has one or more significant limitations. Despite this, there may be situations in which a certain therapy is indicated. As an example, patients with moderate-to-severe asthma who develop refractory CU are candidates for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Therapies with significant limitations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/1\">",
"      Joint Task Force on Practice Parameters. The diagnosis and management of urticaria: a practice parameter part I: acute urticaria/angioedema part II: chronic urticaria/angioedema. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol 2000; 85:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/2\">",
"      Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/3\">",
"      Powell RJ, Du Toit GL, Siddique N, et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy 2007; 37:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/4\">",
"      Bonney RJ, Wightman PD, Dahlgren ME, et al. Inhibition of the release of prostaglandins, leukotrienes and lysosomal acid hydrolases from macrophages by selective inhibitors of lecithin biosynthesis. Biochem Pharmacol 1983; 32:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/5\">",
"      Bozeman PM, Learn DB, Thomas EL. Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone. Biochem Pharmacol 1992; 44:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/6\">",
"      Booth SA, Moody CE, Dahl MV, et al. Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol 1992; 98:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/7\">",
"      Debol SM, Herron MJ, Nelson RD. Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol 1997; 62:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/8\">",
"      Theron A, Anderson R. Investigation of the protective effects of the antioxidants ascorbate, cysteine, and dapsone on the phagocyte-mediated oxidative inactivation of human alpha-1-protease inhibitor in vitro. Am Rev Respir Dis 1985; 132:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/9\">",
"      Lang PG Jr. Sulfones and sulfonamides in dermatology today. J Am Acad Dermatol 1979; 1:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/10\">",
"      Cassano N, D'Argento V, Filotico R, Vena GA. Low-dose dapsone in chronic idiopathic urticaria: preliminary results of an open study. Acta Derm Venereol 2005; 85:254.",
"     </a>",
"    </li>",
"    <li>",
"     Morgan M, unpublished data, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/12\">",
"      Kosseifi SG, Guha B, Nassour DN, et al. The Dapsone hypersensitivity syndrome revisited: a potentially fatal multisystem disorder with prominent hepatopulmonary manifestations. J Occup Med Toxicol 2006; 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/13\">",
"      Sener O, Doganci L, Safali M, et al. Severe dapsone hypersensitivity syndrome. J Investig Allergol Clin Immunol 2006; 16:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/14\">",
"      Gadangi P, Longaker M, Naime D, et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol 1996; 156:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/15\">",
"      Fox CC, Moore WC, Lichtenstein LM. Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci 1991; 36:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/16\">",
"      Suematsu M, Suzuki M, Miura S, et al. Sulfasalazine and its metabolites attenuate respiratory burst of leukocytes--a possible mechanism of anti-inflammatory effects. J Clin Lab Immunol 1987; 23:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/17\">",
"      Imai F, Suzuki T, Ishibashi T, Dohi Y. Effect of sulfasalazine on B cells. Clin Exp Rheumatol 1991; 9:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/18\">",
"      McGirt LY, Vasagar K, Gober LM, et al. Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine. Arch Dermatol 2006; 142:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/19\">",
"      Jaffer AM. Sulfasalazine in the treatment of corticosteroid-dependent chronic idiopathic urticaria. J Allergy Clin Immunol 1991; 88:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/20\">",
"      Hartmann K, Hani N, Hinrichs R, et al. Successful sulfasalazine treatment of severe chronic idiopathic urticaria associated with pressure urticaria. Acta Derm Venereol 2001; 81:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/21\">",
"      Berkun Y, Shalit M. Successful treatment of delayed pressure urticaria with montelukast. Allergy 2000; 55:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/22\">",
"      Chakravarty K, McDonald H, Pullar T, et al. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology (Oxford) 2008; 47:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/23\">",
"      Goldman FD, Gilman AL, Hollenback C, et al. Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood 2000; 95:3460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/24\">",
"      Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 1993; 23:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/25\">",
"      Reeves GE, Boyle MJ, Bonfield J, et al. Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. Intern Med J 2004; 34:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/26\">",
"      Kaplan AP. What the first 10,000 patients with chronic urticaria have taught me: a personal journey. J Allergy Clin Immunol 2009; 123:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/27\">",
"      Marone G, Triggiani M, Cirillo R, et al. Cyclosporin A inhibits the release of histamine and peptide leukotriene C4 from human lung mast cells. Ric Clin Lab 1988; 18:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/28\">",
"      Thomson AW. The effects of cyclosporin A on non-T cell components of the immune system. J Autoimmun 1992; 5 Suppl A:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/29\">",
"      Wershil BK, Furuta GT, Lavigne JA, et al. Dexamethasone and cyclosporin A suppress mast cell-leukocyte cytokine cascades by multiple mechanisms. Int Arch Allergy Immunol 1995; 107:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/30\">",
"      Barlow RJ, Ross EL, MacDonald DM, et al. Treatment of severe, chronic urticaria with cyclosporin A. Eur J Dermatol 1993; 3:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/31\">",
"      Ilter N, G&uuml;rer MA, Akkoca MA. Short-term oral cyclosporine for chronic idiopathic urticaria. J Eur Acad Dermatol Venereol 1999; 12:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/32\">",
"      Marsland AM, Beck MH. Cold urticaria responding to systemic ciclosporin. Br J Dermatol 2003; 149:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/33\">",
"      Loria MP, Dambra PP, D'Oronzio L, et al. Cyclosporin A in patients affected by chronic idiopathic urticaria: a therapeutic alternative. Immunopharmacol Immunotoxicol 2001; 23:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/34\">",
"      Di Gioacchino M, Di Stefano F, Cavallucci E, et al. Treatment of chronic idiopathic urticaria and positive autologous serum skin test with cyclosporine: clinical and immunological evaluation. Allergy Asthma Proc 2003; 24:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/35\">",
"      Galindo Bonilla PA, Borja Segade J, G&oacute;mez Torrijos E, Feo Brito F. Urticaria and cyclosporine. Allergy 2002; 57:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/36\">",
"      Fradin MS, Ellis CN, Goldfarb MT, Voorhees JJ. Oral cyclosporine for severe chronic idiopathic urticaria and angioedema. J Am Acad Dermatol 1991; 25:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/37\">",
"      Edstr&ouml;m DW, Ros AM. Cyclosporin A therapy for severe solar urticaria. Photodermatol Photoimmunol Photomed 1997; 13:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/38\">",
"      Toubi E, Blant A, Kessel A, Golan TD. Low-dose cyclosporin A in the treatment of severe chronic idiopathic urticaria. Allergy 1997; 52:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/39\">",
"      Vena GA, Cassano N, Colombo D, et al. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2006; 55:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/40\">",
"      Kessel A, Toubi E. Cyclosporine-A in severe chronic urticaria: the option for long-term therapy. Allergy 2010; 65:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/41\">",
"      Hollander SM, Joo SS, Wedner HJ. Factors that predict the success of cyclosporine treatment for chronic urticaria. Ann Allergy Asthma Immunol 2011; 107:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/42\">",
"      Doshi DR, Weinberger MM. Experience with cyclosporine in children with chronic idiopathic urticaria. Pediatr Dermatol 2009; 26:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/43\">",
"      Grattan CE, O'Donnell BF, Francis DM, et al. Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria. Br J Dermatol 2000; 143:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/44\">",
"      Baskan EB, Tunali S, Turker T, Saricaoglu H. Comparison of short- and long-term cyclosporine A therapy in chronic idiopathic urticaria. J Dermatolog Treat 2004; 15:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/45\">",
"      Toubi E, Bamberger E, Kessel A. Prolonged cyclosporin-A treatment for severe chronic urticaria. Allergy 2003; 58:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/46\">",
"      Kessel A, Bamberger E, Toubi E. Tacrolimus in the treatment of severe chronic idiopathic urticaria: an open-label prospective study. J Am Acad Dermatol 2005; 52:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/47\">",
"      Morgan M. Treatment of refractory chronic urticaria with sirolimus. Arch Dermatol 2009; 145:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/48\">",
"      Mackenzie M, Wood LA. Lingual angioedema associated with everolimus. Acta Oncol 2010; 49:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/49\">",
"      Mah&eacute; E, Morelon E, Lechaton S, et al. Angioedema in renal transplant recipients on sirolimus. Dermatology 2007; 214:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/50\">",
"      Er F, Nia AM, Erdmann E. [67-year-old patient with speech disorder and dysphagia]. Dtsch Med Wochenschr 2008; 133:2463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/51\">",
"      Fuchs U, Zittermann A, Berthold HK, et al. Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema. Transplantation 2005; 79:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/52\">",
"      Moder KG. Mycophenolate mofetil: new applications for this immunosuppressant. Ann Allergy Asthma Immunol 2003; 90:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/53\">",
"      Shahar E, Bergman R, Guttman-Yassky E, Pollack S. Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients not responding to antihistamines and/or corticosteroids. Int J Dermatol 2006; 45:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/54\">",
"      Zimmerman AB, Berger EM, Elmariah SB, Soter NA. The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: experience in 19 patients. J Am Acad Dermatol 2012; 66:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/55\">",
"      Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007; 99:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/56\">",
"      Kaplan AP, Joseph K, Maykut RJ, et al. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008; 122:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/57\">",
"      Spector SL, Tan RA. Therapeutic alternatives for chronic urticaria: additional reports on omalizumab. Ann Allergy Asthma Immunol 2008; 101:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/58\">",
"      G&uuml;zelbey O, Ardelean E, Magerl M, et al. Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy 2008; 63:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/59\">",
"      Romano C, Sellitto A, De Fanis U, et al. Maintenance of remission with low-dose omalizumab in long-lasting, refractory chronic urticaria. Ann Allergy Asthma Immunol 2010; 104:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/60\">",
"      Groffik A, Mitzel-Kaoukhov H, Magerl M, et al. Omalizumab--an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy 2011; 66:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/61\">",
"      Metz M, Altrichter S, Ardelean E, et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol 2011; 154:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/62\">",
"      Ferrer M, Gamboa P, Sanz ML, et al. Omalizumab is effective in nonautoimmune urticaria. J Allergy Clin Immunol 2011; 127:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/63\">",
"      Boyce JA. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol 2006; 117:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/64\">",
"      Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011; 128:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/65\">",
"      Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011; 128:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/66\">",
"      Maurer M, Ros&eacute;n K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013; 368:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/67\">",
"      Sewell WA, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology 2002; 107:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/68\">",
"      O'Donnell BF, Barr RM, Black AK, et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol 1998; 138:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/69\">",
"      Kroiss M, Vogt T, Landthaler M, Stolz W. The effectiveness of low-dose intravenous immunoglobulin in chronic urticaria. Acta Derm Venereol 2000; 80:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/70\">",
"      Pereira C, Tavares B, Carrapatoso I, et al. Low-dose intravenous gammaglobulin in the treatment of severe autoimmune urticaria. Eur Ann Allergy Clin Immunol 2007; 39:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/71\">",
"      Klote MM, Nelson MR, Engler RJ. Autoimmune urticaria response to high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 2005; 94:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/72\">",
"      Asero R. Are IVIG for chronic unremitting urticaria effective? Allergy 2000; 55:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/73\">",
"      Wetter DA, Davis MD, Yiannias JA, et al. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience. Mayo Clin Proc 2005; 80:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/74\">",
"      Borcea A, Greaves MW. Methotrexate-induced exacerbation of urticarial vasculitis: an unusual adverse reaction. Br J Dermatol 2000; 143:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/75\">",
"      Matteson EL. Interferon alpha 2a therapy for urticarial vasculitis with angioedema apparently following hepatitis A infection. J Rheumatol 1996; 23:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/76\">",
"      Hermes B, Prochazka AK, Haas N, et al. Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol 1999; 103:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/77\">",
"      Magerl M, Philipp S, Manasterski M, et al. Successful treatment of delayed pressure urticaria with anti-TNF-alpha. J Allergy Clin Immunol 2007; 119:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/78\">",
"      Kelly SJ, Uri AJ, Freeland HS, et al. Effects of colchicine on IgE-mediated early and late airway reactions. Chest 1995; 107:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/79\">",
"      Cronstein BN, Molad Y, Reibman J, et al. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995; 96:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/80\">",
"      Lawlor F, Black AK, Ward AM, et al. Delayed pressure urticaria, objective evaluation of a variable disease using a dermographometer and assessment of treatment using colchicine. Br J Dermatol 1989; 120:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/81\">",
"      Tharp MD. Chronic urticaria: pathophysiology and treatment approaches. J Allergy Clin Immunol 1996; 98:S325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/82\">",
"      Criado RF, Criado PR, Martins JE, et al. Urticaria unresponsive to antihistaminic treatment: an open study of therapeutic options based on histopathologic features. J Dermatolog Treat 2008; 19:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/83\">",
"      Pho LN, Eliason MJ, Regruto M, et al. Treatment of chronic urticaria with colchicine. J Drugs Dermatol 2011; 10:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/84\">",
"      Brestel EP, Thrush LB. The treatment of glucocorticosteroid-dependent chronic urticaria with stanozolol. J Allergy Clin Immunol 1988; 82:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/85\">",
"      Parsad D, Pandhi R, Juneja A. Stanozolol in chronic urticaria: a double blind, placebo controlled trial. J Dermatol 2001; 28:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/86\">",
"      Cream JJ, Pole DS. The effect of methotrexate and hydroxyurea on neutrophil chemotaxis. Br J Dermatol 1980; 102:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/87\">",
"      Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002; 4:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/88\">",
"      Sperling RI, Coblyn JS, Larkin JK, et al. Inhibition of leukotriene B4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate. Arthritis Rheum 1990; 33:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/89\">",
"      Gerards AH, de Lathouder S, de Groot ER, et al. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford) 2003; 42:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/90\">",
"      Weiner MJ. Methotrexate in corticosteroid-resistant urticaria. Ann Intern Med 1989; 110:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/91\">",
"      Gach JE, Sabroe RA, Greaves MW, Black AK. Methotrexate-responsive chronic idiopathic urticaria: a report of two cases. Br J Dermatol 2001; 145:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/92\">",
"      Montero Mora P, Gonz&aacute;lez P&eacute;rez Mdel C, Almeida Arvizu V, Matta Campos JJ. [Autoimmune urticaria. Treatment with methotrexate]. Rev Alerg Mex 2004; 51:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/93\">",
"      Stack PS. Methotrexate for urticarial vasculitis. Ann Allergy 1994; 72:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/94\">",
"      Perez A, Woods A, Grattan CE. Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria. Br J Dermatol 2010; 162:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/95\">",
"      Sagi L, Solomon M, Baum S, et al. Evidence for methotrexate as a useful treatment for steroid-dependent chronic urticaria. Acta Derm Venereol 2011; 91:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/96\">",
"      Donaldson VH, Bernstein DI, Wagner CJ, et al. Angioneurotic edema with acquired C1- inhibitor deficiency and autoantibody to C1- inhibitor: response to plasmapheresis and cytotoxic therapy. J Lab Clin Med 1992; 119:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/97\">",
"      Bernstein JA, Garramone SM, Lower EG. Successful treatment of autoimmune chronic idiopathic urticaria with intravenous cyclophosphamide. Ann Allergy Asthma Immunol 2002; 89:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/98\">",
"      Asero R. Oral cyclophosphamide in a case of cyclosporin and steroid-resistant chronic urticaria showing autoreactivity on autologous serum skin testing. Clin Exp Dermatol 2005; 30:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/99\">",
"      Eiser AR, Singh P, Shanies HM. Sustained dapsone-induced remission of hypocomplementemic urticarial vasculitis--a case report. Angiology 1997; 48:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/100\">",
"      Cugno M, Marzano AV, Asero R, Tedeschi A. Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications. Intern Emerg Med 2010; 5:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/101\">",
"      Berova N, Petkov I, Andreev VC. Treatment of chronic urticaria with a proteinase (kallikrein) inhibitor. Br J Dermatol 1974; 90:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/102\">",
"      Tant D. Tranexamic acid in chronic urticaria. Br Med J 1979; 1:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/103\">",
"      Laurberg G. Tranexamic acid (Cyklokapron) in chronic urticaria: a double-blind study. Acta Derm Venereol 1977; 57:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/104\">",
"      Asero R, Tedeschi A, Cugno M. Heparin and tranexamic Acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study. Int Arch Allergy Immunol 2010; 152:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/105\">",
"      Asero R, Tedeschi A, Riboldi P, Cugno M. Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. J Allergy Clin Immunol 2006; 117:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/106\">",
"      Kaplanski G, Fabrigoule M, Boulay V, et al. Thrombin induces endothelial type II activation in vitro: IL-1 and TNF-alpha-independent IL-8 secretion and E-selectin expression. J Immunol 1997; 158:5435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/107\">",
"      Fagiolo U, Cancian M, Bertollo L, et al. Inhibitory effect of heparin on skin reactivity to autologous serum in chronic idiopathic urticaria. J Allergy Clin Immunol 1999; 103:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/108\">",
"      Parslew R, Pryce D, Ashworth J, Friedmann PS. Warfarin treatment of chronic idiopathic urticaria and angio-oedema. Clin Exp Allergy 2000; 30:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/109\">",
"      Barlow RJ, Greaves MW. Warfarin in the treatment of chronic urticaria/angio-edema. Br J Dermatol 1992; 126:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/110\">",
"      Chua SL, Gibbs S. Chronic urticaria responding to subcutaneous heparin sodium. Br J Dermatol 2005; 153:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/111\">",
"      Mahesh PA, Pudupakkam VK, Holla AD, Dande T. Effect of warfarin on chronic idiopathic urticaria. Indian J Dermatol Venereol Leprol 2009; 75:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/112\">",
"      Biondi M, Reggiani M. [Theophylline in the therapy of urticaria]. G Ital Dermatol Venereol 1986; 121:LXXI.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/113\">",
"      Kalogeromitros D, Kempuraj D, Katsarou-Katsari A, et al. Theophylline as 'add-on' therapy to cetirizine in patients with chronic idiopathic urticaria. A randomized, double-blind, placebo-controlled pilot study. Int Arch Allergy Immunol 2006; 139:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/114\">",
"      Berroeta L, Clark C, Ibbotson SH, et al. Narrow-band (TL-01) ultraviolet B phototherapy for chronic urticaria. Clin Exp Dermatol 2004; 29:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/115\">",
"      Olafsson JH, Lark&ouml; O, Roupe G, et al. Treatment of chronic urticaria with PUVA or UVA plus placebo: a double-blind study. Arch Dermatol Res 1986; 278:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/116\">",
"      Horio T. Indications and action mechanisms of phototherapy. J Dermatol Sci 2000; 23 Suppl 1:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/117\">",
"      Khafagy NH, Salem SA, Ghaly EG. Comparative study of systemic psoralen and ultraviolet A and narrowband ultraviolet B in treatment of chronic urticaria. Photodermatol Photoimmunol Photomed 2013; 29:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/118\">",
"      Mori O, Hashimoto T. Autologous whole blood intramuscular injection as a cure for chronic urticaria: report of a patient in whom intradermal injection of autologous serum continued to cause a weal-and-flare response. Br J Dermatol 1999; 140:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/119\">",
"      Staubach P, Onnen K, Vonend A, et al. Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: a placebo-controlled trial. Dermatology 2006; 212:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/120\">",
"      Kocat&uuml;rk E, Akta S, T&uuml;rkolu Z, et al. Autologous whole blood and autologous serum injections are equally effective as placebo injections in reducing disease activity in patients with chronic spontaneous urticaria: a placebo controlled, randomized, single-blind study. J Dermatolog Treat 2012; 23:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/121\">",
"      Patten E. Therapeutic plasmapheresis and plasma exchange. Crit Rev Clin Lab Sci 1986; 23:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/122\">",
"      Jiang X, Lu M, Ying Y, et al. A case report of double-filtration plasmapheresis for the resolution of refractory chronic urticaria. Ther Apher Dial 2008; 12:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/53/30554/abstract/123\">",
"      Grattan CE, Francis DM, Slater NG, et al. Plasmapheresis for severe, unremitting, chronic urticaria. Lancet 1992; 339:1078.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8111 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-67DC1C7482-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_53_30554=[""].join("\n");
var outline_f29_53_30554=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1920020\">",
"      DEFINITION OF CHRONIC URTICARIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1919908\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H642386\">",
"      Terminology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1920133\">",
"      Choice of initial intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1920120\">",
"      Goal of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANTIINFLAMMATORY AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Dapsone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Sulfasalazine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Hydroxychloroquine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treatment strategies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Maintenance of successful therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      IMMUNOSUPPRESSANT AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1920489\">",
"      Agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Sirolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Mycophenolate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Choice of agent and dosing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      THERAPIES WITH SIGNIFICANT LIMITATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Omalizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H681450\">",
"      TNF-inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Colchicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Androgens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Antifibrinolytics and anticoagulants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Methylxanthines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Non-drug therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/8111\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8111|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/62/16365\" title=\"table 1\">",
"      Glucocorticoid side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=related_link\">",
"      An overview of angioedema: Pathogenesis and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=related_link\">",
"      Anti-IgE therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=related_link\">",
"      Antimalarial drugs in the treatment of rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=related_link\">",
"      Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=related_link\">",
"      Chronic urticaria: Standard management and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=related_link\">",
"      Clinical features, diagnosis, and treatment of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15721?source=related_link\">",
"      Cold urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=related_link\">",
"      Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=related_link\">",
"      Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29658?source=related_link\">",
"      Hereditary angioedema: Prevention of attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=related_link\">",
"      Intravenous immune globulin: Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2855?source=related_link\">",
"      Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/17/18706?source=related_link\">",
"      Patient information: Chronic hives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24666?source=related_link\">",
"      Physical urticarias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33160?source=related_link\">",
"      Psoralen plus ultraviolet A (PUVA) photochemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/60/32714?source=related_link\">",
"      Urticarial vasculitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_53_30555="Potential candidates for screening for pancreatic cancer";
var content_f29_53_30555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F83695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F83695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential candidates for screening for pancreatic cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        An affected individual with PJS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        An affected individual with hereditary pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Three or more first-, second-, or third-degree relatives with pancreatic cancer, with &ge;1 pancreatic cancer in a first-degree relative*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A known mutation carrier of a",
"        <em>",
"         BRCA1",
"        </em>",
"        ,",
"        <sup>",
"         &bull;",
"        </sup>",
"        <em>",
"         BRCA2",
"        </em>",
"        ,",
"        <em>",
"         p16",
"        </em>",
"        ,",
"        <em>",
"         MLH1",
"        </em>",
"        ,",
"        <sup>",
"         &bull;",
"        </sup>",
"        <em>",
"         MSH2",
"        </em>",
"        ,",
"        <sup>",
"         &bull;",
"        </sup>",
"        <em>",
"         MSH6",
"        </em>",
"        ,",
"        <sup>",
"         &bull;",
"        </sup>",
"        or",
"        <em>",
"         PMS2",
"        </em>",
"        <sup>",
"         &bull;",
"        </sup>",
"        mutation and &ge;1 first- or second- degree relative with pancreatic cancer",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PJS: Peutz-Jeghers Syndrome.",
"     <br/>",
"     * Screening may also be considered in individuals with two first-degree relatives with pancreatic cancer.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Data are more limited in these categories.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Grover S, Syngal S. Hereditary pancreatic cancer. Gastroenterology 2010; 139:1076. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_53_30555=[""].join("\n");
var outline_f29_53_30555=null;
var title_f29_53_30556="Management of subsolid pulmonary nodules detected at CT";
var content_f29_53_30556=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F87146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F87146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for the management of subsolid pulmonary nodules detected at CT: A statement from the Fleischner Society",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Nodule type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Management recommendations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Additional remarks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Solitary pure GGNs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &le;5 mm",
"       </td>",
"       <td>",
"        No CT follow-up required",
"       </td>",
"       <td>",
"        Obtain contiguous 1-mm-thick sections to confirm that nodule is truly a pure GGN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;5 mm",
"       </td>",
"       <td>",
"        Initial follow-up CT at&nbsp;three months to confirm persistence, then annual surveillance CT for a minimum of&nbsp;three years",
"       </td>",
"       <td>",
"        FDG PET is of limited value, potentially misleading, and therefore not recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Solitary part-solid nodules",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Initial follow-up CT at&nbsp;three months to confirm persistence. If persistent and solid component &lt;5 mm, then yearly surveillance CT for a minimum of&nbsp;three years. If persistent and solid component &ge;5 mm, then biopsy or surgical resection.",
"       </td>",
"       <td>",
"        Consider PET/CT for part-solid nodules &gt;10 mm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Multiple subsolid nodules",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pure GGNs &le;5 mm",
"       </td>",
"       <td>",
"        Obtain follow-up CT at&nbsp;two and&nbsp;four years",
"       </td>",
"       <td>",
"        Consider alternate causes for multiple GGNs &le;5 mm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pure GGNs &gt;5 mm without a dominant lesion(s)",
"       </td>",
"       <td>",
"        Initial follow-up CT at&nbsp;three months to confirm persistence and then annual surveillance CT for a minimum of&nbsp;three years",
"       </td>",
"       <td>",
"        FDG PET is of limited value, potentially misleading, and therefore not recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dominant nodule(s) with part-solid or solid component",
"       </td>",
"       <td>",
"        Initial follow-up CT at&nbsp;three months to confirm persistence. If persistent, biopsy or surgical resection is recommended, especially for lesions with &gt;5 mm solid component.",
"       </td>",
"       <td>",
"        Consider lung-sparing surgery for patients with dominant lesion(s) suspicious for lung cancer",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CT: computed tomography; FDG PET: 18-fluoro-2-deoxyglucose positron emission tomography; GGN: ground glass nodule.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Naidich DP, Bankier AA, MacMahon H, et al. Recommendations for the Management of Subsolid Pulmonary Nodules Detected at CT: A Statement from the Fleischner Society. Radiology 2013; 266:304-317. Copyright &copy; 2013 Radiological Society of North America.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_53_30556=[""].join("\n");
var outline_f29_53_30556=null;
var title_f29_53_30557="Airway pressure mechanical vent";
var content_f29_53_30557=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Airway pressures during various modes of ventilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 337px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Airway pressures (Paw) during inspiration and expiration with controlled mechanical ventilation (CMV), assist-control (AC), intermittent mandatory ventilation delivered by a continuous flow circuit (IMV-CF), and synchronized intermittent mandatory ventilation delivered by demand valve circuit (SIMV-DV).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Tobin, MJ, Dantzker, DR, In: Cardiopulmonary Critical Care, Dantzker, DR (Ed), Grune and Stratton, Orlando, 1986.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_53_30557=[""].join("\n");
var outline_f29_53_30557=null;
var title_f29_53_30558="H reflex";
var content_f29_53_30558=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F81004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F81004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    H reflex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 464px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The H reflex with tibial nerve stimulation in the popliteal fossa, recording from the soleus muscle. The H reflex is visible only with submaximal stimulation. With a slow increase in stimulus strength, the H reflex appears as the stimulus changes from subthreshold to submaximal. The amplitude of the H reflex is greatest just below the threshold for the appearance of the compound muscle action potential (CMAP or M response). With increasing stimulus strength, the H reflex amplitude declines as M response amplitude increases. The H reflex disappears with maximal and supramaximal stimulation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_53_30558=[""].join("\n");
var outline_f29_53_30558=null;
var title_f29_53_30559="Endotracheal tube positioning";
var content_f29_53_30559=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endotracheal tube positioning",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 339px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagrammatic representation of key distances related to endotracheal tube positioning. Malpositioning of the endotracheal tube can be suspected from the depth of insertion. In the average adult, the 18-24 cm mark will show at the incisors when the tip of the tube is midway between the vocal cords and the carina.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Stone, DJ, Bogdonoff, DL, Anesth Analg 1992; 74:276.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_53_30559=[""].join("\n");
var outline_f29_53_30559=null;
